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Mucoadhesive Films for the Buccal Delivery of Insulin 
 
Javier Octavio Morales, Ph.D.  
The University of Texas at Austin, 2012 
 
Supervisor: Jason T. McConville 
Co-Supervisor: Robert O. Williams 
 
To address the need of a patient friendly and therapeutically effective method of 
administration of insulin (Ins) we sought to develop mucoadhesive films for delivery 
through the buccal mucosa. Ins is a labile molecule exhibiting limited activity and 
stability in solid solutions in films and other solid delivery devices. Early investigations 
outlined in Chapter 3 revealed the need for a certain particle size (below the one 
micrometer) for the addition of particulate material in films. In Chapter 4 a novel method 
for the manufacture of protein-coated nanoparticles (PCNP) is depicted. Successful 
particle batches were achieved in terms of size, uniformity, stability and activity and 
these particles were further investigated for their inclusion on films for buccal delivery. 
The method of manufacture of particles was based on an antisolvent co-precipitation 
process that immobilized macromolecules to the surface of crystalline core particles 
resulting in high yields and highly active protein loaded particles. Films loaded with 
PCNP were developed and characterized in Chapter 5. Lysozyme was utilized as a model 
macromolecule and high yields and activity were obtained after manufacture, 
demonstrating that after all the processing the protein is subjected to, activity is 
preserved. Using Eudragit® RLPO (ERL) as the matrix forming polymer, films with 
excellent mucoadhesion were developed. Here is described a high mucoadhesion for ERL 
 viii
that was even further increased by the addition of the water soluble PCNP. This occurred 
by the water movement into the ERL matrix that the solubilizing particles generate. 
Finally, films containing Ins were developed and assayed for permeation through buccal 
mucosa. By adapting the method of manufacture, Ins-coated nanoparticles were obtained 
and embedded in films. ERL films corroborated previous findings by exhibiting excellent 
performance. Investigations on the permeation of Ins through buccal mucosa revealed 
that the inclusion of Ins in films enhanced its permeation in comparison with a control Ins 
solution. Thus here is described the successful development of mucoadhesive films for 
the buccal delivery of Ins.  
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1. Introduction1 
ABSTRACT 
The buccal route of administration has a number of advantages including 
bypassing the gastrointestinal tract and the hepatic first pass effect. Mucoadhesive films 
are retentive dosage forms, and release drug directly into a biological substrate. 
Furthermore, films have improved patient compliance due to their small size and reduced 
thickness, compared for example to lozenges and tablets. The development of 
mucoadhesive buccal films has increased dramatically over the past decade because it is a 
promising delivery alternative to various therapeutic classes including peptides, vaccines, 
and nanoparticles. The “film casting process” involves casting of aqueous solutions 
and/or organic solvents to yield films suitable for this administration route. Over the last 
decade, hot-melt extrusion has been explored as an alternative manufacturing process, 
and has yielded promising results. Characterization of critical properties such as the 
mucoadhesive strength, drug content uniformity, and permeation rate represent the major 
research areas in the design of buccal films. This chapter will consider the literature that 
describes the manufacture and characterization of mucoadhesive buccal films. 
  
                                                 
1 Significant parts of this chapter were taken from: J.O. Morales and J.T. McConville, Manufacture and 
characterization of mucoadhesive buccal films, European Journal of Pharmaceutics and Biopharmaceutics. 
(2011) 77, 187–199. 
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1.1. OVERVIEW 
Films as dosage forms have gained relevance in the pharmaceutical arena as 
novel, patient friendly, convenient products. More recently, orally disintegrating films (or 
strips) have come to light thanks to their improved mechanical properties [1]. This 
translates into a less friable dosage form compared to most commercialized orally 
disintegrating tablets, which usually require special packaging [2]. Mucoadhesive buccal 
films share some of these advantages and more. Due to their small size and thickness they 
have improved patient compliance, compared to tablets [3–5]. Moreover, since 
mucoadhesion implies attachment to the buccal mucosa, films can be formulated to 
exhibit a systemic or local action [6]. Many mucoadhesive buccal films have been 
formulated to release drug locally in order to treat fungal infections in the oral cavity 
such as oral candidiasis [7–11]. Due to the versatility of the manufacturing processes, the 
release can be oriented either towards the buccal mucosa or towards the oral cavity, in 
this latter case it can provide controlled release via gastrointestinal (GI) tract 
administration. Alternatively, films can be formulated to release the drug towards the 
buccal mucosa. Films releasing drug towards the buccal mucosa exhibit the advantage of 
avoiding the first pass effect by directing absorption through the venous system that 
drains from the cheek [12]. Previously, many articles have reviewed the development of 
mucoadhesive buccal systems in global terms [13–17], or their specific attributes such as 
permeation enhancers [18] or mucoadhesive polymers [19–21]. The following is a review 
of the relevant literature which provides a background for understanding the rationale 
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behind the formulation of mucoadhesive buccal films, as well as reviewing the most 
crucial characterization techniques for these dosage forms. The reader should notice that 
the literature use the term film and patch interchangeably. 
1.2. PHYSICOCHEMICAL PROPERTIES OF THE ORAL MUCOSA 
The oral mucosa presents differently depending on the region of the oral cavity 
being considered [22]. The masticatory mucosa covers those areas that are involved in 
mechanical processes, such as mastication or speech, and includes the gingival and hard 
palate. This masticatory region is stratified and has a keratinized layer on its surface, 
similar to the structure found at the epidermis, and covers about 25% of the oral cavity 
[23]. The specialized mucosa covers about 15%, corresponding to the dorsum of the 
tongue, and is a stratified tissue with keratinized as well as non-keratinized domains [24]. 
Finally, the lining mucosa covers the remaining 60% of the oral cavity, consisting of the 
inner cheeks, floor of the mouth, and underside of the tongue. This lining epithelium is 
stratified and non-keratinized on its surface [25]. The buccal mucosa covers the inner 
cheeks and is classified as part of the lining mucosa, having approximately 40 to 50 cell 
layers resulting in an epithelium 500 to 600 μm thick (Figure 1.1) [26]. The epithelium is 
attached to underlying structures by a connective tissue or lamina propia, separated by a 
basal lamina. These lining mucosa and the lamina propia regions provide mostly 
mechanical support and no major barrier for penetration of actives [12,27]. The 
connective tissue also contains the blood vessels that drain into the lingual, facial, and 
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retromandibular veins, which then open into the internal jugular vein [12]. This is one of 
the main advantages of buccal over oral delivery: absorption through the buccal 
epithelium avoids the gastrointestinal tract conditions, such as gastric pH, enzyme 
content, and the first pass effect due to direct absorption into the portal vein. Once a 
given drug molecule reaches the connective tissue, it may be readily distributed, thus the 
permeation barrier is across the whole thickness of the stratified epithelium [12]. 
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Figure 1.1. Diagram of a cross-section of the buccal mucosa. The keratinized layer is 
only present in most rodent models while the human has a non-keratinized 
buccal mucosa. Adapted from ref. [28]. 
The existence of membrane-coating granules in the epidermis has been well 
characterized and it is known to be the precursor of the keratin layer or stratum corneum 
[18,29]. Even though the existence of approximately 2 μm in diameter cytoplasmic 
membrane-coating granules in the buccal epithelium has been proven, less is known in 
terms of their function; however, the permeation barrier is believed to be related to the 
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presence of membrane-coating granules in the buccal mucosa [30,31]. Squier described 
these membrane-coating granules as organelles containing amorphous material that is 
extruded into the intercellular space after membrane fusion [30]. More recently, it has 
been reported that some of these granules also contain lipid lamellae domains organized 
to some extent [32]. This fact contrasts with the content of the membrane-coating 
granules in the epidermis, which contains very organized electron-dense lipid lamellae. 
Therefore, the intercellular space of the stratified non-keratinized buccal mucosa is filled 
with a combination of amorphous material presenting some domains where short stack of 
lipid lamellae can be observed. This important difference in the intercellular space 
composition is responsible for the difference in permeability between the buccal and 
keratinized mucosae for exogenous compounds [33]. 
Although the buccal mucosa is more permeable than keratinized epithelium, the 
existence of a permeability barrier has been described [34]. It was demonstrated that this 
barrier is located in the upper one third to one quarter of the epithelium layer using 
horseradish peroxidase, and by following its permeation through the epithelium. After 
topical application, the horseradish peroxidase only permeated through the first 1 to 3 cell 
layers. However, when injected subepithelially it was found to permeate through as deep 
as the connective tissue and up as far as the membrane-coating granules zone was [34]. 
This suggested that the permeability barrier is located in the upper region of the 
epithelium and is correlated with the rich lipid content of this zone. As well as the 
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keratinized epithelium, the intercellular space of the buccal mucosa is rich in lipids, but it 
is the difference in composition and the absence of the keratin layer that accounts for its 
permeation characteristics [33,35–38]. The lipid composition in the buccal epithelium has 
a higher content of phospholipids, cholesterol esters, and glycosylceramides, while the 
content of ceramides is minimal, compared to the skin and keratinized regions of the oral 
cavity [33]. This composition results in a higher concentration of polar lipids in the 
intercellular space [35]. Therefore, it is not only due to the highly organized lipid 
lamellae found in the keratinized epithelia, but also the nature of the lipid content that 
accounts for the increased permeation of the buccal mucosa compared to the skin and 
other keratinized epithelia. 
Due to the polar nature of the lipids in the intercellular space, two different 
domains can be differentiated in the buccal epithelium: the lipophilic domain, 
corresponding to the cell membranes of the stratified epithelium; and the hydrophilic 
domain corresponding to the extruded content from the membrane-coating granules, into 
the intercellular space. These two domains have led to postulate the existence of different 
routes of transport through the buccal epithelium, namely the paracellular and the 
transcellular route [22]. The lipophilic nature of the cell membranes favors the pass of 
molecules with high log P values across the cells. Similar to the absorption mechanism in 
the small intestine, it is believed that lipophilic molecules are carried through the 
cytoplasm [18]. However, there still is a lack of evidence supporting this assumption. The 
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polar nature of the intercellular space favors the penetration of more hydrophilic 
molecules across a more tortuous and longer path [28,39,40]. It has been demonstrated 
that some hydrophilic molecules are subject to carrier-mediated transport through the 
buccal mucosa [41]. Most of the descriptions of molecules permeating through the buccal 
epithelium, in the literature, are related to the paracellular route of absorption. In an early 
study, it was found that tritiated water permeated through the paracellular route [37]. 
Using light microscopy autoradiography, it has been determined that water, ethanol, 
cholesterol, and thyrotropin release hormone, penetrate through the paracellular route as 
well [42,43]. More recently it was demonstrated using confocal laser scanning 
microscopy, that dextrans with 4 and 10 kDa average molecular weight and labeled with 
fluorescein-isothiocyanate, permeated through the paracellular route [44,45]. Even 
though there is no evidence that supports the idea of molecules permeating through the 
transcellular route, it is important to assess and understand the permeation route in order 
to determine strategies to enhance the absorption of actives when formulating buccal 
films.  
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1.3. FORMULATION AND MANUFACTURE OF BUCCAL DELIVERY FILMS 
 
There are many factors in determining the optimum formulation of buccal 
delivery films, but three major areas have been extensively investigated in the 
mucoadhesive buccal film literature, namely mucoadhesive properties, permeation 
enhancement, and controlled release of drugs. Most of the polymers that are used as 
mucoadhesives are predominantly hydrophilic polymers that will swell and allow for 
chain interactions with the mucin molecules in the buccal mucosa [6]. Examples of these 
swellable polymers include hydroxypropyl cellulose (HPC), hydroxypropylmethyl 
cellulose (HPMC), hydroxyethyl cellulose (HEC), sodium carboxymethyl cellulose 
(SCMC), poly(vinyl pyrrolidone) (PVP), and chitosan; a full list of polymers used in the 
manufacture of buccal films, with additional descriptions and properties, is depicted in 
Table 1.1.  
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Table 1.1. Mucoadhesive and film forming polymers used in the literature 
Mucoadhesive 
polymer in films Relevant properties and findings 
Use in the 
literature 
 
Hydroxyethyl 
cellulose (HEC) 
 
Non-ionic polymer 
High swelling properties and rapid erosion [46] 
Low mucoadhesive properties increased by the addition of 
SCMC [47] 
Zero order release kinetics of miconazole [46] and 
chlorpheniramine [48]  
 
 
[46–51] 
Hydroxypropyl 
cellulose (HPC) 
Non-ionic polymer 
Increased swelling in ethylcellulose/HPC films [52]  
Moderate mucoadhesive properties [52,53] 
Zero order release kinetics of lidocaine [54] and clotrimazole 
[55] associated with erosion 
Square-root of time release kinetics of lidocaine [56] 
 
[8,9,49,52–68] 
Hydroxypropylmeth
yl cellulose (HPMC) 
Non-ionic polymer 
Rapid swelling that plateaus [52] 
Moderate mucoadhesive properties [52,53,69] 
Initial burst followed by diffusion of nicotine hydrogen 
tartrate [70] 
 
[4,46,47,50–
53,56,69–84] 
Sodium 
carboxymethyl 
cellulose (SCMC) 
Anionic polymer 
High swelling properties that does not plateau [52] 
High mucoadhesive properties [47,52,78] 
Zero order release of miconazole nitrate [46] 
Diffusion governed release of ibuprofen [78] 
 
[4,11,46,47,52,71,7
2,75,77,78,85–89] 
Poly(vinyl 
pyrrolidone) (PVP) 
Non-ionic polymer 
As film forming polymer exhibits non-fickian release of 
ketorolac [52] and progesterone [90] 
Used to tailor the release of propranolol [91] and miconazole 
[46] 
High swelling properties [90–92]  
Used as coadjuvant to increase mucoadhesion [78,93] 
 
[46,49,50,52,75,77,
78,80,86,90–97] 
Poly(vinylalcohol) 
(PVA) 
Non-ionic polymer 
Moderate swelling [73] and mucoadhesive properties [77,92] 
Anomalous release of miconazole [46] 
 
[5,49,64,70,73,77,9
2] 
Chitosan Cationic polymer 
High to moderate swelling [47,98] and mucoadhesive 
properties [53,69,98,99] 
Sustained release of miconazole [46] 
 
[10,46,51,53,69,74,
81,82,90,92,94,95,
98–108] 
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Table 1.1 continued 
 
Alginate, sodium Anionic polymer 
Rapid swelling and dissolution [47,104] 
High mucoadhesive properties [53]  
 
[47,53,75,77,81,83,
104,109–111] 
Agar  Poor and stable swelling properties 
 
[104] 
Carrageenan type λ Poor and stable swelling and moderate mucoadhesive 
properties 
 
[86] 
Acacia Very poor mucoadhesion 
 
[69] 
Guar gum As an additive, conveyed moderate swelling and good 
mucoadhesive properties, and anomalous non-fickian release 
of miconazole 
 
[51] 
Poly-L(lactide-co-
glycolide) (PLGA) 
Micromatrices in buccal films to control the release of 
ipriflavone [101] 
 
[101,112] 
Polyacrilic acid, 
Carbopol® 
Rapid, high and stable swelling [52,70,76,91] 
High mucoadhesive properties [53,69] 
As a film forming polymer, conveyed sustained release of 
buprenorphine [69] 
Used as an additive to tailor the release of propranolol 
[70,91] 
 
[3–5,8,11,47,52,53, 
57,69–72,76,77,79, 
80,83,84,86–89, 
91,93,105,110,113
–118] 
Polycarbophil Non-ionic polymer 
As an additive, conveyed moderate and stable swelling 
[86]and high mucoadhesive properties [47,56,58,86,119,120] 
 
[9,47,56,58,70,86,1
19–122] 
Poly(ethylene oxide)  Non-ionic polymer 
High mucoadhesion with high molecular weight [123,124] 
Zero order release kinetics of clotrimazole [123] and 
tetrahidrocannabinol [124] associated with erosion of the 
polymeric matrix 
 
[56,123–125] 
Poly(methacrylates) Used as film former, exhibited very poor bioadhesive 
properties and low swelling capability [47,91,119] 
The salt form has high mucoadhesive properties [126] 
 
[47,72,74,78,91,10
0,119–122,126, 
127] 
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Table 1.1 shows that polymers from the families of the poly(acrylic acid) 
(Carbopols) and cellulosic derivatives have been extensively used as mucoadhesives, 
being part of the so called “first generation” mucoadhesives [128]. These polymers 
require to be hydrated in order to exhibit their mucoadhesive properties; however, a 
critical degree of hydration limits the phenomenon [129]. Above this critical value, over-
hydration occurs leading to the formation of a slippery mucilage lacking mucoadhesive 
properties. In an early publication, Guo reported that the use of Carbopol® 934P alone 
exhibited the triple average peeling strength compared to the one exhibited by HPMC 
[69]. More recently, Semalty et al. demonstrated using a modified disintegration 
apparatus that the in vitro residence time of films formulated with a combination of 
Carbopol® 934P and HPMC E15 was almost the double than films containing only 
HPMC E15 [71]. Moreover, the combined polymers exhibited more resistance to rupture, 
as demonstrated using the the folding endurance test. Another important polymer widely 
used in the formulation of mucoadhesive films is HPC. In one of the earliest publication 
on mucoadhesive films, Anders and Merkle showed that the use of different grades of 
HPC or HEC had superior mucoadhesive properties compared to PVP and poly(vinyl 
alcohol) (PVA) as film forming polymers [49]. More recently, it was reported that film 
formulations, containing different ratios of Carbopol® and HPC exhibited longer in vitro 
residence times when the concentration of HPC was increased [57].  
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Natural and semi-natural polymers have also been reported in the literature as 
mucoadhesives. Chitosan was first introduced in 1994 by Guo for its use in 
mucoadhesive film formulations [69]. Following Carbopol® and HPMC as polymeric 
matrices for mucoadhesive films, chitosan exhibited better adhesion than acacia in a 
peeling test using an Instron 4201. In a more recent study, Shidhaye et al. described the 
manufacture, permeation, and mucoadhesive properties of chitosan films, containing 
gelatin and PVP in different proportions, for the buccal delivery of sumatriptan succinate 
[94]. It was demonstrated that an increase in the chitosan component increased the 
mucoadhesive strength of films. The authors attributed the increasing concentration of 
chitosan having the effect of increasing the number of amine groups that can interact with 
the negative charge groups (carboxyl, sulphate, etc.) which are present on the buccal 
epithelium surface [130]. Recently, mucoadhesive films have been developed and used as 
platforms for the oral delivery of nanoparticles [98,109]. Cui et al. reported on the 
manufacture of carboxylation chitosan-grafted nanoparticles (CCGNs) added to chitosan-
ethylenediamine tetraacetic acid (C-EDTA) films with a backing layer of ethyl cellulose 
(EC) [98]. Films loaded with CCGNs exhibited higher mucoadhesion than that of placebo 
films. This high mucoadhesion effect was attributed to the high number of carboxyl 
groups that the CCGNs have, increasing the chance of hydrogen bonding with the 
mucosa [98]. 
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It is evident that most of the mucoadhesive polymers explored in the literature are 
hydrophilic, or show some of the essential features for mucoadhesion. However, it has 
been reported that different insoluble Eudragit® grades can exhibit some mucoadhesive 
properties when used alone [72,100], or in combination with other hydrophilic polymers 
[47]. Films containing propranolol hydrochloride, Eudragit RS100, and triethyl citrate as 
a plasticizer exhibited almost three times the mucoadhesion force than that of films 
prepared with chitosan as the mucoadhesive polymer [100]. The authors proposed that 
the plasticizer is responsible for the increase on mucoadhesion. However, since the use of 
a plasticizer is necessary in Eudragit RS100 films, such film formulations may then be 
suitable for the manufacture of mucoadhesive dosage forms. Salts of soluble 
polymethacrylate derivatives, namely Eudragit S100 and L100, have been reported to 
increase mucoadhesion [126]. This study was based on the assumption that ionizable 
polymers exhibit the best mucoadhesive characteristics [131–133], which combined with 
low-swellable properties would allow for better patient compliance. It was demonstrated 
that, even though the Eudragit S100 and L100 did not exhibit mucoadhesive properties, 
their sodium and potassium salts performed equally or better than the positive 
mucoadhesive controls, namely Carbopol® 934P and HPMC [126]. 
The body of literature that explores different aspects of formulating mucoadhesive 
buccal films is extensive in terms of polymers used, mucoadhesive properties, and 
permeation characteristics for formulations. However, only a handful of products have 
 
15 
 
reached the market, and currently only two products for oral mucosal drug delivery have 
been successfully commercialized, and one further product has finished a phase 2 clinical 
study. BioDelivery Sciences International have used their BioErodible MucoAdhesive 
(BEMA™) technology platform to develop Onsolis™, a fentanyl buccal soluble film 
indicated to be administered in the buccal mucosa for the management of breakthrough 
pain in patients with cancer[134]. The formulation contains the mucoadhesive polymers 
carboxymethyl cellulose, hydroxyethyl cellulose, and polycarbophil, along with a 
backing layer to direct drug release towards the buccal mucosa. Using the same 
technology platform, BioDelivery Sciences International have completed a phase 2 
clinical study for BEMA™ Buprenorphine with a significant improvement in the primary 
efficacy endpoint, SPID-8 (sum of pain intensity differences at 8 hours), compared to that 
exhibited by the placebo. The other commercialized film product is Suboxone™ Film, a 
buprenorphine and naloxone sublingual film. Using a polymeric matrix based on 
polyethylene oxide and hydroxypropylmethyl cellulose rapid dissolution and absorption 
are achieved [135]. 
The mucoadhesion process and the strategies used to control and enhance drug 
delivery and permeation will be discussed in later Sections 4 and 5. The following section 
will discuss the main manufacturing processes involved in making mucoadhesive buccal 
films, namely film casting and hot-melt extrusion. 
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1.3.1. Film casting 
The film casting method is undoubtedly the most widely used manufacturing 
process for making films found in the literature. This is mainly due to the ease of the 
process and the low cost that the system set up incurs at the research laboratory scale. 
The process consists of at least six steps: preparation of the casting solution; deareation of 
the solution; transfer the appropriate volume of solution into a mold; drying the casting 
solution; cutting the final dosage form to contain the desired amount of drug; and 
packaging. During the manufacture of films particular importance is given to the 
rheological properties of the solution or suspension, air bubbles entrapped, content 
uniformity, and residual solvents in the final dosage form [136]. The rheology of the 
liquid to be casted will determine the drying rates and uniformity in terms of the active 
content as well as the physical appearance of the films. During the mixing steps of the 
manufacturing process air bubbles are inadvertently introduced to the liquid and removal 
of air is a critical step for homogeneity reasons [2]. Films cast from aerated solutions 
exhibit an uneven surface and heterogeneous thickness. Another recurrent concern in the 
manufacture of films for buccal delivery is the presence of organic solvents. The use of 
organic solvents is normally questioned, not only due to problems related to solvent 
collection and residual solvents, but also because organic solvents are undesired hazards 
for the environment and health [136]. However, due to the physicochemical properties of 
both the drug and excipients many formulations rely on the use of organic solvents, in 
which case they should be selected from ICH Class 3 solvent list [137]. Even though the 
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current literature on buccal films is mostly focused on platforms for specific drugs and 
diseases, manufacturing and processing parameters have been systematically reported. 
Examples of these research areas are related to the composition of the casting solution 
[53,96,102,118,140], drug concentration, the drug addition process, and cast solution 
rheology [86,87].  
Since the early development of medicated films, content uniformity has been a 
major challenge for the pharmaceutical scientist. Schmidt proposed one of the earliest 
approaches to increase the drug uniformity of medicated films [138], by stating that the 
non-uniformity of films is inherent to their monolayerd nature. Schmidt proposed a 
multistep method for the manufacture of multilayerd films to overcome the heterogeneity 
of the monolayered form. However, Yang et al. reported that using the protocol proposed 
by Schmidt did not render uniform films [139], and went on to say that to overcome the 
non-uniformity of films, a manufacturing process for orally disintegrating films could be 
easily adapted for the manufacture of mucoadhesive buccal films. Yang et al. indicated 
that self-aggregation was one of the main reasons why films usually show poor 
uniformity, and in particular the drying process was found to be crucial in preventing 
aggregation or conglomeration of the ingredients of the film formulation [139]. During an 
inherently long drying processes, intermolecular attractive and convective forces are 
favored leading to the problem of self aggregation. In order to avoid non uniformity, 
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addition of viscous agents such as gel formers or polyhydric alcohols was proposed to 
alleviate potential self aggregation [139]. 
Recently, one of the main challenges in the film casting process, content 
uniformity along the casting surface, has been addressed [74]. Film characterization in 
terms of mucoadhesive, mechanical, permeation, and release properties have been widely 
investigated. However, prior to 2007 few reports pertaining to drug content uniformity 
can be found [70,86,99-101,141,151,153]. The most common approach to measure the 
content uniformity is the determination of drug by weight and not by casting area. 
Perumal et al. postulate that the determination by weight is erroneous because the final 
dosage form is determined by area instead of weight in the particular case of films. They 
demonstrate that custom made silicone molded trays, with individual casting wells for 
each dosage form, improved several characteristics significantly, including: the content 
uniformity per casting area unit, mucoadhesive properties, drug release, and thickness 
uniformity of monopolymeric or multipolymeric films [74]. Even though this approach 
may solve the problem of uniformity per dosage form, it does not guarantee the 
uniformity along the dosage unit itself, and also imposes limitations on scaling up 
possibilities. 
1.3.2. Hot-melt extrusion of films 
In hot melt extrusion, a blend of pharmaceutical ingredients is molten and then 
forced through an orifice (the die) to yield a more homogeneous material in different 
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shapes, such as granules, tablets, or films [140]. Hot-melt extrusion has been used for the 
manufacture of controlled release matrix tablets, pellets, and granules [141]; as well as 
orally disintegrating films [142]. However, only a handful of articles have reported the 
use of hot-melt extrusion for manufacturing mucoadhesive buccal films. Repka and 
coworkers have extensively conducted research on the use of hot-melt extrusion for the 
manufacture of mucoadhesive buccal films, evaluating different matrix formers and 
additives for the processing of the blend [9,56,58,59,123,124]. In an early publication, it 
was found that even though films containing exclusively HPC could not be obtained, the 
addition of plasticizers, such as PEG 8000, triethyl citrate, or acetyltributyl citrate 
allowed for the manufacture of thin, flexible, and stable HPC films over 6 months [60]. It 
has also been found that increasing the molecular weight of HPC decreases the release of 
hot-melt extruded films and allows for zero order drug release [55]. According to the 
models applied [143,144], the drug release was solely determined by erosion of the 
buccal film. 
The most recent publications on mucoadhesive extruded buccal films involves the 
inclusion of ∆9-tetrahydrocannabinol (THC) and its hemiglutarate ester prodrug (THC-
HG) [58,124,125]. Successful mucoadhesive films could be obtained for THC at 120, 
160, and 200°C while still containing at least 94% of the active ingredient. The greatest 
degradation into cannabinol was observed at 200°C (1.6%) [58]. For the formulation of 
the thermally labile prodrug THC-HG, the type of plasticizer was found to be crucial on 
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the post-processing stability [125]. The degradation of the drug in presence of PEG 8000, 
triacetin, or vitamin E succinate as plasticizers was found to be 1.7%, 1.1%, and 0.4% 
respectively, the latter being the most efficient plasticizer in preventing degradation at 
90°C and 130°C [125]. 
1.4. MUCOADHESIVE AND MECHANICAL PROPERTIES OF BUCCAL FILMS 
1.4.1. Overview of Mucoadhesion 
Bioadhesion is the general term describing adhesion between any biological and 
synthetic surface. Mucoadhesion is a specific term describing the particular interaction of 
a mucosal membrane with a synthetic surface [145]. The phenomenon of mucoadhesion 
has been explained by applying any of the five theories of adhesion into the interaction of 
the dosage form and the biological substrate [13,145,146]. The reader is directed to 
detailed explanations of the electronic [147], adsorption [148,149], wetting [129,150], 
diffusion [129,151], and fracture theory [152], here we briefly summarize theories related 
to mucoadhesion theory. Since mucoadhesive buccal films include the interaction of a 
dry polymeric matrix that undergoes hydration, drug release, and sometimes erosion; the 
phenomenon is very complex. Smart has defined four possible scenarios for the analysis 
of the mucoadhesion process based on the hydration state of the dosage form and on the 
amount of mucus layer available for mucoadhesion [153]. Mucoadhesive buccal films 
can be classified as a “case 3” scenario since they are solid dry substrates that come in 
contact with a mucosa having thin or discontinuous mucus layers [153]. Relevant to the 
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analysis of the mucoadhesion of polymeric films on the buccal mucosa, are the adhesion 
theories of adsorption and diffusion. The adsorption theory states that the main 
contributors to the adhesive bond are the inter-polymer interactions, such as hydrogen 
bonds and van der Waals’ forces [154]. The diffusion theory assumes that polymeric 
chains from the solid substrate, i.e. the mucoadhesive film, and the biological substrate, 
i.e. mucin in the mucosa layer, interdiffuse across the adhesive interface [145]. Important 
variables in this process are the diffusion coefficient of the polymer into the mucin layer 
and vice versa, the contact time, and the molecular chain length and their mobility 
[155,156]. 
Most of the mucoadhesive phenomena have two main stages that control the 
performance of the dosage form: the contact stage and the consolidation stage (Figure 
1.2) [17,133]. Since mucoadhesive films are dosage forms that are brought in contact 
with the biological membrane by the patient, the contact stage is initiated by the patient. 
During the contact process the film will start dehydrating the mucus gel layer and will 
itself hydrate, initiating the interpenetration of the polymeric chains into the mucus and 
vice versa. For mucoadhesive films, which usually are designed to remain for prolonged 
times in contact with the buccal mucosa, a second stage, the consolidation stage, needs to 
take place in order to maintain this bond. In the consolidation stage the mucoadhesive 
strength will be determined by the polymer in the formulation, and how readily the 
dosage form hydrates upon contact with the mucus gel layer. This process is explained by 
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the dehydration theory, which explains that when a material capable of gelation, such as a 
mucoadhesive polymer in a buccal film, is brought into contact with an aqueous viscous 
colloid water will move until equilibrium is reached between the two layers [133,153]. 
The strength of the mucoadhesive bond will then be determined by the extent of 
intermixing that occurs after water migrates and reaches equilibrium. 
 
 
Figure 1.2. Contact and consolidation stages of mucoadhesion. Adapted from ref. [133]. 
Mucoadhesive films have been designed to remain in contact with the buccal 
mucosa for therapeutic purposes for prolonged periods of time. The measurement of the 
mucoadhesive strength and time of mucoadhesion have been described in parallel with 
formulation design since the very earliest publications in the field [49,69], this is further 
discussed in the following section. 
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1.4.2. Determination of mucoadhesion 
The earliest approaches to measure bioadhesion were indirect and provided an 
idea of the trend that different formulations followed. In these experiments, instead of 
measuring the force of adhesion, the studies were focused on determining the time of 
adhesion or retention time of the dosage form in various models [8,49]. In vitro 
experiments usually consist of attaching a film to a glass plate, or to the sides of a beaker, 
and a mechanical force is applied either by moving the plate or by stirring the media in 
the beaker [46,76,119,122]. The first approach is normally done by modifying a standard 
USP disintegration apparatus [71]. In these experiments, a suitable substrate is attached to 
the surface of a glass slab, which is connected with the mobile arm of the disintegration 
apparatus. The film is then allowed to adhere to the substrate and the time necessary for 
complete erosion or detachment is recorded as the in vitro residence time [46]. 
Conditions such as the medium composition, pH, temperature, salts addition, or nature of 
the substrate can be controlled [77] and will modify the results, hence it is important to 
report the conditions used to obtain reproducible data [11,90,92,94]. The second 
approach often used in the literature requires the adhesion of the film into a static surface, 
normally the side of a beaker, and detachment force is applied by the stirring media [76]. 
Modifications of this approach include the adhesion of a biological substrate to the side 
of the beaker, normally a non-keratinized tissue layer such as porcine buccal mucosa [78] 
to further mimic the physiology of the human buccal epithelium. Again, controlling the 
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composition of the media, temperature, pH, or the nature of the substrate (either  from a 
biological or synthetic source), will determine the final mucoadhesion or in vitro 
residence time [47,90,91,110]. 
Even though the measurement of the in vitro mucoadhesion or residence time 
provides information to optimize formulations, it does not elicit the real strength of the 
mucoadhesive bond. The first article to report on a peeling test for mucoadhesive buccal 
films was published by Guo in 1994. In these experiments a load cell is attached to the 
mobile section of the instrument and force of detachment is obtained and plotted against 
either distance or time. The mucoadhesion strength of films formulated with Carbopol® 
934P, HPMC, chitosan, or acacia gum was expressed as the maximum peeling strength or 
load using an texture analyzer, such as the Instron 4201 [69]. After this publication a 
number of other articles reported on the use of tensile testing instruments, such as the 
Instron for the measurement of bioadhesive properties. Li et al. were the first to publish 
the use of a biological membrane as the adhesive substrate for measuring mucoadhesion 
of buccal films [3]. Freshly excised rabbit buccal mucosa was glued onto a stainless-steel 
platform. Likewise, a buccal film sample was attached to another platform, and following 
the addition of a drop of water, the film and the substrate were allowed to adhere for a 
predetermined amount of time. The mucoadhesion strength was measured as the 
maximum applied force needed in order to detach the film from the substrate [3]. The 
development of the bench top texture analyzer that allowed for accurate measurement of 
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very small variations, as well as being able to control the contact force and time, 
increased the number of publications that reported on mucoadhesion and tensile 
properties of buccal films. The first report on the use of the TA.TX2® texture analyzer 
(Stable Micro Systems) to measure the mucoadhesion strength of buccal films utilized 
chicken pouch as the biological membrane upon which the films were allowed to adhere 
[72]. The instrument measures detachment forces from its mobile arm, which after 
normalizing is considered as adhesive forces and the maximum force is normally referred 
to as mucoadhesive force. The use of this type of texture analyzer for the measurement of 
mucoadhesion on different dosage forms, such as buccal tablets had already been 
published [102,157]. This previous research had focused on the importance of the method 
variables, which ultimately determine, together with the film and the substrate properties, 
the value of mucoadhesion strength [157]. Using the instrument depicted in Figure 1.3, 
the authors demonstrate that contact force, contact time, and the speed of probe 
withdrawal during the mucoadhesion experiment, all affect the experimental outcome. 
The contact time and contact force represent the effort the patient needs to provide in 
order to bring the dosage form in contact with the buccal mucosal surface, and allow for 
mucoadhesion at the “contact stage” mentioned previously. The contact time was found 
to be more critical in the affecting the mucoadhesive strength than the contact force. With 
the exception of an increase in contact time from 10 to 30 seconds, increasing the contact 
time significantly increased the measured mucoadhesive strength. However, the authors 
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demonstrated that increasing the contact force from 0.05 N to 0.1 N, or 0.5 N to 1.0 N did 
not significantly increase the mucoadhesive force [157]. Since the development of the 
mucoadhesive strength test by Wong et al., several modifications have been used to 
determine this parameter on buccal films [7,56,58,70,78,86,100,123,124]. Measuring the 
peak force needed to detach a biological substrate attached to a mobile probe, from a 
wetted mucoadhesive film at various sections of a film cast surface, has been used to 
demonstrate that the texture analyzer can be used to determination of mucoadhesion 
uniformity along the casting area [9]. This is particularly important since the few articles 
published in the literature account only for the drug content uniformity, and do not report 
any uniformity assessment of film functionality [74]. Some other approaches to measure 
mucoadhesion include the modification of different mass balance apparatuses to 
determine the detachment force from the mucoadhesive joint between the buccal film and 
usually a biological substrate [75,79,88,91,93–95,98,109,110]. The reader should note 
that there is no standardized mucoadhesion test in the literature, which makes the 
experimental conditions different from paper to paper so extrapolation and comparison of 
results should be cautious. Moreover, methods that rely on excised tissue are prone to 
exhibit larger standard deviations compared to in vitro conditions. 
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Figure 1.3. Mucoadhesion testing apparatus using the texture analyzer TA.XT2, modified 
from ref. [157]. 
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1.4.3. Determination of mechanical properties of mucoadhesive films 
Besides the important parameter of mucoadhesion strength and residence time of 
buccal films, the mechanical properties play a crucial role on the physical integrity of the 
dosage form [4]. Several values can be obtained from a regular stress-strain curve; 
however, most relevant to the study of buccal films are the tensile strength, the elongation 
at break, and the elastic modulus, also known as Young’s modulus [4,158]. The 
determination of the mechanical properties of a buccal film is usually based on the 
ASTM D882 method [159] and measured using instruments such as a texture analyzer. 
The tensile strength of a film is defined as the resistance of the material to a force tending 
to tear it apart [60–62,94,99,100,103,123,160], and normally identified as the maximum 
stress in the stress-strain curve and it can be computed in accordance to Equation 
(1)[161].  
 
ܶ݁݊ݏ݈݅݁	ݏݐݎ݁݊݃ݐ݄ ൌ ܨ݋ݎܿ݁ ܽݐ ݂݈ܽ݅ݑݎ݁ܥݎ݋ݏݏ െ ݏ݁ܿݐ݅݋݈݊ܽ ܽݎ݁ܽ ݋݂ ݐ݄݁ ݂݈݅݉ 
(1)
 
 
The elongation at break is a measurement of the maximum deformation the film 
can undergo before tearing apart and is calculated using Equation (2): 
 
ܧ݈݋݊݃ܽݐ݅݋݊	ܽݐ	ܾݎ݁ܽ݇ ൌ ܫ݊ܿݎ݁ܽݏ݁ ݅݊ ݈݁݊݃ݐ݄ ܽݐ ܾݎ݁ܽ݇ܫ݊݅ݐ݈݅ܽ ݂݈݅݉ ݈݁݊݃ݐ݄ ൈ 100 
(2)
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In general, elongation (or strain) will increase with an increasing content of 
suitable plasticizing agents in a given formulation [162]. 
Young’s modulus is an evaluation of the stiffness or how the film deforms in the 
elastic region [142]. It is defined in the initial elastic phase of deformation and is obtained 
from the ratio of applied stress and corresponding strain and can be computed from the 
slope of the stress-strain curve using Equation (3): 
 
ܻ݋ݑ݊݃ᇱݏ ݉݋݀ݑ݈ݑݏ ൌ ݈ܵ݋݌݁ ݋݂ ݏݐݎ݁ݏݏ െ ݏݐݎܽ݅݊ ܿݑݎݒ݁ܨ݈݅݉ ݐ݄݅ܿ݇݊݁ݏݏ ൈ ܥݎ݋ݏݏ െ ݄݁ܽ݀ ݏ݌݁݁݀ 
(3)
 
It has been described that soft and weak polymers have a low tensile strength, 
Young’s modulus and elongation at break; while a soft and strong polymer exhibits a 
moderate tensile strength, low Young’s modulus, and a high elongation at break 
[163,164]. Desired mechanical properties will vary depending on the formulation goals 
and the method chosen, but in general some examples of behaviors obtained from stress-
strain curves can be depicted, as shown in Figure 1.4 [162]. 
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Figure 1.4. Examples of behaviors observed in stress-strain curves in polymeric films 
(Adapted from ref. [162]). 
Tear resistance of a film is normally obtained from stress-strain curves but using 
very low rates of loading (displacement of 51 mm/min). It is a complex function of the 
film ultimate resistance to rupture and is obtained from the maximum stress value and is 
reported as the correspondent force [2,165]. 
Finally, another test normally used and reported in the literature, is the 
determination of the folding endurance of the film. The test is performed by repeated 
folding the film at the same place until film failure [95]. A maximum of 300 times is 
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sometimes reported as a limit to the test [166], and the value is reported as the number 
times the film can be folded prior to rupture. 
1.5. ASSESSMENT AND ENHANCEMENT OF PERMEATION THROUGH THE BUCCAL 
MUCOSA 
1.5.1. Permeation rate determination 
Since the early research on the development of mucoadhesive buccal films, drug 
release from polymeric matrices have been well characterized and reported [54,69,113]. 
However, these studies were usually conducted using standard or modified dissolution 
apparatus, thus obtaining only an estimate of the rate of drug release from the film and 
not penetration rates through the buccal mucosa. Although it is well known that the 
bioavailability of drugs administered through the buccal route can be highly impacted by 
the permeation rate through the biological membrane, in vitro characterization of 
permeation properties has not been addressed until recently 
[7,52,71,77,80,85,91,94,96,110,114]. The experimental procedure typically involves the 
use of a diffusion cell, which can be either vertical, such as a Franz diffusion cell, or 
horizontally oriented, such as the side-by-side or Ussing diffusion cell. In these cells a 
donor compartment is separated from a receptor compartment by a membrane acting as 
the mucosa model. Conditions such as temperature, composition of the receptor and 
donor media, pH, cell dimensions, and hydrodynamic conditions are normally controlled 
in these experiments.  
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One of the most important components is the membrane that separates the donor 
from the receptor chambers. It is reported that these membranes may come from either 
synthetic or biological sources. Synthetic membranes provide a consistent porous path 
and thus can be used to effectively performance rank different formulations [50]. As a 
substitute for excised animal buccal mucosa, synthetic membranes decrease the large 
sample to sample variation due to the high structural homogeneity they exhibit, compared 
to ex vivo methods [167,168]. However, their use is limited due to the absence of a 
stratified non-keratinized epithelium that is present in the buccal mucosa. Depending on 
the physicochemical characteristics of the drug, permeation of different absorption 
pathways and interactions with the epithelium will be found, all of which are not 
applicable in synthetic membranes [168]. Thus, freshly excised mucosa is widely used as 
the barrier membrane in diffusion studies since it most closely resembles the in vivo 
permeation scenario [27,169]. Consequently, the selection of the animal model is of high 
importance due to the anatomical differences observed in buccal mucosa among species. 
Even though rodents are normally the first choice as animal models, their use for buccal 
delivery purposes is very limited due to their keratinized buccal membrane (Figure 1.1). 
The best model among rodents is the rabbit due to its para-keratinized buccal membrane 
[170]. In general, large animals exhibit a non-keratinized stratified buccal mucosa, which 
is more similar to the anatomy of the human, and is differentiated mostly in the thickness 
and permeation properties of the tissue [12]. In terms of availability, thickness, and 
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permeation properties, the swine buccal mucosa appears to be the most suitable animal 
model, and this is demonstrated widely in the literature [71,77,94,96,110]. Other potential 
models to study buccal permeation are the dog and the monkey but due to availability, 
cost, or ethical concerns they are not commonly used in buccal film research [12]. 
Another crucial consideration for the permeation test is the tissue storage and isolation 
before the experiment. This is often overlooked and not reported hindering an adequate 
interpretation of results. Even though the permeation barrier is believed to be located in 
the upper one third or one quarter of the epithelium, the connective tissue should be 
removed before the test in order to prevent differences in permeating path, which could 
translate into large sample to sample variations [169]. The use of chemical, thermal, and 
enzymatic treatments for removing the connective tissue are not considered to be the 
methods of choice, as they have either demonstrated to alter permeation, or are topics of 
debate as to their applicability [169,171]. Thus, surgical removal of the connective tissue 
is the preferred treatment and it is normally performed right before the permeation 
experiment by soaking the tissue in phosphate buffer at controlled pH [52,94,110,114]. 
Integrity of the epithelium before and after the experimental procedure is desired, and it 
is normally determined by measuring permeation of a non-permeating molecule 
[172,173] or by light microscopy [114,169]. 
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From a more practical standpoint, the permeability coefficient (P) and the 
diffusion coefficient (D) are derived from the diffusion process described in one 
dimension by Fick’s second law transformed and simplified to Equation (4) [169]. 
ܨ ൌ ܲ ∙ ܵ
஽ܸ
ቈݐ െ ݄
ଶ
6ܦ቉ 
(4)
Where the fraction of drug transported (F) is obtained from the relationship 
between P, the surface area of the tissue (S) (the opening of the diffusion cell), the 
volume of the donor compound (VD), time (t), the effective length of buccal mucosa the 
drug must traverse (h), and D. During a standard diffusion study, P is obtained from the 
slope of the fraction permeated versus time curve while D is calculated from the x-axis 
intercept as seen in Equation (4). 
1.5.2. Permeation enhancers in mucoadhesive buccal films 
Due to the limited permeability of the buccal mucosa compared to that of the 
intestinal epithelium, the use of permeation enhancers has been widely investigated in 
dosage forms for buccal delivery [18]. Permeation enhancers are pharmaceutical 
ingredients included in a formulation in order to improve the permeation characteristics 
of the drug through the target mucosa and are desired to demonstrate null or very limited 
toxicity or tissue damage [174]. It is known that permeation through the buccal 
epithelium occurs either by the transcellular or paracellular route as previously described, 
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but in general the overall process can be considered to be governed by passive diffusion 
[175] and modeled by Fick’s first law of diffusion, as shown [18] in Equation (5): 
ܬ௦௦ ൌ ܦ ∙ ܭ݄ ∙ ܥ஽ 
(5)
Where, the steady state flux (Jss) is determined by D of the drug within the buccal 
mucosa, the partition coefficient (K) of the drug between the buccal mucosa and the 
donor chamber solution, the concentration of drug in the donor compartment (CD), and h. 
Most of the permeation enhancers will alter the mucosa or the permeating molecule in 
such a way that D or K or both can be enhanced. Based on the physicochemical 
characteristics of the drugs, delivery using different permeation enhancers will be 
suitable. As seen in Table 1.2, permeation enhancers used in the buccal mucosa favor the 
paracellular route of drug absorption, or it has been suggested that they work in such a 
way. Even though many permeation enhancers have been described to be effective in the 
buccal mucosa [176–179], few buccal film formulations have studied the inclusion of 
such agents in their compositions. One of the earliest studies with penetration enhancers 
in the formulation included the use of glycyrrhizic acid in lidocaine containing HPC 
mucoadhesive buccal films. In this study, the authors found a direct relationship between 
an increase of glycyrrhizic acid content and the penetration rate through freshly excised 
hamster buccal epithelium. Thus in this example, a permeation enhancement effect of 
glycyrrhizic acid in the presence of the active ingredient was seen through the keratinized 
rodent epithelium [63]. In a previous report that same authors hypothesized that the effect 
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of glycyrrhizic acid is due to the formation of an amorphous state of lidocaine in the 
dosage form [54]. In another study, oleic acid and propylene glycol monolaurate were 
used as penetration enhancers for lidocaine hydrochloride in mucoadhesive buccal films 
made of Carbopol® 971P. The permeation studies for these lidocaine films were 
performed using Franz diffusion cells, and utilizing porcine buccal mucosa as the model 
membrane. After demonstrating that oleic acid as the penetration additive exhibited the 
best enhancing characteristics, the authors performed in vivo studies and proved that 
incorporation of oleic acid did not produce any discernible redness or irritation of the 
buccal mucosa after 8 hours of exposure [114]. More recently, films formulated with 
chitosan and PVP K30 as mucoadhesives with different permeation enhancers were 
tested to determine the highest increase in diffusion of sumatriptan succinate through 
porcine buccal mucosa [94]. It was determined that the use of dimethyl sulfoxide in the 
highest concentration studied (3% w/w) exhibited the best enhancing characteristics 
compared to transcutol 5% w/w or polysorbate-80 1% w/w. The addition of penetration 
enhancers did not modify the physicochemical properties of their formulations, making 
them ideal for the manufacture of improved mucoadhesive buccal films. 
  
 
37 
 
Table 1.2. List of permeation enhancers used for buccal delivery.  
Permeation 
enhancer 
Proposed mechanism of 
action 
Preferred route 
enhanced Examples 
 
Surfactans 
 
 
Lipid extraction from the 
mucosa 
 
 
Paracellular 
 
Sodium dodecyl sulfate 
[180] 
Sodium lauryl sulfate [181] 
Bile salts 
 
Lipid extraction from the 
mucosa 
Paracellular  sodium glycocholate 
[45,182] 
sodium taurocholate, sodium 
glycodeoxycholate, and 
sodium taurodeoxycholate 
[45] 
sodium deoxycholate [85] 
 
Fatty acids Increase fluidity of 
intercellular lipids 
Paracellular* Oleic acid [114,183,184] 
eicosapentaenoic acid and or 
docosahexaenoic acid [184] 
 
Ethanol  Disrupt arrangement of 
intercellular lipids 
 
Paracellular*  [185,186] 
Chitosan Increase retention time of 
drug in contact with mucosa 
and disruption of intercellular 
lipid organization 
 
Paracellular*   
* No definitive evidence 
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1.6. CONCLUSION 
The buccal mucosa is a promising delivery route for drugs that need to avoid the 
gastrointestinal tract due to degradation by the gastric pH, intestinal enzymes, or due to a 
substantial hepatic first pass effect. It can also be an alternative to skin, pulmonary, or 
nasal delivery. The physiology of the buccal mucosa allows for the penetration of active 
substances and due to its rapid cellular turnover and recovery, the use of penetration 
enhancers is possible. Moreover, recent publications have proved that the addition of 
permeation enhancers on buccal films did not hinder the manufacturing capability nor 
imposed mucosal irritation or toxicity. In the lab scale, film casting remains as the 
manufacturing process of choice. Nonetheless, hot-melt extrusion has been successfully 
explored as a method for obtaining mucoadhesive buccal films for the delivery of THC 
through the buccal mucosa. Many possibilities remain in the design of buccal films, 
including their recent application as platforms for the delivery of nanoparticles. In this 
dissertation the use of particulate material in films is described. Insulin-loaded 
nanoparticles were developed and the physicochemical implications they impose on films 
were investigated and are depicted below.   
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2. Research Outline 
2.1. OVERALL OBJECTIVE 
In this dissertation it was hypothesized that films could be manufactured to 
contain insulin in a stable, active, and uniformly distributed form for its buccal delivery. 
Insulin was sought to be formulated into particles in such a way that it would keep its 
activity and high yield at the end of the process. For this, the goal of this project was to 
establish both a polymer platform (i.e. a film) that could serve as a buccal solid vehicle 
for macromolecular actives (e.g. insulin). This research sought to study a myriad of 
materials for the manufacture of films for buccal delivery. This work describes, in 
contrast to what has been assumed in the literature, some hydrophobic materials such as 
polymethacrylates exhibit excellent mucoadhesion, and they were further explored in 
conjunction with the particle manufacturing process. In that regard, another objective was 
to develop a nanoparticle manufacturing process for a variety of macromolecules. For 
this goal, bovine serum albumin (BSA), lysozyme (Lys), and insulin (Ins) were studied as 
models to render high yields, high activity, and narrow nanoparticle polydispersity.  
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2.2. SPECIFIC OBJECTIVES 
2.2.1. Development of Water-Swellable Polymethacrylate Mucoadhesive 
Buccal Films Containing Caffeine Particles 
After preliminary work on several materials for the manufacture of films for 
buccal delivery, it was sought to further investigate the polymethacrylate derivatives 
commercialized as Eudragit® RLPO (ERL) and RSPO (ERS). We successfully developed 
films with adequate mechanical properties evaluated in vitro by analyzing stress versus 
strain profiles of film strips were successfully developed. Also for the first time ERL was 
described as being an excellent mucoadhesive polymer in vitro, especially by comparing 
its performance with typically referred to as mucoadhesive polymers in the literature, 
such as Carbopol® 974P and polycarbophil. By imaging cross sections by scanning 
electron microscopy of the films, the ultrastructure was explored and a correlation 
between size of caffeine particles and mucoadhesive and mechanical performance was 
established. Furthermore, various release profiles could be achieved with all formulations 
studied, more specifically for ERS. Caffeine release was found to be governed by first 
order release kinetics and also affected by the size of caffeine particles. Thus we were 
able to manufacture films for buccal delivery and also establish a particle size cutoff for 
optimal mechanical, mucoadhesive, and release performance. 
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2.2.2. A Design of Experiments to Optimize a New Manufacturing Process 
for High Activity Protein-Containing Submicron Particles 
To incorporate macromolecules in the films that we had obtained, we sought to 
develop a novel manufacturing process for high activity and yield of macromolecule-
containing submicron particles. The need for such particle size had been described in the 
previous chapter based on the physicochemical properties that particles impart to films. 
Based on an antisolvent co-precipitation process, the effect of various mixing techniques 
and various means of adding the aqueous phase into the organic phase were studied. The 
effect of a variety of organic solvents as the antisolvent phase; type and amount of the 
amino acidic core material of particles; and the use of surfactants both in the aqueous and 
the organic phase were also investigated. Ultimately, it was found that the combined use 
of high energy mixing by means of a sonicator, stabilizing surfactants in the organic 
phase, and increased surface area for addition of the aqueous phase by means of 
nebulization allowed for submicron sized and nanosized batches of particles coated with 
either BSA or Lys on crystalline cores of D,L-valine. To further optimize the novel 
method, multiple designs of experiments (DoE) were performed in order to define the 
critical processing parameters. Optimized conditions allowed for high yields, high 
activity, as well as control over polydispersity of submicron sized particles. 
 
2.2.3. Protein-coated Nanoparticles Embedded in Films for Buccal Delivery 
As initially planned, it was sought to combine both research efforts into protein-
loaded films for buccal delivery. The need for the addition of the macromolecules in a 
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more stable form compared to solid solution was sought to be addressed with the use of 
the novel method of manufacture of nanoparticles. This method was further optimized at 
this stage by studying the controlling effects of pH over size and polydispersity of 
protein-coated nanoparticles (PCNP). High yield and high activity Lys-containing 
particles were obtained and further formulated into films for buccal delivery. By using 
ERL as the film forming matrix, PCNP-loaded films were successfully manufactured and 
evaluated for their physicochemical properties. Excellent mechanical and mucoadhesive 
properties were achieved in ERL films and Lys release was found to be tunable by the 
addition of the water-swellable and soluble HPMC. Sustained release was observed over 
four hours and full activity of Lys was retained during this period of time.  
 
2.2.4. Development of Films of Insulin-Coated Nanoparticles for use in 
Buccal Delivery 
Finally to achieve the goal of this dissertation, films for buccal delivery of insulin 
were developed. The method of particle manufacture was adapted to obtain Ins-coated 
nanoparticles (ICNP) with high yield, stability upon storage, and narrow polydispersity. 
These particles were then formulated into films for buccal delivery applications. Films 
were characterized for their mechanical and mucoadhesive performance and ERL was 
found to render films with optimal properties. Ins release was found to be similar for ERL 
and ERL-HPMC combinations and the films were further analyzed for permeation 
through a human buccal mucosa model. Three dimensional models of human model 
mucosa obtained by differentiation of normal human keratinocytes were used to study the 
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permeation characteristics of the Ins-loaded films. Franz diffusion and well plate 
diffusion studies were conducted and an enhancement effect could be evidenced by 
including Ins in films as solid dosage forms in comparison to a control solution of insulin.  
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3. Development of Water-Swellable Polymethacrylate Mucoadhesive 
Buccal Films Containing Caffeine Particles2 
ABSTRACT 
The aim of this work was to investigate the influence of particles on the properties 
of polymethacrylate films intended for buccal delivery. A solvent casting method was 
used with Eudragit RS and RL (ERS and ERL, respectively) as film forming rate 
controlling polymers, with caffeine as a water soluble model drug. The physicochemical 
properties of the model films for a series of formulations with increasing concentrations 
of caffeine were determined in terms of morphology, mechanical and mucoadhesive 
properties, drug content uniformity, and drug release and associated kinetics. Typically 
regarded as non-mucoadhesive polymers, ERS and mainly ERL, were found to be good 
mucoadhesives, with ERL01 exhibiting a work of mucoadhesion (WoA) of 118.9 μJ 
which was about 5-6 times higher than that observed for commonly used mucoadhesives 
such as Carbopol 974P (C974P, 23.9 μJ) and polycarbophil (PCP, 17.4 μJ). The 
mucoadhesive force (MAF) for ERL01 was found to be significantly lower yet 
comparable to C974P and PCP films (211.1 vs. 329.7 and 301.1 mN, respectively). 
Inspection of cross-sections of the films indicated that increasing the concentration of 
caffeine was correlated with the appearance of recrystallized agglomerates. In conclusion, 
caffeine agglomerates had detrimental effects in terms of mucoadhesion, mechanical 
                                                 
2 Significant portions of this chapter were taken from: J.O. Morales, R. Su, J.T. McConville, The Influence 
of Recrystallized Caffeine on Water-Swellable Polymethacrylate Mucoadhesive Buccal Films, AAPS 
PharmSciTech. (2012) In Press. 
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properties, uniformity, and drug release at large particle sizes. ERL series of films 
exhibited very rapid release of caffeine while ERS series showed controlled release. 
Analysis of release profiles revealed that kinetics changed from a diffusion controlled to 
a first order release mechanism.  
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3.1. INTRODUCTION 
The development of films as mucoadhesive dosage forms for buccal delivery of 
actives is a field that continues to grow due to unique characteristics that are 
advantageous for drug delivery [1–3]. In physical terms, films may be preferred over 
tablets due to size, flexibility and comfort [1]. As adhesive dosage forms, films can be 
formulated for a variety of delivery regimens as well providing the opportunity for 
locally treating diseases by direct application. The buccal route also offers interesting 
advantages over the oral route mainly for molecules that could be rendered inactive 
through the gastrointestinal tract, i.e. peptides and proteins. In addition, rapid absorption 
and peak concentration can be elicited through the venous system that drains from the 
cheek [4]. 
Most mucoadhesive films for buccal delivery are manufactured by the solvent 
casting technique regardless of the growing body of literature describing film 
manufacture by hot-melt extrusion [5–8]. The solvent casting technique is scalable, 
simple to execute, and cost-effective in the laboratory scale [3]. However this method of 
manufacture is limited by environmental concerns, due to the use of organic solvents, and 
additionally long processing times that can impose budget limitations [8]. The solvent 
casting technique involves the solubilization or dispersion of all the ingredients in a 
suitable solvent system and then controlled drying to yield the drug-containing films. 
Arising from manufacturing challenges, a recent publication has surveyed the literature 
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regarding drug content uniformity and revealed the lack of reports addressing this issue 
[9], which is a basic yet an utterly important variable in film manufacture. In the 
manufacture of films, cast sheets are cut into unit doses which could result in high 
variability of drug content if this is not addressed adequately during the developmental 
stages of the formulation. The main concern raised in the literature is the appearance of 
agglomerates upon drying of films [10]. This was attributed to long drying times that 
allow for attractive forces between molecules to build up and result in the formation of 
agglomerates and was dealt with the addition of viscosing agents that could prevent 
agglomeration during drying. In an alternative to this strategy, Perumal et al. (2008) 
created casting trays that would allow for the manufacture of unit doses without the need 
to cut strips from a cast sheet. Even though, this method improves results in terms of 
content uniformity it does not address uniformity among the surface of the single unit, 
and it could be impractical for scaling up purposes [9]. 
Several excipients can be used to control for different properties of the films. 
Usual materials can include but are not limited to film forming polymers, mucoadhesive 
polymers, backing polymeric layer, plasticizers, taste masking or sweetening ingredients, 
stabilizers, and rate controlling polymers [3,11,12]. However, the polymer system that 
controls the release of the active is one of the most prominent areas of development of 
films. Most recent reports on the use of polymethacrylates as film forming polymers 
feature them mainly as a drug controlling materials in the formulation [13–15]. In these 
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studies, Eudragits have either been part of the drug containing layer or as part of the 
release rate controlling layer. Only few articles have described the use of Eudragits as a 
mucoadhesive material [16,17]. Eudragit RS (ERS) and Eudragit RL (ERL) are 
polymethacrylates possessing a quaternary ammonium group branching out of their 
polymer backbone. The presence of these cationic groups allow for water permeability, 
resulting in swelling of the polymer matrices. In a systematic comparative study, both 
ERS and ERL were found to be non-mucoadhesive materials with very low adhesion, 
similar to that determined in the same study for alginic acid and chitosan [18], both of 
which are normally considered mucoadhesive materials [19]. Conversely, a more recent 
publication by Perumal et al. (2008) has shown that ERS films can elicit high 
mucoadhesive properties measured both in terms of maximum detachment force and 
work of adhesion [17]. Moreover, films containing only ERS exhibited increased 
mucoadhesive properties compared to those found in ERS-chitosan films. On another 
study, ERL was found to be the least mucoadhesive material and the polymer that 
showed the lowest swelling capacity in comparison to HPMC-E15, sodium 
carboxymethyl cellulose (SCMC), and Carbopol 934P (C934P). However, in the same 
study the in vitro residence time was found to be 1.75 hours, comparable to that observed 
for HPMC-E15 [20]. One investigation that utilized Eudragit L100 (EL100) and S100 
(ES100) as mucoadhesive materials required prior modification into sodium and 
potassium salts [16]. The modified salt form was used to enhance the mucoadhesive 
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properties of these polymethacrylates by promoting the ionized state of the polymer. 
Being ERL and ERS cationic polymethacrylates, their mucoadhesive properties could be 
explained by the positive charge in the polymer structure.  
In this investigation we sought to evaluate systematically the performance of ERS 
and ERL as mucoadhesive polymers to be suitable for the delivery of the water soluble 
model drug caffeine. A series of films containing increasing quantities of caffeine 
revealed the appearance of agglomerates and the effect of these was evaluated in terms of 
mucoadhesion as well as content uniformity, mechanical properties, drug release, and 
morphology. 
3.2. MATERIALS 
Eudragit RSPO and RLPO (ERS and ERL) were kindly donated by Evonik 
Industries (Essen, Germany). Carbopol® 974P (C974P) and Noveon® AA-1 
Polycarbophil (PCP) were donated by Lubrizol Advanced Materials (Cleveland, OH). 
Triethyl citrate (TEC; Morflex Inc., Greensboro, NC), mucin (Spectrum Chemical, New 
Brunswick, NJ), and caffeine (CAF, Sigma-Aldrich, St. Louis, MO) were purchased and 
used as received. All other chemicals used were of analytical or reagent grade. 
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3.3. METHODS 
3.3.1. Preparation of films 
For ERS and ERL series of films, polymers were firstly dissolved in an 
acetone:isopropanol (4:6 ratio) solvent system and then 10% w/w TEC was added as 
plasticizer. Increasing quantities of caffeine were added to yield solutions containing 1, 2, 
3, 4, or 5% w/w caffeine. Films made of both, ERS and ERL polymers were obtained for 
each concentration. These solutions were casted on PTFE plates and let to dry overnight 
at 40 °C to yield the final product. Films were peeled off and stored in aluminum foil 
sachets in a dessicator until characterization. To compare with conventional 
mucoadhesive materials, films containing C974P and PCP were manufactured similarly. 
Adequate amounts of the polymers were dissolved in ethanol and then cast in the same 
fashion as described above. 
3.3.2. Morphology of films 
To observe the ultrastructure of films, scanning electron microscopy (SEM) was 
performed on the surface and cross sections of films. Samples were obtained by a freeze 
fracture method to ensure clean-cut edges and to avoid plastic deformation (often 
resulting from mechanical cutting). Fragments of the surface of the film were frozen by 
submerging in liquid nitrogen and thus cracked by freezing. Pieces of the films were 
fixed on aluminum stubs by means of conductive carbon tape. A Cressington 208 HR 
 
74 
 
sputter coater (Cressington Scientific Instruments Ltd, Watford, UK) was used to coat 
samples with Pt/Pd to a thickness of 10–15 nm in a high vacuum evaporator. A Hitachi S-
5500 field emission scanning electron microscope (SEM, Hitachi High-Technologies 
Corp., Tokyo, Japan) was operated for imaging of coated particles. The electron beam 
voltage was kept at 2-5 kV to avoid structural deformation during imagining [21]. 
An energy dispersive spectroscopy detector (Bruker EDS Quantax 4010) installed 
in the SEM was used to analyze elemental distribution and 2-dimensional mapping of 
selected elements. Although caffeine and both Eudragit possess the same elements, the 
concentration of nitrogen in caffeine is higher and was used to elucidate caffeine-rich 
domains in cross-sections of films. 
3.3.3. Mechanical properties of films 
Using a TA.XTPlus texture analyzer (Stable Micro Systems, Godalming, UK) 
equipped with a 5Kg load cell, stress versus strain curves were obtained and the 
mechanical properties of film strips were determined. Briefly, rectangular strips of 1 x 5 
cm2 were cut and 1 cm on each end was held between clamps attached to the texture 
analyzer, leaving a testing area of 1 x 3 cm2 for determination of mechanical properties. 
The upper clamp (connected to the mobile arm of the texture analyzer) was moved 
upwards at a rate of 0.5 mm/sec until film failure. Stress is obtained from the force 
measurements obtained from the instrument divided by the cross-sectional area of the 
film, while strain is computed by dividing the increase in length by the initial film length. 
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From the plot, the tensile strength (TS) and the elongation at break (EB) are obtained 
from the peak stress and the maximum strain, respectively, also represented by the 
following equations [3]: 
 
ܶ݁݊ݏ݈݅݁	ݏݐݎ݁݊݃ݐ݄	ሺܶܵሻ ൌ ܲ݁ܽ݇	ݏݐݎ݁ݏݏܥݎ݋ݏݏ െ ݏ݁ܿݐ݅݋݈݊ܽ	ܽݎ݁ܽ	݋݂	݂݈݅݉ 
 
ܧ݈݋݊݃ܽݐ݅݋݊	ܽݐ	ܾݎ݁ܽ݇	ሺܧܤሻ ൌ ܫ݊ܿݎ݁ܽݏ݁	݅݊	݈݁݊݃ݐ݄	ܽݐ	ܾݎ݁ܽ݇ܫ݊݅ݐ݈݅ܽ	݂݈݅݉	݈݁݊݃ݐ݄ ൈ 100 
 
Additionally, the elastic modulus (EM) was obtained from the initial elastic 
deformation region in the stress vs. strain plot [22]. Since the rate of the mobile arm was 
constant during the test as well as for all different experiments, direct comparison of the 
slope in this region can be done. To further evaluate mechanical properties three 
additional parameters were computed from the conventional mechanical parameters 
obtained from the plot as follows [23]: 
 
ܶ݁݊ݏ݈݅݁	ݏݐݎ݁݊݃ݐ݄	ݐ݋	݉݋݀ݑ݈ݑݏ	ݎܽݐ݅݋ ൌ ܶܵܧܯ 
 
ܴ݈݁ܽݐ݅ݒ݁	ݏݑݎ݂ܽܿ݁	݁݊݁ݎ݃ݕ	ሺܴܵܧሻ ൌ ܶܵ
ଶ
2 ൈ ܧܯ 
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ܶ݋ݑ݄݃݊݁ݏݏ	݅݊݀݁ݔ	ሺܶܫሻ ൌ 23 ൈ ܶܵ ൈ ܧܤ 
 
3.3.4. Mucoadhesion of films 
Mucoadhesion tests were conducted on the texture analyzer equipped with a 5 Kg 
load cell. Briefly, films were held in the horizontal position and 5 μL of model mucus (a 
freshly made 2% w/v mucin solution) was placed on top of the film. This amount is 
sufficient to mimic the thickness of the average saliva thickness [24]. A 7 mm diameter 
stainless steel cylindrical probe was attached to the mobile arm of the texture analyzer 
and it was brought in contact with the film and mucin solution, held at an applied force of 
50 mN for 15 seconds and then withdrawn at a 0.5 mm/second rate. Mucoadhesive force 
(MAF) and work of adhesion (WoA) are obtained from the peak and the area under the 
curve in the force versus distance profile, respectively. 
3.3.5. Caffeine assay 
Caffeine concentration in samples obtained above was determined by UV 
spectroscopy using a μQuant microplate reader (Bio-Tek Instruments, Inc, Winooski, 
VT). Briefly, 300 µL aliquots were added in each well in the microplate in triplicates. UV 
absorbance was measured at 273 nm and the concentration was calculated from a 
calibration curve of a stock solution of caffeine. 
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3.3.6. Drug content uniformity 
To measure the average amount of drug loading in the films and to determine 
homogeneity among the cast surface, film samples were analyzed for caffeine content 
uniformity. Samples were cut to yield 1 x 1 cm2 squares and allowed to release caffeine 
for 24 hours in 15 mL phosphate buffer pH 6.8 in an orbital shaker at 20 °C. Aliquots 
from these vials were analyzed for caffeine content using the UV spectroscopy method 
described above. 
3.3.7. In vitro drug release 
Dissolution tests were conducted to determine drug release profiles from Eudragit 
films. A small vessel USP apparatus I (basket) was used for this purpose and 150 mL 
phosphate buffer pH 6.8 was used as dissolution media. Film were cut into 1 x 1 cm2 
samples and dissolved into each vessel with a rotating speed of 25 rpm at 37 °C. At 
intervals of 0, 0.25, 0.5, 1, 2, 3, and 4 hours 1 mL samples were withdrawn and replaced 
with 1 mL of fresh warm media. Caffeine concentration was determined as depicted 
above using a UV spectroscopy method of quantification. Comparison of the release 
profiles was performed using the similarity factor, f2 [25]. 
3.3.8. Kinetic analysis of release profiles 
Kinetic models were used to compare the release mechanisms from the various 
caffeine-containing films. The Higuchi [26], Korsmeyer-Peppas [27], and first order 
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kinetic models were used to fit the data and were compared on the basis of R2 adjusted 
[28] and the Akaike information criterion (AIC) [29]. The evaluation of the drug 
transport mechanism was addressed in accordance with the Korsmeye-Peppas model. 
3.3.9. Statistical analysis 
All statistical analyses were performed with the software Minitab Release 14® 
(Minitab Inc., State college, PA). One-way ANOVAs were used for multiple 
comparisons and Tukey's post-hoc pairwise comparisons were performed to compare 
which results led to significant differences. All values are reported as the mean and 
standard deviation of the mean in parenthesis. For the evaluation of the kinetics models 
and calculation of adjusted R2 values the software Origin® 8.0 (Northampton, MA) was 
used to perform the non-linear regressions for each equation. 
3.4. RESULTS AND DISCUSSION 
3.4.1. Morphology of films 
SEM images shown in Figure 3.1 and 3.2 reveal that increasing the concentration 
of caffeine in both ERS and ERL films leads to an increasing appearance of agglomerates 
in cross sections of films obtained by freeze fracture. A survey of cross sections reveals 
that the use of ERS leads to a higher quantity and larger size of these agglomerates at 
similar concentrations of caffeine compared to those seen in ERL films. For example, 
ERS03 reveals a larger number of the needle-like agglomerates compared to ERL03 
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(Figure 3.2). In addition, ERS04 reveals the appearance of larger agglomerates possibly 
composed of aggregation of the needle like caffeine crystals observed at lower 
concentrations, while ERL04 still shows only needle like agglomerates.  
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Figure 3.1. SEM images of ERS and ERL films at various concentrations of caffeine. Bar 
represents 30 μm. 
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Figure 3.2. SEM images of ERS and ERL films at various concentrations of caffeine. Bar 
represents 10 μm. 
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EDS mapping of nitrogen (Figure 3.3) on SEM scan fields revealed that the 
agglomerates consist of caffeine and appear to have an organized crystalline structure, 
which is also appreciated at higher magnification micrographs obtained for formulations 
with higher content of caffeine (Figure 3.2). Even though, the polymer structure possess 
nitrogen atoms branching out of the backbone, the density of nitrogen atoms is higher in 
the caffeine molecule than the polymer, thus for the same time of detection of X-rays 
emitted from the field of view of the sample, the bulk of the signal can be attributed to 
caffeine [30]. The shape of the agglomerates observed in cross-sections of the films is 
also consistent with caffeine crystals shapes reported in the literature. It has been reported 
in the literature that when recrystallized from organic solvents, anhydrous caffeine 
crystals can adopt different space groups in a rhombohedral lattice system including but 
not limited to R3c and R3 [31,32]. These space groups result in hexagonal prisms, which 
concur with the SEM observations. The difference in the extent of caffeine 
recrystallization and size and number of agglomerates can be attributed to the differences 
in hydrophillicity elicited by both ERS and ERL [33]. Both, ERS and ERL, are pH 
independent and insoluble but swellable in water polymers. This is due to the quaternary 
ammonium groups that branch out of the polymethacrylate backbone of the polymer 
structure. The ammonium groups are present as salts and allow for swelling of the 
polymer. ERL is the more permeable polymer due to its content of about 10% of the ionic 
functional groups, while the content for ERS is approximately 5% [34]. Therefore, ERL 
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can solubilize to a higher extent than ERS, and caffeine in the polymer matrix 
increasingly retards the appearance of large agglomerates with increasing concentrations. 
A similar effect has been observed by Omari et al. (2004) where the interaction between 
lactic acid and ERL and ERS were compared [35]. Lactic acid-containing ERL films 
revealed a higher extent of interaction by differential scanning calorimetry (DSC) and 
nuclear magnetic resonance (NMR) studies. This effect was attributed to the higher 
hydrophillicity featured by ERL compared to ERS allowing for a further ionic interaction 
with the acid. This effect also accounted for an increase in drug permeation when release 
of paracetamol was studied. It was found that lactic acid clearly modified the release in 
ERL due to the higher extent of interaction as opposed to ERS films in which the 
modification of permeation was less pronounced. 
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Figure 3.3. SEM images merged with EDS mapping for nitrogen (in green) showing that 
caffeine is highly concentrated in the crystalline agglomerates found in 
ERS05 and ERL05. Bar represents 10 μm. 
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3.4.2. Mechanical and mucoadhesive properties 
The mechanical properties of a film as a solid dosage form are of great 
importance since they account for the ability of the film to withstand various sources of 
stress. First, films need to withstand the stress imposed by the manufacturing, handling, 
and administration [17]. Additionally, films for buccal delivery need to be able to remain 
in contact with the mucosa for as long as the delivery of the active is ongoing [36]. This 
involves mechanical stress originating from various mouth activities. Therefore, films are 
preferred to exhibit a relatively high TS, EB, and a low EM [36]. In addition, regarding 
derived mechanical parameters, a relatively high TS/EM, RSE, and TI are desired 
[23,35]. 
From stress vs. strain curves, TS, EB, and EM were obtained and the derived 
magnitudes of TS/EM, RSE, and TI were computed for each sample and are summarized 
in Table 3.1 and 3.2. TS/EM is a measure of the level of internal stress in a film. The 
larger its value the higher the film crack resistance. RSE is also utilized to estimate crack 
resistance and is approximated from the surface energy of the film. Finally, TI is an 
estimation of energy absorbed per unit volume of film under stress [23]. In Table 3.1, it 
can be evidenced that films from the ERL series have a significantly lower TS and EM, 
but a higher EB than each of the corresponding ERS film, indicating that ERL is a softer 
and more elastic material than ERS. However, when both TS and EB are taken into 
account as TI we can observe that the increase in EB for ERL compensates the decrease 
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in TS yielding tough films at all concentrations of caffeine except for ERL05. 
Additionally, analysis of TI also reveals that ERS04 and ERS05 are less tough films, 
which is not evident by a direct analysis of conventional mechanical parameters [35]. 
Results of TS, EB, and EM indicated a significant difference on both ERS05 and ERL05, 
as well as ERS04 with respect of EB. As discussed above, as concentration of caffeine 
increases the capacity of the polymer to dissolve the drug content reaches a saturation 
point allowing for recrystallization. It has been suggested in the literature that 
unsolubilized drug, which in our case would result in recrystallization, can physically 
interrupt the polymer matrix resulting in hard and brittle films [37]. This is also 
consistent with inspection of ERS04 micrographs in which we can observe large 
agglomerates, similar to those found in ERL05. 
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Table 3.1. Mechanical properties of formulations from ERS and ERL series. Values are 
represented as average and standard deviation in parenthesis. 
Formulation Tensile Strength /N/mm2 
Elongation at Break  
/% 
Elastic Modulus 
/N/mm2/% 
ERS01 5.71 (1.72)a 142.19 (35.46)ab 1.19 (0.46) 
ERS02 3.62 (0.61) 162.40 (44.06)cde 1.18 (0.04) 
ERS03 4.16 (0.86) 82.88 (20.74)c 1.33 (0.26) 
ERS04 4.04 (0.83) 35.30 (6.24)ad 1.27 (0.36) 
ERS05 2.48 (0.14)a 35.82 (17.99)be 0.80 (0.09) 
ERL01 1.51 (0.19)ab 233.04 (23.85)a 0.43 (0.05)ab 
ERL02 1.17 (0.13)acd 262.21 (34.06)b 0.34 (0.05) 
ERL03 0.75 (0.06)bcef 275.23 (35.84)cd 0.24 (0.03)a 
ERL04 1.26 (0.17)e 221.83 (30.38)ce 0.43 (0.04) 
ERL05 1.51 (0.14)df 93.41 (9.65)abde 0.63 (0.07)b 
a, b, c, d, e, f: Among parameters and between series of formulations, statistically significant differences 
are paired by the same letters (p<0.01). 
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Table 3.2. Derived mechanical parameters calculated from conventional mechanical 
properties derived from a Stress vs. Strain plot. Values are represented as 
average and standard deviation in parenthesis. 
Formulation TS:EM %-1 
Relative Surface Energy 
N/mm2·% 
Toughness index 
N/mm2·% 
ERS01 4.98 (0.84)a 13.90 (3.23)abcd 515.88 (38.39)abc 
ERS02 3.23 (0.53)a 6.25 (1.95)a 391.16 (116.40)def 
ERS03 3.14 (0.46) 6.60 (1.97)b 222.07 (5.69)adg 
ERS04 3.35 (1.14) 6.91 (3.27)c 96.82 (34.12)be 
ERS05 3.16 (0.54) 3.95 (0.91)d 58.53 (28.48)cfg 
ERL01 3.31 (0.65) 2.38 (0.71) 233.04 (27.10)ab 
ERL02 3.29 (0.23) 1.80 (0.07) 204.80 (33.14)cd 
ERL03 3.14 (0.71) 1.17 (0.37) 136.80 (8.07)ac 
ERL04 2.94 (0.57) 1.88 (0.63) 186.94 (41.36)e 
ERL05 2.44 (0.39) 1.86 (0.45) 94.53 (15.45)bde 
a, b, c, d, e, f, g: Among parameters and between series of formulations, statistically significant differences 
are paired by the same letters (p<0.01). 
 
Being ERS and ERL both water-insoluble polymers they are normally regarded in 
the literature as non-mucoadhesive materials [16,18]. The results observed in Figure 3.4 
and 3.5 reveal that the mucoadhesive properties of ERS are very limited both in terms of 
MAF and WoA and comparatively always lower than their ERL counterparts. Only when 
caffeine is in a solid solution with the polymer (ERS01) a significantly higher MAF of 
65.04±6.44 mN is found compared to other ERS formulations (p<0.05), although in 
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comparison with the more hydrophilic ERL MAF is much lower (211.11±24.29 mN for 
ERL01). Conversely, ERL is highly mucoadhesive under the test conditions utilized here. 
This is not surprising when we consider that even though the polymers are water-
insoluble they are swellable in water due to the presence of the quaternary nitrogen 
groups. The ability of hydrophilic polymers to swell in water is a common characteristic 
in materials generally recognized as mucoadhesives and is consistent with various of the 
theories of mucoadhesion [38–40]. In saliva, the most relevant component to 
mucoadhesive interactions is mucin which is the main component in our saliva model. 
Mucins are composed of a protein core and carbohydrate side chains, which are 
responsible for the non-covalent bonding that occurs when a mucoadhesive material is 
brought in contact with mucosa [41,42]. According to the diffusion theory [38] 
interpenetration and entanglement between polymer chains (mucin and mucoadhesive 
material) is believed to be the main reason for mucoadhesive bonding. Control 
experiments utilizing only the mucus model and the stainless steel probe revealed very 
little contribution of the mucus-steel interface to the measured force (MAF equals 
12.96±1.95 mN and WoA equals 2.70±0.28 μJ). Use of the same experimental set up 
revealed that the extent of mucoadhesion found with ERL is comparable to that of typical 
mucoadhesive materials, namely C974P and PCP (Figure 3.5) [19,43]. Particularly, the 
formulation exhibiting the highest MAF (ERL01) is about 30% significantly lower than 
both C974P and PCP (211.1 vs. 329.7 and 301.1 mN, respectively). It was found however 
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that the WoA was about 80% significantly higher than conventional mucoadhesive 
materials (118.9 vs. 23.9 and 17.4 μJ), demonstrating that a highly swellable polymer, 
such as ERL, regardless of being water-insoluble, can elicit strong mucoadhesiveness 
based on its capacity for entanglement. The various films in the ERL series exhibit high 
WoA and high MAF when the drug is solubilized in the polymer or small micron size 
agglomerates are found (ERL01-ERL04); however, the highest concentration of caffeine 
that renders large recrystallized agglomerates results in a significant decrease of both 
mucoadhesive variables. This is also in correlation with findings discussed above in 
terms of morphology and mechanical properties.  
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Figure 3.4. Mucoadhesive properties of ERS films: Maximum Adhesive Force () MAF, 
with non-significant differences indicated in pairs of letters (a-f); and Work 
of Adhesion (■) WoA, with non-significant differences indicated in pairs of 
roman numerals (i-v). 
The consistent decrease of mucoadhesive and mechanical properties as 
concentration of caffeine increased led us to investigate the existence of a correlation 
between the two. After a linear regression analysis, the data shows a strong positive 
correlation between EB and MAF regardless of the polymer type (r = 0.9). Although 
further investigation would be required on this topic, particularly isolating variables to 
allow for a more accurate evaluation, there could be a connection between elasticity of 
films and measurement of mucoadhesion by the method utilized here. This could be 
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explained as follows: stiff films will not be able to deform enough to allow for a 
prolonged contact during detachment; therefore, resulting in less force needed to break 
the detachment. More ductile films will be able to support the mucoadhesive bond for 
longer and will require larger inputs of energy for detachment. This is further 
corroborated by a strong correlation between EB and WoA for ERL (r = 0.9) indicating 
the possibility for such interaction between mechanical and mucoadhesive properties for 
films as dosage forms. 
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Figure 3.5. Mucoadhesive properties of ERL films and C974P and PCP as conventional 
mucoadhesive polymers: Maximum Adhesive Force () MAF, with non-
significant differences indicated in pairs of letters (a-g); and Work of 
Adhesion (■) WoA, with non-significant differences indicated in pairs of 
roman numerals (i-vi). 
3.4.3. Drug content uniformity, drug release, and kinetics 
The increase of caffeine in films was correlated with an increase in heterogeneity 
of drug distribution in the casting surface of films as can be depicted in Figure 3.6. Up to 
a content of 2% caffeine, films exhibit very high drug content uniformity (relative 
standard deviation ≤1.7%), while at higher concentrations heterogeneity is evident. This 
is in accordance with the ultrastructure of films obtained by SEM. Both ERS03 and 
ERL03 present with more numerous agglomerates of caffeine which are not uniformly 
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distributed when panning under the microscope is performed in larger areas (Figure 3.1). 
A similar situation is found at higher concentrations of caffeine in addition to the 
appearance of larger recrystallized agglomerates of caffeine, which contributes to the loss 
of homogeneity. As hinted above, the extent of the drying times has been acknowledged 
in the literature as one factor that will allow for particle agglomeration [9,10,44]. 
Strategies such as the addition of gelling and viscosing agents, increasing the rate of 
drying, and/or casting in unitary wells have all been addressed in the literature as means 
to increase uniformity and could allow us to improve uniformity at higher concentrations 
of caffeine. 
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Figure 3.6. Caffeine content uniformity for ERL and ERS series. Darker grey columns 
represent the ERL series, while the lighter grey columns represent the ERS 
series. Values (mean ± standard deviation, n=4-6) are reported as 
percentages of the theoretical amount of caffeine in each sample studied. 
Differences among all ten formulations are not statistically significant 
(p>0.05). 
Due to the high permeability to water of ERL no differences could be evidenced 
in release profiles and almost complete release of the drug regardless of the concentration 
was achieved after 30 minutes (Figure 3.7). Using the similarity factor, f2 [25], it was 
determined that all of the release profiles were similar (f2 >50%, Table 3.3). Conversely, 
all the release profiles for the ERS series, except between ERS02 and ERS04, were 
different between each other per f2 (data not shown). ERS behaved as expected from the 
literature allowing for controlled release of caffeine at every concentration studied as 
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depicted in Figure 3.8 [45]. As the concentration of caffeine increased the rate of drug 
release increased as well. This can be attributed to a faster penetration of the water front 
through the polymer by dissolving agglomerates rather than displacing caffeine 
molecules from the polymer matrix (ERS01) [46].  
 
 
Figure 3.7. Drug release profiles for ERL series in phosphate buffer pH 6.8 at 37 °C, 
showing (♦) ERL05, (■) ERL04, (▲) ERL03, (●) ERL02, and () ERL01. 
Values are presented as mean ± standard deviation, n=6. 
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Figure 3.8. Drug release profiles for ERS series in phosphate buffer pH 6.8 at 37 °C, 
showing (♦) ERS05, (■) ERS04, (▲) ERS03, (●) ERS02, and () ERS01. 
Values are presented as mean ± standard deviation, n=6. 
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Table 3.3. Differences among formulations of ERS and ERL series based on the 
similarity factor, f2. Release profiles are similar if f2 ≥50. 
f2 ERS05 ERS04 ERS03 ERS02 ERS01 
ERS01 21.0 41.2 48.0 37.7 -- 
ERS02 12.9 25.0 54.3 --  
ERS03 16.1 30.4 --  
ERS04 26.8 --  
ERS05 --  
f2 ERL05 ERL04 ERL03 ERL02 ERL01 
ERL01 73.5 56.9 61.9 51.1 -- 
ERL02 58.6 52.0 50.3 --  
ERL03 66.9 81.2 --  
ERL04 64.0 --  
ERL05 --  
 
In Table 3.4, it is interesting to note that as the concentration of caffeine increases 
the release mechanism model that best explains the data (by comparison of the adjusted 
R2 and AIC) changes from a diffusion controlled mechanism (Korsmeyer-Peppas kinetics 
model) to a first order mass balance (first order model). In the Kormeyer-Peppas release 
kinetics model, n is the release exponent, and is an indicative of the drug release 
mechanism [27]. In the particular case of n equal to 0.5 the drug release mechanism is 
purely Fickian diffusion (the particular solution that constitutes the Higuchi model 
equation). When n equals 1 the equation describes a zero order release mechanism, and 
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the region ranging from 0.5 <n <1 represents the so-called anomalous transport. The first 
order kinetics applies to dosage forms that normally contain water-soluble drugs and 
porous polymer matrices. In said systems, drug release is proportional to the amount of 
drug remaining inside; therefore, the rate of drug release decreases with time. In 
accordance with the Korsmeyer-Peppas model, all except for ERS02 follow an 
anomalous transport implying that drug is transported by a combination of diffusion and 
case-II transport, characteristic of systems swelling in water (Table 3.4). ERS02 follows 
what has been described as a super case-II transport mechanism [28] and has been 
attributed to the result of an increased plasticization at the relaxing boundary (gel layer) 
[47,48]. 
Table 3.4. Model parameters, adjusted R2, and Akaike information criteria (AIC) values 
for ERS series. 
Formulation 
Korsmeyer-Peppas 
ܳ ൌ ݇ ൈ ݐ௡ 
Higuchi 
ܳ ൌ ݇ ൈ ݐ଴.ହ 
First order 
ܳ ൌ ݇ ൈ ሺ1 െ ݁ି௡௧ሻ 
 k n Adj R
2 AIC k Adj R2 AIC K n Adj R2 AIC 
ERS01 0.637 0.660 0.9998 10.09 0.604 0.9912 10.15 0.876 1.288 0.9966 9.29 
ERS02 0.586 1.119 0.9876 10.77 0.540 0.9391 37.07 1.090 0.693 0.9849 29.36 
ERS03 0.657 0.973 0.9957 6.86 0.602 0.9409 29.45 5.993 0.116 0.9986 6.10 
ERS04 0.703 0.974 0.9896 12.15 0.625 0.9421 31.10 5.854 0.127 0.9964 11.66 
ERS05 0.940 0.528 0.9125 20.40 0.929 0.9873 18.61 1.055 2.106 0.9964 13.92 
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3.5. CONCLUSION 
In contrast with what has been previously reported in the literature, we have found 
that ERS and more noticeably ERL have substantial mucoadhesive properties. This was 
further corroborated by direct comparison with materials typically regarded in the 
literature as being good adhesives, namely Carbopol 974P and Polycarbophil. In 
accordance with the diffusion theory of mucoadhesion, this was attributed to the swelling 
capacity of these polymers due to the presence of quaternary ammonium groups that 
increase hydrophilicity. Additionally, we have found through direct observations under 
the microscope that increasing concentrations of caffeine in ERS and ERL matrices 
yielded recrystallized agglomerates. These agglomerates increase in number and size due 
to solubility saturation as the concentration of caffeine was increased, which translated 
not only in a detriment of the mucoadhesive properties, but also in reduced mechanical 
and uniformity properties in the film. Finally, it was shown that the presence of these 
agglomerates changes the release kinetics of the films from a diffusion controlled 
mechanism to a first order mass balance with the increased caffeine loading. Thus, size of 
particulate material in films was found to preferably be below one micron. This 
determined the need for submicron or nanoparticles to carry the macromolecules 
investigated in this dissertation. The method of manufacture of nanoparticles and the 
addition of nanoparticles on films for buccal delivery are depicted in the following 
chapters.  
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4. A Design of Experiments to Optimize a New Manufacturing Process 
for High Activity Protein-Containing Submicron Particles3 
ABSTRACT 
A novel method for the manufacture of protein/peptide-containing submicron 
particles was developed in an attempt to provide particles with increased activity while 
using high energy input technologies. The method consists of antisolvent co-precipitation 
from an aqueous solution containing both an amino acid core material (e.g. D,L-valine), 
and either bovine serum albumin (BSA) or lysozyme (Lys) as model proteins. The 
aqueous solution was added to the organic phase by means of a nebulizer to increase the 
total surface area of interaction for the precipitation process. Sonication proved to be an 
effective method to produce small particle sizes while maintaining high activity of Lys. 
The use of a polysorbate or sorbitan ester derivatives as stabilizers proved to be necessary 
to yield submicron particles. Particles with very high yields (approximately 100%) and 
very high activity after manufacture (approximately 100%) could be obtained. A particle 
size of 439.0 nm, with a yield of 48.8% and with final remaining activity of 98.7% was 
obtained. By studying various factors using a design of experiments strategy (DoE) we 
were able to establish the critical controlling factors for this new method of manufacture. 
  
                                                 
3 Significant portions of this chapter were taken from: J.O. Morales, G.M. Joks, A. Lamprecht, A.C. Ross, 
J.T. McConville, A design of experiments to optimize a new manufacturing process for high activity 
protein-containing submicron particles, Drug Development and Industrial Pharmacy. (2012) In Press. 
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4.1. INTRODUCTION 
Recent increases in the number of products under review by the FDA or 
undergoing late phase clinical trials demonstrates the fact that protein and peptide 
therapeutics is a rapidly growing field in the pharmaceutical industry [1]. The 
development of delivery strategies for proteins and peptides has generally been limited to 
intravenous administration with very little success for other routes of administration; this 
is despite a plethora of articles in the literature supporting the fact that there is a need for 
alternative routes of delivery for protein and peptides. Within the literature, the most 
prominent alternative route of administration is by oral delivery [2–4]. However, the 
many limitations for gastrointestinal tract delivery has led to the exploration of other 
routes of delivery [5,6], such as pulmonary [7,8], nasal [9], transdermal [10], and buccal 
[11] routes. Regardless of the route of delivery, protein-containing submicron-/nano-
particulate systems have been continuously investigated as an approach to overcome the 
various limitations imposed by different delivery routes [1,12]. 
An advantage associated with the development of submicron or sub-/nano-
particulate systems is the increased amount of active solids that can be incorporated into 
smaller particles. Additionally, intravenous administration of smaller particles leads to 
faster dissolution in the blood increasing the potential to reach target organs [13]. 
However, one concern in the development of methods of manufacture for proteins or 
peptides is their labile nature. Therefore, the activity maintained following manufacture is 
a critical factor for consideration during the developmental stage. For example, it is 
known in the literature that methods where there is an interaction between 
proteins/peptides and organic solvents could decrease the activity due to denaturation 
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[14,15]. Nonetheless, recent advances in enzyme immobilization have opened the 
potential for antisolvent co-precipitation as a method of manufacture for protein/peptide 
particulate systems with similar or increased activity, when compared to similar 
lyophilized products [16,17]. The systems reported to date though, only describe the 
manufacture of particles in the range of 5-10 μm. The goal of this investigation was to 
adapt an antisolvent co-precipitation method for the manufacture of protein/peptide 
submicron particles. 
Generally the antisolvent precipitation process consists of solubilizing the 
molecule of interest in a suitable solvent and precipitation is then triggered by adding this 
solution to a miscible antisolvent. In the method described here, an additional co-
precipitant acts as core seed for the final precipitated particle. The co-precipitant is 
included in the aqueous solution containing the protein/peptide. An improvement in 
stability can occur following precipitation, by immobilizing the protein molecule in its 
native form [18,19]. An aqueous solution containing the protein/peptide and seed co-
precipitant is initially prepared and admixed with an organic water-miscible solvent (e.g. 
2-propanol), which can optionally contain a surfactant. Figure 4.1 depicts the general 
process involved in our presented antisolvent co-precipitation system. This work 
describes the development of the method of manufacture of submicron particles, and an 
investigation of the main variables controlling the process.  
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Figure 4.1. Antisolvent co-precipitation process comprising the amino acid (AA) co-
precipitant and the protein molecule in the aqueous phase. The surfactant 
contained in the antisolvent (IPA) dehydrates the water soluble molecules 
yielding the submicron protein-loaded particles. 
 
4.2. MATERIALS 
Bovine serum albumin (BSA), D,L-valine (Val), L-valine, glutamine and 
lysozyme (Lys), were obtained from Sigma-Aldrich (St. Louis, MO). Polysorbate 80 
(Tw80), sorbitan monostearate (Sp60), and sorbitan monooleate (Sp80), were obtained 
from Spectrum Chemical (New Brunswick, NJ). Deionized water was obtained in house 
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and 2-propanol (IPA) was obtained from Fisher Scientific (Fair Lawn, NJ). All other 
chemicals used were of analytical or reagent grade. 
4.3. METHODS 
4.3.1. Particle manufacturing process 
The manufacturing method used was based in an antisolvent co-precipitation 
approach. As an overview, aqueous solutions containing the model protein and the core 
material (an amino acid) are prepared with the desired concentration of both ingredients. 
This solution is then added to the antisolvent organic phase that is completely miscible 
with the aqueous phase but in which there is no solubility for either the model protein or 
the core forming amino acid. Unless otherwise noted, the organic phase used in these 
studies consisted of IPA containing either Sp60 or Sp80 as surfactants. The addition of 
the aqueous phase was performed by spray nebulization using an Aeroneb Pro® vibrating 
mesh nebulizer (Aerogen, Dangan, Ireland). Depending on the formulation, either 1 mL 
or 5 mL was nebulized to dryness at a set rate. The total nebulization time ranged from 5–
13 minutes depending on the fill volume of the nebulizer reservoir. During, and after 
addition of the aqueous phase via nebulization, mixing was provided by means of a 
Branson Sonifier 450 probe sonicator (Branson Ultrasonics, Danbury, CT). Figure 4.2 
depicts the apparatus configuration that allowed for the manufacture of submicron 
particles by antisolvent precipitation.  
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Figure 4.2. Diagram of the setup for antisolvent precipitation utilized in this investigation 
to yield protein-loaded submicron particles. 
4.3.2. Determination of particle size  
Particle sizing was performed either by using laser diffraction (LD) or dynamic 
light scattering (DLS) depending on the estimated particle size range after manufacture. 
Laser diffraction studies were performed using a Sympatec Helos system 
(Sympatec Inc, Pennington, NJ). Approximately 10 mL of slurry was added to a 1 cm 
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path length cuvette for particle size determination (n = 4). Dilution with IPA was 
necessary to obtain a laser obscuration of 10-15% prior to analysis. From the particle size 
distributions D50 was calculated, corresponding to the diameter at which the cumulative 
sample volume was under 50%. Refractive indices of 1.590 and 1.378 were used for the 
precipitated particles and IPA respectively. To characterize polydispersity in these studies 
the particle size span was calculated as depicted in Equation 1 
 
ܵ݌ܽ݊ ൌ ሺܦ90 െ ܦ10ሻܦ50  
(1) 
 
Dynamic light scattering studies were conducted using a Zetasizer Nano ZS 
(Malvern Instruments Ltd., Worcester, UK). Approximately 1 mL of slurry, diluted with 
IPA when needed, was added into 1 cm path length polystyrene cuvettes for analysis of 
particle size. A total of 3 determinations of 15–18 runs each were conducted using the 
instrument. Particle size was characterized by the Z-average. The same refractive indices 
were used for DLS measurements. After measurement a polydispersity index (PdI) was 
computed by the software and it was utilized to rank slurries based on how broad the 
distribution was. 
4.3.3. Zeta potential analysis 
Zeta potentials of slurries were obtained by laser Doppler micro-electrophoresis 
using a Malvern Zetasizer Nano ZS (Malvern Instruments Ltd., Worcester, UK). 
Approximately 1 mL of slurry, diluted with IPA when needed, was added to a 
polycarbonate capillary cell for determination of zeta potential. A total of 3 
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determinations of 20–30 runs each were conducted to obtain the average zeta potential of 
the slurries. 
4.3.4. Morphology of particles 
A Hitachi S-5500 field emission scanning electron microscope (SEM, Hitachi 
High-Technologies Corp., Tokyo, Japan) was used for imaging coated particles. Particles 
were separated by centrifugation at 12,000 rpm then dried overnight at room temperature 
with an air current. Samples were mounted onto aluminum stubs using conductive carbon 
tape for coating. Coating was performed with a 208 HR Cressington sputter coater 
(Cressington Scientific Instruments Ltd, Watford, UK) with Pt/Pd to a thickness of 10–15 
nm in a high vacuum evaporator. To avoid structural deformation during imaging, the 
electron beam voltage was kept at 2–5 kV. 
4.3.5. Lysozyme yield by RP-HPLC 
Lysozyme content after manufacture was determined by RP-HPLC. A known 
weight of dry solids was dissolved in sufficient pH 7.0 phosphate buffer, and a 500 µL 
aliquot was filtered and stored in vials for HPLC quantification of lysozyme. 
Chromatography was performed using a Zorbax 300SB® C18 Rapid Resolution column 
(3.5 μm, 4.6 mm ID x 150 mm length) (Agilent Technologies, Santa Clara, CA).The 
mobile phase consisted of two solvents with different polarities: solvent A consisted of 
water and with 5% v/v acetonitrile and 0.1% v/v trifluoroacetic acid, while solvent B 
consisted of acetonitrile, 5% v/v water, and 0.085% v/v trifluoroacetic acid. The mobile 
phase consisted initially of 10% v/v solvent B with a solvent gradient of 60% v/v solvent 
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B in 16 minutes. The flow rate was set to 1 mL/min and temperature remained constant at 
25 °C. The injection volume was 50 μL and the UV detector was set at 215 nm. 
4.3.6. Lysozyme activity 
The enzymatic activity of lysozyme after manufacture of particles was determined 
turbidimetrically based on the method reported previously [20]. Activity is correlated 
with a decrease in absorbance at 450 nm of solutions containing Micrococcus 
lysodeikticus due to the lytic activity of lysozyme on the cell walls. A cell suspension of 
0.3 mg/mL (0.9 mL) was mixed with a stock lysozyme solution containing 1 mg/mL (0.1 
mL) to determine the maximum lytic effect. After separation and drying of particles, the 
solid was dissolved in a pH 6.2 phosphate buffer to a concentration of 1 mg/mL. 
Following the same procedure, sample solutions were assayed against a M. lysodeikticus 
suspension and absorbance was measured at 450 nm. Percentage activity was calculated 
by normalizing against the absorbance measured for a Lys stock solution with a known 
100% activity. 
4.3.7. Statistical analysis 
All statistical analyses were performed with the software Minitab Release 14® 
(Minitab Inc., State college, PA). One-way ANOVAs were used for multiple 
comparisons and Tukey's post hoc pairwise comparisons were performed to compare 
which results led to individual significant differences. The design of experiments (DoE) 
and subsequent statistical analyses were also conducted using Minitab Release 14®. All 
values are reported as the mean and standard deviation of the mean shown in parenthesis. 
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4.4. RESULTS AND DISCUSSION 
4.4.1. The influence of the antisolvent, core material, and the mechanism of 
addition of aqueous 
Our antisolvent co-precipitation system as stated above is composed of a water 
miscible organic solvent as the antisolvent and an aqueous phase containing both the 
protein of interest and the core material. In our studies the selected amino acid core 
material demonstrated chemical compatibility with proteins. Table 4.1 summarizes the 
preliminary conditions that were studied using a near saturation solution of amino acid 
(61.2 mg/mL for Val) loaded with 10% w/w BSA as the aqueous phase. Neither acetone 
nor ethanol were suitable solvents to trigger the precipitation of Val, which was attributed 
to a higher solubility in these solvents. Both ethanol and acetone have higher polarity 
indices than IPA, which allow them to solubilize better the water-soluble molecules 
resulting in an impediment in supersaturation, ultimately resulting in the absence of 
precipitates. The use of IPA only resulted in smaller particle sizes when it was 
dehydrated. The presence of water in the organic phase makes the extraction of water 
from the added aqueous phase slower, which increases the mixing time, yielding larger 
particles during the antisolvent co-precipitation process. 
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Table 4.1. Study of the influence of antisolvent, core material, and style of addition of the 
aqueous phase in the process over particle size (D50 and span determined by 
LD). Results are represented as the mean and standard deviation in 
parenthesis. Unless specified otherwise, all pairwise comparisons are 
significantly different with a p≤0.01 
Conditions D50 /μm Span 
Antisolvent: IPA/water 95/5 11.04 (0.30) 1.08 (0.03) 
Antisolvent: Acetone unable to trigger precipitation 
Antisolvent: Ethanol unable to trigger precipitation 
Core material: Val 4.98 (0.09) 1.58 (0.01)b,c 
Core material: L-valine 17.18 (0.14) 1.75 (0.04)a,c 
Core material: Glutamine very large precipitates 
Aqueous added with needle 8.11 (0.27) 15.52 (0.41) 
Aqueous added with nebulizer 3.04 (0.02) 1.70 (0.08)a,b 
a, b, c: pairs of letters represent averages that do not exhibit statically significant differences with 
p>0.5. 
In the antisolvent co-precipitation process, the co-precipitant needs to be water 
soluble and compatible with the molecules of interest (in this work BSA or Lys). Salts 
[21], sugar, or amino acids [22] have been proposed and investigated as core materials. 
Val in particular has been shown to yield enzyme-coated microcrystals [23]. We have 
found that among a variety of amino acids, Val provides the best characteristics as a 
precipitant yielding small and narrow size distributions for BSA (Table 1). Glutamine 
precipitated into very large, immediately sedimenting flakes, whereas L-tyrosine, L-
isoleucine, L-tryptophan, N-acetyl-L-tyrosine, and L-leucine did not elicit particle 
formation (data not shown). It is interesting to note that L-valine yielded larger particles 
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than those obtained by the use of the racemic mixture. The difference in solubility (58.5 
and 68.0 mg/mL for L-val and Val respectively) translated into different rates of 
precipitation. Since L-val has a lower solubility, the degree of supersaturation is reached 
faster. The nucleation rate is faster for L-val; however, the condensation and coagulation 
rates are also favored which results in wider particle size distribution. 
During the development of the manufacturing process in this current study, the 
addition of the aqueous solution was performed using a syringe pump to control the rate 
of delivery of aqueous solution in a drop-wise fashion [24]. To explore the influence of 
the total surface area of interaction between the aqueous and the organic phase we 
analyzed the use of a nebulizer to provide droplets in the size range of 1 – 5 μm. As can 
be seen in Table 1, a significant decrease in D50 was observed when nebulization was 
utilized as a means to add the aqueous in the organic phase (3.04 vs 8.11 μm). In 
addition, using the nebulizer provided very narrow polydispersity reflected in the span of 
the size distribution. An increase in surface area by decreasing the size of the aqueous 
droplets that can come in contact with the organic phase is akin to an increasing Reynolds 
number (Re), [25] whereby there is a substantial decrease in the mixing and dehydration 
times. These results led us to conclude that a high surface area at the aqueous/organic 
interface was needed to approach smaller particle sizes with our manufacturing process. 
4.4.2. Manufacture of Lys submicron particles 
In previous investigations we compared the mixing methods of magnetic stirring, 
homogenization, and sonication (data no shown). Sonication was found to be the most 
effective in providing high energy mixing and small particle sizes [24,26]. During 
sonication, ultrasound-driven mechanical vibrations generate cavitation, where 
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rarefaction and compression cycles during sonication create vapor bubbles which burst 
after achieving a critical size. This violent cavitation creates high energy turbulence 
which, in addition to high speed fluid jets, is responsible in providing extremely high 
mixing energy to the system. This high energy mixing is equivalent to an overall 
reduction in the required mixing time. According to the Damkohler number (Da) 
reducing the mixing time (τmix) can ultimately result in faster rates of nucleation by 
supersaturation, this is portrayed in Equation 2: 
 
ܦܽ ൌ ߬௠௜௫߬௣௥௘௖௜௣ 
(2) 
 
Where τprecip is precipitation time, which is composed of τcond and τcoag 
(condensation and coagulation times respectively) [27]. As the energy for mixing is 
increased, the mixing time is decreased, favoring the rate of nucleation.  
Studies performed with the combination of probe sonication, the aqueous phase 
added by spray nebulization, and the use of a surfactant in the organic phase revealed that 
submicron particle sizes could be achieved for Lys-loaded particles and for Val only 
control particles. As can be seen in Figure 4.3, particles obtained by the antisolvent co-
precipitation process conform to the typical flake-like shape of valine crystals loaded 
with Lys or BSA. By SEM observation, the absence of individual aggregates of different 
shape and the consistent flake-like shape of the particles, with and without protein, leads 
us to believe that the protein precipitates on the surface of the particles. This finding is 
similar to that described in earlier antisolvent co-precipitation studies. Kreiner et al. 
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(2005) used confocal laser scanning fluorescence microscopy to demonstrate that DNA 
was distributed on the surface of crystals by observing higher fluorescence intensity at 
the microcrystal edges [28]. Similarly, subtilisin Carlsberg-loaded microcrystals have 
been found to have a fairly uniform layer of the enzyme on the surface of the crystals by 
using atomic force microscope and tapping mode [23].  
 
Figure 4.3. SEM micrographs of micro and submicron particles obtained from (a) Only 
Val /Sp60, (b) Only Val /Tw80, (c) Val and 10% Lys /Sp60, and (d) Val and 
10% BSA /Sp60. The bar represents 1 μm. 
It is known from previous investigations that stabilizer can arrest particle growth 
by impeding the coagulation or condensation processes [24,29–32]. Since surfactants are 
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often used as stabilizers, we explored the use of polysorbate and sorbitan derivatives, 
which are soluble in aqueous and organic solvents respectively [33,34]. Since the 
antisolvent co-precipitation is a bottom up process is critical that all components are fully 
dissolved prior to beginning. The direct effect of the surfactant is to increase τcond and 
τcoag which results in a decreased of the τprecip yielding smaller particle sizes [27]. As 
depicted in Figure 4 the presence of surfactants, allowed submicron particles to form as 
either blank particles (only Val) or Lys co-precipitated particles. The inclusion of BSA in 
this system was not successful due to the appearance of large agglomerates that were seen 
with laser diffraction. Lysozyme was found to be effective in hindering further particle 
growth upon precipitation, due to its smaller molecular weight when compared to BSA. 
Optimally, the use of 10% Lys in the aqueous solution further decreased Z-average from 
888 nm (Val only /Sp60) to 473 nm. This is in agreement with previous findings where 
enzyme-coated microcrystals had smaller particle size than a crystal control [23]. The 
smaller particle size of enzyme-coated crystals was attributed to the precipitation of the 
protein on the surface of the submicron particles. We believe that this surface coverage 
works to slow the condensation and coagulation steps of the precipitation process limiting 
particle growth, much like the effect of surfactants. Additionally, polydispersity was 
significantly narrowed (p<0.01) by the use of Lys to 0.19.  
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Figure 4.4. The influence of surfactant and protein model over Z-average ( ) and 
polydispersity index (■). *: no statistical significance in difference (p>0.5). 
All other values were significantly different to a p≤0.01 level. **: since 
BSA was determined by LD, Size is expressed as D50 and polydispersity is 
expressed as span here and not PdI. 
4.4.3. The effect of processing variables 
To investigate the importance of processing variables in the manufacture of 
submicron particles an aqueous formulation composed of Val 15.3 mg/mL (a quarter of 
90% saturation solubility) and 10% w/w of Lys solids were used. A three factor two level 
full factorial DoE was designed to study the effect of sonication time, sonication 
intensity, and sonicating lapse duration. Sonication time was set either at 5 or 20 minutes, 
intensity was set either at 320 or 400 Watts, and the duration of sonicating lapse was set 
to either 0.3 or 0.6 seconds (Table 4.2). 
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Table 4.2. DoE to study the effect of process variables such as sonication time, intensity, 
and duration of lapse over particle size (Z-average and PdI). Results are 
represented as the mean and standard deviation in parenthesis. 
Experiment Sonication time /min 
Sonication 
intensity /Watts 
Sonication 
lapse duration 
/sec 
Z-average /nm PdI 
SPV1 5 8 30 780.2 (50.9) 0.33 (0.03) 
SPV2 20 8 30 473.2 (3.1) 0.19 (0.09) 
SPV3 5 10 30 1011.4 (79.1) 0.44 (0.10) 
SPV4 20 10 30 742.1 (9.4) 0.34 (0.03) 
SPV5 5 8 60 1231.7 (70.7) 0.42 (0.11) 
SPV6 20 8 60 961.5 (54.2) 0.57 (0.13) 
SPV7 5 10 60 1194.0 (38.3) 0.37 (0.06) 
SPV8 20 10 60 723.7 (60.3) 0.42 (0.09) 
Effect on 
particle 
size 
-329.2 56.1 276.0 -- -- 
 
After statistical analysis of the DoE all three factors were associated with 
significant control over the process (p<0.02). Sonication time was the strongest factor in 
terms of effect over Z-average (-329.2) and was the only factor that contributed to 
reducing the particle size when increased from 5 to 20 minutes (Table 4.2). Sonicating 
during the precipitation process reduces the mixing time, thus increasing the rate of 
nucleation. However, sonication also increases the overall precipitation time by impeding 
coagulation and condensation. Increasing both intensity and lapse duration during 
sonication was associated with larger particle sizes, probably due to a plateau in 
performance of sonication, warranting a more detailed exploration of these variables 
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beyond the scope of this study. From these results we can conclude that longer times, a 
low intensity and short duration of lapses demonstrate a high level of control for particle 
size in these studies. Only a decrease in the duration of the sonication lapse resulted in a 
significant decrease in PdI (p<0.01). With the exception of SPV6 all polydispersity 
results had acceptable values, with PdI ranging from 0.2 – 0.4 [35,36] indicating that the 
process overall provides narrowly distributed submicron particles (Table 4.2). It is 
important to note that particle shape also plays a role in the determination of particle size 
and size homogeneity by DLS [37]. Since, the submicron particles take on the flake-like 
shape of Val crystals they are asymmetric and thus they decrease homogeneity upon 
determination of PdI. Similar findings have been described in platelet-like solid lipid 
nanoparticles (SLN) and nanostructured lipid carriers (NLC). Asymmetric particle shape 
has been found to increase PdI values ranging from 0.1 – 0.3 [37]. 
4.4.4. The effect of formulation variables 
These findings led us to investigate the formulation variables controlling particle 
size. Firstly, the type of surfactant, concentration of surfactant, Val concentration, and the 
volume of aqueous phase added to the process were controlled in a 4 factors 2 levels 
fractional factorial DoE (Table 4.3). 
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Table 4.3. DoE to study the effect of surfactant concentration and type, Val 
concentration, and aqueous volume added over particle size (Z-average and 
PdI). Results are represented as the mean and standard deviation in 
parenthesis. 
Experiment Surfactant type 
Surfactant 
conc. 
Val conc. 
/mg/mL 
Aqueous 
volume 
added /mL 
Z-average  
/nm PdI 
SFV01_01 Span60 CMC 15.3 1 576.6 (19.2) 0.33 (0.05) 
SFV01_02 Span80 CMC 15.3 1 534.2 (38.1) 0.24 (0.02) 
SFV01_03 Span60 4CMC 15.3 1 929.4 (99.4) 0.66 (0.05) 
SFV01_04 Span80 4CMC 15.3 1 636.7 (8.6) 0.81 (0.04) 
SFV01_05 Span60 CMC 30.6 1 720.0 (21.9) 0.41 (0.04) 
SFV01_06 Span80 CMC 30.6 1 696.5 (22.3) 0.39 (0.06) 
SFV01_07 Span60 4CMC 30.6 1 736.3 (71.4) 0.43 (0.04) 
SFV01_08 Span80 4CMC 30.6 1 735.2 (3.2) 0.37 (0.02) 
SFV01_09 Span60 CMC 15.3 5 721.4 (45.5) 0.31 (0.04) 
SFV01_10 Span80 CMC 15.3 5 1057.8 (142.6) 0.58 (0.03) 
SFV01_11 Span60 4CMC 15.3 5 1255.0 (172.7) 0.63 (0.01) 
SFV01_12 Span80 4CMC 15.3 5 977.7 (206.5) 0.17 (0.04) 
SFV01_13 Span60 CMC 30.6 5 901.4 (16.9) 0.40 (0.04) 
SFV01_14 Span80 CMC 30.6 5 622.5 (37.7) 0.16 (0.02) 
SFV01_15 Span60 4CMC 30.6 5 630.2 (59.1) 0.21 (0.07) 
SFV01_16 Span80 4CMC 30.6 5 784.3 (15.8) 0.30 (0.03) 
Effect on size -53.18 106.80 -107.78 173.18 -- -- 
 
All variables had a significant effect on particle size (Z-average, p<0.05). Sp60 
and Sp80 were found to be similarly effective in arresting particle growth as organic 
soluble surfactants [38], which follows since they are from the same family of surfactants 
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with very similar physicochemical characteristics. Thus the surfactant types used in this 
study had the least effect on decreasing particle size (-53.18). In this set of experiments 
we also observed an increase in particle size when surfactant concentrations were 
increased beyond the CMC. The formation of micelles acts by decreasing the amount of 
surfactant molecules available to arrest particle growth in solution [27]. Decreasing the 
volume of the aqueous phase added, and increasing Val concentration were both 
associated with a decrease in D50 (p<0.05). Both of these factors contribute to an 
increase in the rate of nucleation and overall precipitation [39], consequently resulting in 
a reduced the final particle size, as discussed above. Polydispersity was significantly 
controlled by all the factors studied (p<0.05). When using Sp80, decreasing the 
concentration of surfactant, increasing the amount of aqueous volume added, as well as 
increasing Val concentration from 15.3 to 30.6 mg/mL were associated with a decrease in 
polydispersity; however, only Val concentration and the volume of aqueous volume 
affected the polydispersity profoundly. 
By using the most relevant factors in the process and formulation variables we 
sought to investigate the influence of variables over the yield and activity of Lys. As 
stated above, proteins and peptides are labile molecules that could be rendered inactive 
by interacting with organic solvents, thus we measured remaining Lys activity as an 
indicator of structure stability following manufacture. For this, a 4 level 2 factor 
fractional factorial DoE was designed using Sp60 at its CMC. Val concentration was 
varied from 30.6 to 61.2 mg/mL, Lys concentration (Lys/%), amount of aqueous added, 
and total organic volume for precipitation were studied in this DoE as depicted in Table 
4.4. 
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Table 4.4. DoE to study the effect of Val concentration, Lys loading, aqueous volume 
added, and organic volume over particle size (Z-average and PdI), Lys yield, 
and activity after manufacture. Results are represented as the mean and 
standard deviation in parenthesis. 
Experiment 
Val 
conc 
/mg/mL 
Lys 
/% 
Aq 
added 
/mL 
Org vol 
/mL Z-average /nm PdI Lys yield /% Activity /% 
SFV02_01 30.6 10 1 100 813.7 (18.7) 0.31 (0.04) 11.2 (0.6) 97.9 (0.2) 
SFV02_02 61.2 10 1 60 733.4 (2.5) 0.26 (0.06) 9.8 (0.5) 99.0 (0.3) 
SFV02_03 30.6 40 1 60 757.9 (15.5) 0.38 (0.04) 21.2 (1.1) 96.4 (0.6) 
SFV02_04 61.2 40 1 100 439.0 (5.2) 0.53 (0.04) 48.8 (2.4) 98.7 (0.1) 
SFV02_05 30.6 10 5 60 965.9 (29.5) 0.35 (0.03) 14.6 (0.7) 94.5 (0.2) 
SFV02_06 61.2 10 5 100 928.0 (51.8) 0.42 (0.02) 11.7 (0.6) 96.8 (0.5) 
SFV02_07 30.6 40 5 100 699.7 (72.7) 0.92 (0.07) 105.5 (2.3) 93.7 (0.3) 
SFV02_08 61.2 40 5 60 1156.3 (122.6) 0.45 (0.04) 103.3 (2.5) 97.2 (0.1) 
Effect on 
size -96.18 n.s. 199.91 -58.62 -- -- -- -- 
Effect on 
Lys yield 1.42 26.8 12.78 n.s.     
Effect on 
activity 21.46 -35.4 65.68 -18.95     
n.s.: not a statistically significant factor. 
Except for the organic solvent volume, all variables were found to significantly 
control Z-average (p<0.01). Again, decreasing the volume of the aqueous phase added 
had the strongest effect (199.91) in decreasing particle size. A high volume of aqueous 
solution not only provided more precipitant for the process, increasing the rate of 
nucleation and decreasing the precipitation time by favoring coagulation and 
condensation resulting in larger particles. As observed above, increasing Val 
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concentration resulted in a decrease in particle size in terms of Z-average. Increasing the 
concentration of Lys in the aqueous phase resulted in a decrease in particle size. As 
previously described, as the enzyme precipitates on the surface of the growing crystals it 
stabilizes and hinders further particle growth. However, increasing the concentration of 
lysozyme was associated with an increase in PdI. This could be correlated with potential 
self-aggregates of lysozyme at higher concentrations. Normally, increasing the 
concentration of lysozyme does not render aggregates on the larger side of the particle 
sizes (few microns) but mostly in the few hundreds of namometers range. On the other 
hand, increasing the aqueous volume added to the precipitation process resulted in the 
presence of large particles. Increasing the volume of organic phase used only slightly 
correlated with an increase in PdI.  
Increasing the concentration of Lys in the aqueous phase had a strong positive 
impact in the final yield of lysozyme in the precipitated particles. Similarly, a strong 
positive effect can be attributed to aqueous volume added to the precipitating system. A 
slight (yet significant) positive effect can be seen for the amino acid concentration, 
although this does not have a strong control over the final lysozyme content. All factors 
studied had significant effects in controlling the remaining activity of Lys-containing 
particles, and remaining activity after manufacture was excellent for all formulations 
studied. All final activity results were above 93%, and except for two, they ranged from 
96 to 99% remaining activity (Table 4.4), revealing that the remaining Lys after the 
antisolvent co-precipitation manufacturing process is almost completely active compared 
to a control stock solution of Lys. This is in agreement with previous reports on enzyme 
or DNA-coated microcrystals obtained in a similar fashion that resulted in high activity 
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and stability of the biologics after manufacture [17,22,23,28]. This shows that although 
the use of a probe sonicator imparts high energy mixing to the process of precipitation, 
the immobilization of protein to the amino acids crystals imparts enhanced stability to the 
molecule. Moving forward from this investigation we expect to optimize the process 
around SFV02_04 which while maintaining small particle size (439 nm) provided 
adequate yield (around 50%) and high activity after manufacture (98.7%).  
4.5. CONCLUSION 
This novel method of manufacture can yield stable protein-loaded submicron 
particles with suitable control over particle size and a narrow size distribution range. 
Micro and submicron particles obtained in this investigation conformed to the original 
shape of pure valine crystals, demonstrating that the addition of the protein/peptide to the 
system did not affect the morphology of particles following their subsequent precipitation 
on to its surface.  
The combined use of a nebulizer and probe sonicator drastically decreased 
particle size and resulted in narrow particle size distributions. In addition, the use of 2-
propanol was the most effective antisolvent investigated. Additionally, the use of a 
surfactant to stabilize particle growth allowed us to adequately control the manufacture of 
protein/peptide submicron particles. By studying various factors using a design of 
experiments strategy (DoE) we were able to establish the critical controlling factors for 
this new and improved method of manufacture. This optimized method of manufacture 
was sought to be further adapted to more therapeutically relevant actives, such as insulin, 
and its use is decribed below in Chapter 6. 
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5. Protein-coated Nanoparticles Embedded in Films for Buccal 
Delivery4 
ABSTRACT 
The objective of this chapter was to develop a mucoadhesive film for the delivery 
of lysozyme as a model protein and to render the enzyme stable and homogeneously 
distributed in the film by using a newly developed process for the manufacture of Lys-
loaded submicron particles. For this, an antisolvent co-precipitation process was used to 
manufacture Lys-loaded submicron particles. After size, yield, and stability 
characterization the selected batch of particles was further formulated into polymeric 
films. Polymethacrylates and HPMC were used as matrix formers and films were 
obtained by a solvent casting process. Films were characterized for mechanical 
properties, mucoadhesion, Lys release kinetics and activity after manufacture. It was 
found that protein-coated nanoparticles particles (PCNP) could be obtained at pH 6.8. 
Formulation SPH02 had a z-average of 347.2 nm, a zeta potential of 21.9 mV, and 99.2% 
remaining activity after manufacture and was selected for further study. Films with 
Eudragit RLPO (ERL) exhibited excellent mechanical and mucoadhesive properties and 
the release of Lys could be tailored by the addition of HPMC in the polymeric matrix. 
FPH04 consisted of equal amounts of ERL and HPMC and revealed a sustained release 
over the 4 hours period of time of the study with Lys remaining fully active. Thus, 
successful development of film formulations containing Lys-loaded particles was 
achieved. All Eudragit RL films had acceptable mechanical properties, excellent 
                                                 
4 Significant portions of this chapter were taken from: J.O. Morales, A.C. Ross, J.T. McConville, Protein-
coated nanoparticles embedded in films for buccal delivery, Journal of Pharmacy and Pharmacology. 
(2012) Submitted. 
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mucoadhesive properties, and excellent remaining Lys activity. Moreover, the use of 
HPMC allowed for tailoring the profiles in sustained release formulations. 
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5.1. INTRODUCTION 
As earlier mentioned, the recent increase in the number of products under review 
by the FDA or undergoing late phase clinical trials demonstrates the fact that protein and 
peptide therapeutics is a rapidly growing field in the pharmaceutical industry [1]. 
However, it is widely reported in the literature that the efficacious delivery of these 
therapeutic agents can become the determinant factor in product development [2,3]. 
Therefore, in order to achieve the real potential of protein and peptide therapeutics, 
effective smart delivery platforms and strategies, to overcome the formulation and 
delivery challenges, need to be developed. The conventional approach for the delivery of 
macromolecules is through injections [4,5]. This method of delivery is largely associated 
with drawbacks in patient compliance and acceptance. The start of therapies can get 
delayed and patients can develop needle anxiety [6]. In addition, the number of injections 
may lead to compliance issues [7] in therapies that rely on this route of administration. 
Therefore, alternative routes of delivery are vital to achieve successful product 
development. 
Among alternative routes of delivery for proteins and peptides, the oral route has 
been for a long time widely investigated [8–10]. However, several drawbacks in the 
gastrointestinal tract (GIT) make the development of novel delivery platforms for 
macromolecules very challenging. Instability in gastric pH, proteolytic enzyme content in 
the upper GI tract, and insufficient permeation and bioavailability has limited the success 
that has been achieved [11]. These limitations have led to the exploration of other routes 
of delivery [12,13], such as pulmonary, nasal, and transdermal routes. Particularly, the 
buccal route of delivery offers interesting advantages in comparison to the oral route and 
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the GIT limitations for the delivery of protein and peptides [11]. In bypassing the 
absorption via the gut, the stability of macromolecules is not compromised before 
reaching circulation. Other advantages of this route of delivery such as its good vascular 
drainage, ease of administration, and relatively low enzyme levels make it a good 
candidate for the delivery of proteins and peptides [14]. 
Mucoadhesive films as dosage forms for the buccal route of delivery have been 
investigated in the past decade but little efforts have been done with regards to the 
delivery of proteins and peptides in particulate forms [15,16]. From a formulation 
standpoint, actives are usually added to the film by their inclusion to the casting solution, 
then allowing it to dry into the solid form. However, in general the polymers utilized in 
formulations containing proteins are more hydrophobic in comparison to the hydrophilic 
nature of proteins [10]. This could potentially lead to separation and/or aggregation 
during storage, or in vivo, leading to possible instability [17]. Additionally, strategies like 
incorporating insulin as a solid solution into PLGA microspheres, to prevent chemical 
reactions in the solid state and to control the peptide release, have been unsuccessful [18]. 
During PLGA erosion, the microenvironmetal pH drops and deamidation has been found 
to be the main reaction that causes insulin instability [19]. For the delivery of insulin, 
chitosan seems to be a more suitable candidate as a polymer vehicle. Cui et al. (2009) 
have developed chitosan-ethylenediaminetetracetic acid (chitosan-EDTA) films 
containing insulin for buccal delivery and have demonstrated the retention of the physical 
structure of the peptide upon release [20]. However, there is no mention of the uniformity 
of the drug in the film upon solidification which prohibits any conclusion about drug 
distribution homogeneity. More recently, Giovino et al. (2012) have developed chitosan 
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films for the buccal sustained delivery of insulin in PEG-b-PLA nanoparticles as a model 
for buccal macromolecular delivery [21]. Although adequate physico-mechanical 
properties were achieved, very high heterogeneity was revealed by the mechanical 
variables studied (time to break, tensile strength, Young’s modulus, and work done to 
break). This therefore raises concern over the tight control of manufacture necessary to 
prepare films with homogeneous particle distribution, adequate physico-mechanical 
properties, high yield and retention of macromolecule activity. 
In recent years, investigations of enzyme immobilization in organic solvents have 
opened the door for the manufacture of particulates-containing films with enhanced 
activity. In particular, the antisolvent co-precipitation method has been shown to produce 
particles coated with a variety of biologicals including nucleic acids [22], proteins [23], 
enzymes [24], and other particulate systems [25]. However, most of these investigations 
lead to particles in the range of 1–5 μm or higher. To guarantee physical stability of the 
films in terms of mechanical and also mucoadhesive properties, such large particles are 
undesired due to potential for aggregation and loss in active distribution homogeneity 
[26]. Our group has recently published on the manufacture of submicron and nanosized 
particles of lysozyme (Lys) loaded D,L-valine (Val), also known as protein-coated 
nanoparticles (PCNP), and the advantages of this method of manufacture to provide high 
yield and enzymatic stability [27]. Based on previous investigations, it is known that a 
combination of high mixing energy provided by a probe sonicator, the addition of the 
aqueous phase by means of a nebulizer, and the use of surfactant as a stabilizer, can 
altogether yield relatively narrowly distributed submicron protein-containing particles. 
Here, after studying the effect of aqueous phase pH on particle size, we selected an 
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optimized formulation for the manufacture of films. Mucoadhesive films intended for the 
buccal delivery of macromolecules were developed using Lys as model to yield high 
enzyme activity after manufacture and controlled release in vitro. 
5.2. MATERIALS 
D,L-valine (Val) and lysozyme (Lys) were obtained from Sigma-Aldrich (Sigma-
Aldrich, St. Louis, Missouri). Sorbitan monostearate (Span60) was obtained from 
Spectrum (Spectrum Chemical, New Brunswick, New Jersey). Eudragit RSPO and RLPO 
(ERS and ERL) were kindly donated by Evonik (Evonik Industries, Darmstadt, 
Germany). Carbopol® 974P (C974P) and Noveon® AA-1 Polycarbophil (PCP) were 
donated by Lubrizol (Lubrizol Advanced Materials, Cleveland, Ohio). Hydroxypropyl 
methylcellulose (HPMC, Methocel E50 Premium LV) was donated from Colorcon 
(Colorcon, Harleysville, Pennsylvania). Triethyl citrate (TEC; Vertellus Specialties Inc, 
Indianapolis, Indiana), mucin (Spectrum Chemical, New Brunswick, New Jersey), and 
Micrococcus lysodeikticus (Worthington Biochemical Corp., Lakewood, New Jersey) 
were purchased and used as received. HPLC-grade 2-propanol (IPA) was obtained from 
Fisher Scientific (Fisher Scientific, Fair Lawn, New Jersey) while deionized water was 
procured in house. All other chemicals used were of analytical or reagent grade.  
5.3. METHODS 
5.3.1. Protein-coated nanoparticle (PCNP) manufacture 
The manufacturing process was based on antisolvent co-precipitation and our 
approach has been recently published elsewhere [27]. Briefly, the co-precipitant Val and 
the amount of Lys to be precipitated were dissolved in one the buffers and solutions 
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studied (Table 5.1). First, Val was dissolved in the aqueous phase at a concentration of 
61.2 mg/mL (or 90% of its saturation concentration) and then Lys was dissolved in this 
solution to yield a protein content of 40% w/w based on solid content. By means of an 
Aeroneb Pro® vibrating mesh nebulizer (Aerogen, Galway, Ireland), the aqueous phase is 
then added to the antisolvent organic phase. The organic must be miscible with water in 
order to promote the fast dehydration of the precipitant and co-precipitant. We have 
shown previously that IPA containing Span60 is the most effective antisolvent yielding 
smaller particle sizes[27]; therefore, a 0.008 mM Span60 solution was utilized. Finally, 
during the addition of the aqueous phase high energy mixing is provided by means of a 
Branson Sonifier 450 probe sonicator (Branson Ultrasonics, Danbury, Connecticut). After 
addition of the total volume of aqueous phase sonication is maintained for 20 more 
minutes to further stop particle growth during the early stages of coagulation [27]. 
Table 5.1. Formulations prepared to study the effect of pH in the manufacturing process 
of Lys PCNP. 
Formulation Protein model Buffer /solution pH 
SPH01 Lys N Phthalate 5.4 
SPH02 Lys Phosphate 6.8 
SPH03 Lys Borate 10 
SPH04 Lys NaOH 13 
5.3.2. Particle sizing 
To determine the particle size of the slurries obtained in IPA a Zetasizer Nano ZS 
(Malvern Intruments Ltd., Worcestershire, UK) was utilized. Mean particle size was 
obtained as a z-average which corresponds to the intensity weighted mean hydrodynamic 
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size measured by dynamic light scattering (DLS). Additionally, an estimate of the width 
of the distribution was obtained from the instrument as a polydispersity index. 
Approximately 1 mL of IPA slurry was analyzed by DLS in 1cm path length disposable 
polystyrene cuvettes. A total of 3-5 determinations of 15-20 runs each were conducted. 
5.3.3. Zeta potential 
Zeta potentials (ZP) of slurries were obtained by laser Doppler micro-
electrophoresis using a Malvern Zetasizer Nano ZS (Malvern Instruments Ltd., 
Worcestershire, UK). Approximately 1 mL of slurry was added to a polycarbonate 
capillary cell for determination of zeta potential. A total of 5 determinations of 14–20 
runs each were conducted to obtain the average zeta potential of the slurries. 
5.3.4. Lysozyme quantification by RP-HPLC 
Chromatography was performed using a Zorbax 300SB® C18 Rapid Resolution 
column (3.5 μm, 4.6 mm ID x 150 mm length) (Agilent Technologies, Santa Clara, 
CA).The mobile phase consisted of two solvents with different polarities: solvent A 
consisted of water with 5% v/v acetonitrile and 0.1% v/v trifluoroacetic acid, while 
solvent B consisted of acetonitrile with 5% v/v water, and 0.085% v/v trifluoroacetic 
acid. The mobile phase consisted initially of 10% v/v solvent B with a solvent gradient of 
60% v/v solvent B in 16 minutes. The flow rate was set to 1 mL/min and temperature 
remained constant at 25 °C. The injection volume was 50 μL and the UV detector was set 
to 215 nm. For the determination of Lys content on the slurries, particles were separated 
by centrifugation at 12,000 rpm then dried overnight at room temperature with an air 
current. The solids were then resuspended in pH 6.8 buffer and quantified with the RP-
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HPLC method. To determine the content of Lys in films, release of Lys was allowed to 
occur over 24 hours at 37 °C in an orbital shaker and then the media assayed by RP-
HPLC. 
5.3.5. Lysozyme activity with Micrococcus lysodeikticus 
The enzymatic activity of lysozyme after manufacture of particles was determined 
turbidimetrically based on the Shugar method [28]. Activity is correlated with a decrease 
in absorbance at 450 nm of solutions containing Micrococcus lysodeikticus due to the 
lytic activity of lysozyme on the cell walls. A 0.3 mg/mL cell suspension (0.9 mL) was 
mixed with a stock lysozyme pH 6.2 phosphate buffer solution containing 0.1 mg/mL 
(0.1 mL) to determine the maximum lytic effect. After separation and drying of particles, 
the solid was dissolved in a pH 6.2 phosphate buffer to a concentration of 0.1 mg/mL. 
Following the same procedure, sample solutions were assayed against a M. lysodeikticus 
suspension and absorbance was measured at 450 nm to determine maximum activity of 
solutions. Relative activity was calculated considering the absorbance measured for a 
fresh Lys stock solution as 100% activity. To determine the remaining relative activity of 
Lys in films, the same media obtained after overnight shaking depicted in section 5.3.4 
was utilized. 
5.3.6. Preparation of particle-containing films 
Casting solutions were prepared by combining two organic solutions and cast 
overnight in PTFE molds. Acetone was used to dissolve or suspend the polymer 
combinations as depicted in Table 5.2. This solution was combined in a 4:6 acetone to 
IPA ratio with suitable amounts of SPH02 (pH 6.8) of Lys-containing IPA (for the 
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control formulation, FPH06) to yield the final casting solution. After 24 hours, films were 
peeled off and stored in aluminum foil sachets in a dessicator until characterization. 
Table 5.2. Film formulation compositions (as % w/w) that were studied to investigate 
drug release and uniformity of films containing SPH02. 
Formulation Eudragit RL Eudragit RS HPMC TEC IPA solution 
FPH01 90 -- -- 10 SPH02 
FPH02 73 -- 17 10 SPH02 
FPH03 64 -- 26 10 SPH02 
FPH04 45 -- 45 10 SPH02 
FPH05 -- 90 -- 10 SPH02 
FPH06 90 -- -- 10 Lys* 
*: Unprocessed Lys was dispersed in IPA to prepare the control formulation FPH06. 
5.3.7. Morphology of particles and films by SEM 
A scanning electron microscope Quanta 650 FEG (SEM, FEI Company, 
Hillsboro, Oregon) was used for imaging and ultrastructure analysis of both particles and 
particle-containing films. After separation and drying of slurries, samples were mounted 
onto aluminum stubs using conductive carbon tape for coating. For the imagining of 
films, cross-sections were obtained by a freeze fracture method to ensure clean-cut edges 
and to avoid plastic deformation (often resulting from mechanical cutting). Fragments of 
the surface of the film were frozen by submerging in liquid nitrogen and thus cracked by 
freezing. Pieces of the films were fixed on aluminum stubs by means of conductive 
carbon tape for coating. Coating was performed using a 208 HR Cressington sputter 
coater (Cressington Scientific Instruments Ltd, Watford, UK) with Pt/Pd to a thickness of 
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10–15 nm in a high vacuum evaporator. To avoid structural deformation during imaging, 
the electron beam voltage was kept at 2–5 kV [29]. 
5.3.8. Mucoadhesive and mechanical properties of films in vitro 
Mucoadhesion tests were conducted on a TA.XTPlus texture analyzer (Stable 
Micro Systems, Godalming, UK) equipped with a 5 Kg load cell. Briefly, films were held 
in the horizontal position and 5 μL of model mucus (a freshly made 2% w/v mucin 
solution) was placed on top of the film. This amount is sufficient to mimic the average 
saliva thickness [30]. A 7 mm diameter stainless steel cylindrical probe was attached to 
the mobile arm of the texture analyzer and it was brought in contact with the film and 
mucin solution, held at an applied force of 50 mN for 15 seconds and then withdrawn at a 
0.5 mm/second rate. Mucoadhesive force (MAF) and work of adhesion (WoA) were 
obtained from the peak and the area under the curve in the force versus distance profile, 
respectively. 
For the determination of mechanical properties, rectangular strips of 1 x 5 cm2 
were cut and 1 cm on each end was held between clamps attached to the texture analyzer, 
leaving a testing area of 1 x 3 cm2. The upper clamp (connected to the mobile arm of the 
texture analyzer) was moved upwards at a rate of 0.5 mm/sec until film failure. Stress is 
obtained from the force measurements obtained from the instrument divided by the cross-
sectional area of the film, while strain is computed by dividing the increase in length by 
the initial film length. From the plot, the tensile strength (TS) and the elongation at break 
(EB) are obtained from the peak stress and the maximum strain, respectively, also 
represented by the following equations [16]: 
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ܶ݁݊ݏ݈݅݁	ݏݐݎ݁݊݃ݐ݄	ሺܶܵሻ ൌ ܲ݁ܽ݇	ݏݐݎ݁ݏݏܥݎ݋ݏݏ െ ݏ݁ܿݐ݅݋݈݊ܽ	ܽݎ݁ܽ	݋݂	݂݈݅݉ 
 
ܧ݈݋݊݃ܽݐ݅݋݊	ܽݐ	ܾݎ݁ܽ݇	ሺܧܤሻ ൌ ܫ݊ܿݎ݁ܽݏ݁	݅݊	݈݁݊݃ݐ݄	ܽݐ	ܾݎ݁ܽ݇ܫ݊݅ݐ݈݅ܽ	݂݈݅݉	݈݁݊݃ݐ݄ ൈ 100 
 
Additionally, the elastic modulus (EM) was obtained from the initial elastic 
deformation region in the stress vs. strain plot [31]. Since the rate of the mobile arm 
extension was constant for all samples tested, direct comparison of the slope in this 
region can be done. To further evaluate mechanical properties three additional parameters 
were computed from the conventional mechanical parameters obtained from the plot as 
follows [32]: 
 
ܶ݁݊ݏ݈݅݁	ݏݐݎ݁݊݃ݐ݄	ݐ݋	݉݋݀ݑ݈ݑݏ	ݎܽݐ݅݋ ൌ ܶܵܧܯ 
 
ܴ݈݁ܽݐ݅ݒ݁	ݏݑݎ݂ܽܿ݁	݁݊݁ݎ݃ݕ	ሺܴܵܧሻ ൌ ܶܵ
ଶ
2 ൈ ܧܯ 
 
ܶ݋ݑ݄݃݊݁ݏݏ	݅݊݀݁ݔ	ሺܶܫሻ ൌ 23 ൈ ܶܵ ൈ ܧܤ 
 
5.3.9. Lysozyme release and kinetics analysis 
Lysozyme release was performed on Franz diffusion cells with phosphate buffer 
pH 6.8 as media. To support the films and avoid solid disintegration into the receiving 
chamber a 0.1μm nylon membrane filter was additionally placed between the donor and 
receptor compartment. We found that said pore size does not limit diffusion; therefore, it 
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does not have an impact in the release properties from the films (data not shown). Films 
were cut into 1.5 cm diameter circular samples (n=3) and allowed to release into the 
reservoir media for 4 hours. At intervals of 0.25, 0.5, 1, 2, 3, and 4 hours 300 μL samples 
were withdrawn and replaced with fresh media. Lysozyme content was determined with 
the method described in section 5.3.4.  
To analyze the mechanisms involved in the lysozyme release, kinetics models 
were compared to the release profiles. The Higuchi [33], Korsmeyer-Peppas [34], and 
first order kinetic models were used to fit the data and were compared on the basis of R2 
adjusted [35]. The evaluation of the drug transport mechanism was addressed in 
accordance with the Korsmeye-Peppas model. 
5.3.10. Statistical analysis 
All statistical analyses were performed with the software Minitab Release 14® 
(Minitab Inc., State college, PA). One-way ANOVAs were used for multiple 
comparisons and Tukey's post hoc pairwise comparisons were performed to compare 
which results led to significant differences. For the evaluation of the kinetics models and 
calculation of adjusted R2 values the software Origin® 8.0 (Northampton, MA) was used 
to perform the non-linear regressions for each kinetic model equation. All values are 
reported as the mean and standard deviation of the mean shown in parenthesis. 
5.4. RESULTS AND DISCUSSION 
5.4.1. The effect of pH on the particle manufacturing process 
We have previously reported on a method of manufacture of submicron sized and 
nanosized particles containing Lys by an antisolvent co-precipitation method [27]. The 
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optimized method of manufacture consisted of the use of a nebulizer to add the aqueous 
phase into the surfactant containing organic phase under a high-energy mixing input 
generated by a probe sonicator. Here we investigated the effect of pH in the aqueous 
phase containing Lys over particle size, yield, and stability among others. 
A narrow particle size distribution was obtained at optimized conditions. Due to a 
limit of solubility of Val and supersaturation in the aqueous phase upon addition of Lys 
we were unable to manufacture SPH01 particles. SPH02 at pH 6.8 was found to be the 
best condition for the precipitation of Lys. This formulation yielded very small particle 
sizes (347.2±16.9 nm), adequate PdI, and low variability (Table 5.3). The flake-like 
shape of particles obtained for SPH02 are in agreement with previous findings obtained 
by inspection under the SEM (Figure 5.1) [27]. The ZP found for SPH02 is well 
correlated with particles in the nano size and the magnitude indicates good stability of the 
formulation [36]. This explains observations during a one week period of time where 
particles in the slurry remained in suspension in comparison with any other formulation 
that sedimented shortly after manufacture. 
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Table 5.3. Particle size reported as z-average, polydispersity index and zeta potential of 
Lys formulations. Results are represented as the mean and standard 
deviation in parenthesis. 
Formulation Z-average /nm* Polidispersity index* Zeta Potential /mV 
SPH01 --** --** --** 
SPH02 347.2 (16.9) 0.36 (0.02)i 21.9 (3.7)a 
SPH03 1384.0 (152.7) 0.28 (0.13)ii 18.3 (2.0)a 
SPH04 1220.2 (426.6) 0.43 (0.13) 10.1 (1.2) 
*: Among parameters, all differences were statistically significant (p<0.05). a, b: Among parameters, non-
significant differences are indicated in pairs of letters, all other differences are significant (p<0.05). **: co-
precipitant and Lys did not dissolve at pH 5.4. 
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Figure 5.1. SEM micrographs of protein-loaded submicron particles from formulation 
SPH02. The bar represents 1 μm. 
Regardless of the pH, excellent Lys yield and stability was achieved. With yields 
in the range of 70.5-73.4 (no statistical differences found, p >0.05) and remaining relative 
activity in the range of 91.4-101.1 % we corroborated that the method of manufacture of 
nanoparticles by the antisolvent co-precipitation method is successful in rendering 
functional particles. This also indicates that the pH of the buffer solution containing Lys 
before manufacture had little effect on the resulting stability after manufacture. 
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Investigations on the manufacture of microparticles in the range of 1–10 μm obtained 
through a similar process of antisolvent co-precipitation have shown positive results 
regarding the stability of the macromolecules coating an inert core [37,38]. Our findings 
here constitute an improvement over the particles obtained previously where the 
optimized conditions allowed for a z-average of 439 nm with a yield around 50 % and 
remaining activity of 98.7 % [27]. We were also able to obtain nanoparticles with a much 
higher enzyme load (40 % instead of 10 % w/w) which represents an advantage in terms 
of dosing in the final dosage form. 
 
Figure 5.2. Lys yield (■) and relative activity (□) of Lys-containing particle formulations. 
*: No significant differences were found among Lys yield results (p<0.05). 
**: All the activity results were significantly different from each other to a 
p<0.05. 
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5.4.2. Development of Lys particle-containing films 
 
Figure 5.3. SEM micrographs of cross-sections of films obtained by freeze-fracture. (a) 
FPH01, (b) FPH03, (c) FPH04, and (d) FPH05. The bar represents 20 μm. 
Films were successfully manufactured and their surface appeared homogeneous to 
the eye. An SEM observation of cross sections of selected film formulations obtained by 
freeze fracture reveals a uniform distribution of the flake-like particles throughout the 
polymeric matrix (Figure 5.3). A closer look (Figure 5.4) shows that mostly individual 
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particles are separately enclosed resulting in high drug content uniformity in the films. 
Agglomerates of HPMC can also be observed homogeneously distributed under the SEM, 
indicating the composite nature of the film. 
 
Figure 5.4. SEM micrographs of cross-sections of films obtained by freeze-fracture. (a) 
FPH01, (b) FPH03, (c) FPH04, and (d) FPH05. The bar represents 5 μm 
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5.4.2.1. Mucoadhesion and mechanical properties of Lys-containing 
films 
ERS and ERL are more commonly known for their applications on sustained drug 
delivery by controlling drug release rate of dosage forms. However, more recently we 
have reported on the high mucoadhesive properties exhibited by polymethacrylates, and 
more specifically ERL [26]. In accordance with what we previously found, films 
containing ERL showed high or very high mucoadhesive properties. When ERL was used 
as the only polymeric material the MAF achieved was higher (but not statistically 
different, p>0.05) and the WoA was significantly higher than any of the other 
formulations studied (Figure 5.5). We believe that the presence of water-soluble particles 
homogeneously distributed among the film surface allows for a more rapid and 
homogeneous water penetration. According to the theories of mucoadhesion based on 
diffusion [39] and water penetration [40], the presence of water in the interface is 
paramount for the establishment of the mucoadhesive bond. The water rapidly driven in 
by the water-soluble molecules allows for polymer chain mobility resulting in 
entanglement with the mucin molecules in the mucus layer and establishment of the 
mucoadhesive bond. Similar effects have been found in systems where the drug was 
incorporated as particulate material. Panomsuk et al. have described that the inclusion of 
a water soluble drug, such as theophylline, increases the amount of water associated with 
the polymer favoring gelling and swelling [41]. It has also been indicated that the 
presence of particulate material interrupts the polymer matrix continuum, allowing the 
polymer chains to move more freely leading to an increase in water penetration [42]. The 
absence of particulate material in the formulations containing only C974P and PCP leads 
to their inherent mucoadhesion that results from the capacity of the polymer to absorb 
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water and plasticize the polymer chains to interact with mucin [39]. It should be noted 
that the addition of HPMC hinders the full extent of mucoadhesion enhancement possibly 
by capturing the particles (that are more hydrophilic) in HPMC-rich domains. This results 
in slower hydration and thus a weaker mucoadhesive bond that mostly depends on the 
mucoadhesion of HPMC. HPMC has been used in the past as a mucoadhesive material 
but its mucoadhesive power is lower than that observed for PCP and C974P [43,44]. A 
similar trend was found in investigations by Wong et al. performed on films composed of 
a polymethacrylates and HPMC [45]. The authors found that an increase in the HPMC 
concentration resulted in a decrease in mucoadhesion. We believe that higher contents 
than 30% make a substantial change in the material properties and the inherent 
mucoadhesivity of HPMC starts to play a role at high contents. Finally, ERS exhibited 
higher MAF than results of ERL films with drug in solid solution [26]. This in interesting 
considering that ERS is the more hydrophobic material due to its lower content of 
quaternary ammonium groups. We have previously shown that ERS consistently exhibits 
lower MAF and WoA in comparison to ERL [26]. However, we believe that the 
enhancing effect of the water-soluble particulate material discussed earlier is responsible 
for this higher extent in mucoadhesive properties.  
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Figure 5.5. Mucoadhesive properties ( ) MAF and (■) WoA for Lys-containing films. 
The same values for conventional mucoadhesive polymers such as C974P 
and PCP are depicted for comparing the performance of films developed 
here. a – h: Non-significant differences among MAF are indicated in pairs of 
letters (p>0.05). *: Only WoA of FPH01 was significantly different from 
other formulations (p<0.05). All other values were not statistically different 
(p>0.05). 
Films as dosage forms for the buccal route of delivery have the need to withstand 
the stress originating from mouth mechanical activities. Both mechanical and 
mucoadhesive adequate characteristics are needed for the films to remain in contact with 
the mucosa for the desired amount of time of release [46]. Furthermore, another source of 
mechanical stress originates from the processes of manufacturing, handling, and 
administration [47]. Thus, in order to successfully develop films as dosage forms for 
buccal delivery it is desired a relatively high TS, EB, and a low EM [46]. Additionally, 
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derived from the conventional parameters extracted from stress vs. strain curves, a 
relatively high TS/EM, RSE, and TI are desired [32,48].  
Table 5.4. Mechanical properties for Lys-containing films. Results are represented as the 
mean and standard deviation in parenthesis. 
Formulation Tensile strength  N/mm2 
Elongation at break  
% 
Elastic modulus  
N/mm2/% 
FPH01 1.653 (0.160)a 197.9 (26.7)a 0.318 (0.110)a,b 
FPH02 2.783 (0.133) 50.0 (11.0)b,c 0.831 (0.048) 
FPH03 5.169 (0.462)b 25.6 (6.5)b,d 1.554 (0.191) 
FPH04 5.005 (0.464)b 18.0 (4.0)c,d 1.228 (0.129) 
FPH05 0.580 (0.075)c 233.6 (43.9)a 0.153 (0.038)a 
FPH06 1.273 (0.124)a,c 124.7 (12.9) 0.465 (0.093)b 
a – d: Among parameters, non-significant differences are indicated in pairs of letters. 
In Table 5.4 we can observe that adequate control over TS, EB, and EM was 
achieved for FPH01, FPH05, and FPH06, all of which only had either ERL or ERS and 
no other polymer. Quaternary ammonium polymethacrylates have been previously 
described to have suitable properties as film forming material for dosage forms for the 
buccal route [26]. In that study we showed that film formulations containing 10% 
triethylcitrate (TEC) as plasticizer rendered films with medium TS, high EB, and low 
EM. Here, we have found similar conditions for films that did not contain HPMC as a 
release modifier polymer. The addition of HPMC was correlated with an increase in TS, 
decrease in EB, and a slight increase in EM (Table 5.4). This is an indicative of less 
ductile yet more resistant films. The effect of HPMC over the mechanical properties of 
films is clearer after analysis of the derived mechanical parameters. TS/EM in an 
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indicator of the level of internal stress in a film. The larger its value the higher the film 
crack resistance. RSE is also utilized to estimate crack resistance and is approximated 
from the surface energy of the film. Finally, TI is an estimation of energy absorbed per 
unit volume of film under stress [32]. FPH01 is the formulation that possessed the largest 
TS/EM indicating high resistance to cracking (Table 5.5). The addition of HPMC reduced 
this value significantly except for FPH04; however, TS/EM values remained high and 
acceptable. In the same line, RSE of films increased with the increase of the content in 
HPMC, being highest for FPH04 at 10.32 N/mm2·%, indicating crack resistance. 
Comparison of TI indicates that except for FPH01 which resulted to be the toughest 
formulation, TI of all other formulations varies in acceptable ranges (Table 5.5). 
Table 5.5. Derived mechanical parameters calculated from conventional mechanical 
properties derived from a stress vs. strain plot. Results are represented as the 
mean and standard deviation in parenthesis. 
Formulation TS:EM %-1 
Relative Surface Energy 
N/mm2·% 
Toughness index 
N/mm2·% 
FPH01 5.69 (1.94)i,ii,iii 4.59 (1.06)a 216.51 (21.32)i,ii,iii,iv,v 
FPH02 3.36 (0.32)i 4.69 (0.63)a 92.08 (15.55)i 
FPH03 3.34 (0.22)ii 8.62 (0.77)b 88.10 (22.67)ii 
FPH04 4.11 (0.50) 10.32 (1.93)b 60.32 (15.70)iii,vi 
FPH05 3.88 (0.50) 1.11 (0.08)c 89.91 (17.96)iv 
FPH06 2.77 (0.29)iii 1.75 (0.08)c 106.33 (20.12)v,vi 
i - vi: Among parameters, statistically significant differences indicated in pairs of roman numerals 
(p<0.05). a – c: Among parameters, non-significant differences are indicated in pairs of letters. 
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5.4.2.2. Lys release and kinetics study 
 
Figure 5.6. Lys release profiles from particle-containing films FPH01 (♦), FPH02 (■), 
FPH03 (▲), FPH04 (), FPH05 (□), and the control FPH06 (●). 
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Table 5.6. Differences among FPH series of formulations based on the similarity factor, 
f2. Release profiles are similar if f2 ≥ 50. 
f2 FPH01 FPH02 FPH03 FPH04 FPH05 FPH06 
FPH01 -- 40.76 22.47 20.73 27.23 19.40 
FPH02  -- 34.46 31.64 18.11 12.65 
FPH03   -- 56.79 9.75 5.89 
FPH04    -- 9.00 5.29 
FPH05     -- 45.23 
FPH06      -- 
From the drug release profiles we can observe an increase in the release rate and 
extent of release as the concentration of HPMC increased in the formulations (FPH01–
FPH04, Figure 5.6). HPMC is a water swellable and erodible polymer that will dissolve 
from the dosage form; therefore, increasing concentrations of HPMC in formulations 
allow for domains in the film that will release Lys faster than ERL-rich domains. In 
accordance with the similarity value, f2 [49], FPH03 and FPH04 are the only 
formulations that render a similar Lys release profile (Table 5.6). Therefore, an increase 
in the HPMC content from 30 to 50% w/w of polymer did not elicit significant 
differences in the release profile. According to the Korsmeyer-Peppas model, even 
though FPH04 has a higher constant (k equals 0.2800 for FPH04 and 0.2255 for FPH03) 
contributing to faster release at earlier times, the higher exponential term of FPH03 (n 
equals 0.6604for FPH03 and 0.4875 for FPH04) allows for faster release at later times. 
Similar effects have been described before in films combining HPMC and ERL [50]. 
Among the various materials studied, Hassan et al. found that the combination of HPMC 
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and ERL resulted in a lower burst release (< 20% drug released in the first 15 minutes) 
and in formulations that only contained HPMC a more rapid release was found to be 
associated with the swellable soluble matrix that HPMC constitutes in water [51]. 
Another study conducted by Averineni et al. shows the effect of having increasing 
concentrations of HPMC in chitosan-containing film formulations [52]. Over a 210 
minutes period of time, drug release was increased from 52.52% to 73.23% for the 
formulations containing the lowest and highest amount of HPMC. 
In the Kormeyer-Peppas release kinetics model, n is the release exponent, and is 
an indicative of the drug release mechanism [34]. In the particular case of n equal to 0.5 
the drug release mechanism is purely Fickian diffusion (the particular solution that 
constitutes the Higuchi model equation). When n equals 1 the equation describes a zero 
order release mechanism, and the region ranging from 0.5 < n <1 represents the so-called 
anomalous transport. The first order kinetics applies to dosage forms that normally 
contain water-soluble drugs and porous polymer matrices. In said systems, drug release is 
proportional to the amount of drug remaining inside; therefore, the rate of drug release 
decreases with time. In Table 5.7 we can observe that except for FPH04, all formulations 
exhibit an anomalous release of Lys. This is a consequence of systems that are water 
swellable, where drug release occurs by a combination of diffusion and case-II transport. 
In the case of FPH04, the release is more adequately modeled by the Higuchi model 
(evidenced by the higher R2). This indicates that drug release in this system follows 
Fickian diffusion through the polymer matrix. In addition, all formulations are better 
adjusted to the first order kinetics model (according to the R2). This model describes drug 
release from porous matrices, such as that formed in a water swollen polymethacrylate 
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film, having a water soluble drug, such as the Lys-containing particles. In this system, 
drug release is proportional to the amount of drug remaining in the interior of the dosage 
form [35]. From the release profile we can also observe that when Lys was added to the 
film formulation as a solid solution very little release was achieved over the 4 hour period 
of time. Molecules in solid solution are completely surrounded by the polymeric matrix 
and a higher number of interactions between polymer and Lys can be achieved. This 
results in a very slow release over the time period (below LOQ). 
Table 5.7. Model parameters and adjusted R2 values for the FPH series of formulations. 
Formulation Korsmeyer-Peppas ܳ ൌ ݇ ൈ ݐ௡ 
Higuchi 
ܳ ൌ ݇ ൈ ݐ଴.ହ 
First order 
ܳ ൌ ݇ ൈ ሺ1 െ ݁ି௡௧ሻ 
 k N Adj R2 k Adj R2 k n Adj R2 
FPH01 0.1092 0.7702 0.9980 0.1407 0.9391 0.4956 0.2474 0.9995 
FPH02 0.1728 0.6287 0.9955 0.1943 0.9791 0.4702 0.4672 0.9965 
FPH03 0.2255 0.6604 0.9874 0.2612 0.9659 0.6579 0.4335 0.9998 
FPH04 0.2800 0.4875 0.9751 0.2769 0.9881 0.5340 0.8316 0.9966 
FPH05 0.0457 0.5837 0.9961 0.0492 0.9894 0.1114 0.5380 0.9911 
5.4.2.3. Remaining Lys activity after film manufacture 
After release for 24 hours in dissolution media activity of the Lys released was 
evaluated to measure any decrease in activity as an indicator of enzyme stability. As 
depicted in Figure 5.7, Lys remaining activity was excellent for all the formulations 
studied revealing that the processing of the manufactured particles into films for buccal 
delivery did not render the enzyme inactive. As shown above in the characterization of 
nanoparticles, enzyme activity is not compromised during the manufacturing process, and 
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the results obtained in this section show that further processing into polymeric films does 
not render the enzyme inactive. FPH05 exhibited a slightly lower activity which we 
believe was due to partial release of Lys over the 24 hours period (data not shown). 
 
Figure 5.7. Lys relative activity () obtained from infinity release studies from film 
formulations. a: non-significant difference is indicated in pair of letters 
(p>0.05). 
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5.5. CONCLUSIONS 
We have successfully developed mucoadhesive films for the delivery of Lys as a 
protein model. Lys was incorporated in the films as nanoparticles obtained by an 
antisolvent co-precipitation process. By controlling the pH and increasing the loading we 
were able to optimize conditions previously described. The new conditions for the 
method of manufacture allowed for the production of small and narrowly distributed 
particle with high yield and excellent remaining activity. Particles from formulation 
SPH02 were utilized in the manufacture of films for buccal delivery. All films containing 
Lys–coated nanoparticles had acceptable mechanical properties and Eudragit RL was 
shown to have excellent mucoadhesive properties. Additionally, films were able to 
sustain the release of Lys over 4 hours, modulated by the use of HPMC. Finally, we were 
able to achieve excellent enzyme activity maintained in films containing Eudragit RL. 
These films served as a preliminary model for their use with more therapeutically 
relevant macromolecules, such as insulin. The combination of the new particle 
manufacturing process and the use of films as solid delivery devices is depicted in the 
next chapter. 
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6. Development of Films of Insulin-Coated Nanoparticles for use in 
Buccal Delivery 
ABSTRACT 
The goal of this investigation was to develop films containing insulin (Ins) in 
particulate form and assay its performance. The nanoparticle manufacturing process 
previously described was adapted to manufacture Ins-coated nanoparticles (ICNP). 
Particles were characterized for size, zeta potential, and yield after manufacture. ICNP 
were embedded in films utilizing Eudragit® RLPO (ERL) and its combination with 
HPMC by a solvent casting process. Films were characterized for morphology, 
mechanical properties, mucoadhesion, and Ins release. Furthermore, Ins permeation was 
evaluated using a human buccal mucose tridimensional model. ICNP were successfully 
obtained by our antisolvent co-precipitation manufacturing process. Particles adopted the 
typical flake-like morphology, and the batch containing 40% w/w Ins rendered 323±8 nm 
particles with a high zeta potential of 32.4±0.8 mV indicating good suspension stability. 
High yields (around 100%) were obtained after manufacture and the Ins content was 
retained after one month storage in an ongoing stability study. ICNP-embedded films 
using ERL as the polymer matrix presented with excellent mechanical properties, 
mucoadhesion, and release properties. ERL-HPMC-Ins films yielded more brittle films 
with high variability among the cast surfaces that translated into high variability of 
content, release, and permeation. Permeation enhancement was observed for both 
formulations when compared with a control Ins solution. Films containing ICNP were 
successfully developed with high yields of Ins after manufacture. The formulation 
containing ERL was found to be more effective in terms of film performance and 
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permeation enhancement of Ins through a human buccal mucosa model compared to the 
combination of ERL with HPMC.   
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6.1. INTRODUCTION 
Protein and peptide therapeutics is a rapidly growing field in the pharmaceutical 
industry [1]. Due to specificity, which characterizes the action of proteins or peptides, 
only a relatively low dose is generally needed to obtain a therapeutic effect, making them 
ideal therapeutic agents and excellent alternatives for developing new medicines. 
However, it is widely reported in the literature that the efficacious delivery of these 
therapeutic agents can become the determinant factor for a product under development 
[2,3]. Therefore, in order to achieve the real potential of protein and peptide therapeutics, 
effective and smart delivery platforms and strategies, to overcome the formulation and 
delivery challenges, need to be developed. 
More specifically, insulin (Ins) is the main therapeutic agent for the treatment of 
insulin-dependent diabetes type I, and many non-insulin-dependent diabetes type II 
patients [4]. Moreover, since Ins is usually associated with long term therapies, its 
delivery via injections impose several drawbacks in patient acceptance. For example, 
non-Ins dependent patients tend to delay the start of their Ins therapy when prescribed 
and one of the factors associated with this phenomenon, known as ‘psychological insulin 
resistance’, is the patient perception of the Ins injection or needle anxiety [5,6]. This has 
resulted in many attempts to develop different routes of administration, giving mixed 
results in the literature. The oral route has been widely explored and has been reviewed 
previously [7,8]. Many challenges are involved in the development of peptide 
formulations delivered through the oral route, such as gastric pH instability, proteolytic 
enzyme content in the upper GI tract, insufficient permeation and bioavailability. Very 
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limited commercial success has been achieved, as evidenced by the lack of products in 
the market [9]. 
Alternative routes of administration that have been investigated more recently in 
order to avoid the drawbacks of the GI tract [10,11] are the pulmonary, nasal, 
transdermal, and buccal routes. Of these, the buccal route has a number of advantages for 
the delivery Ins, such as the avoidance of the GI tract, and the associated advantages of 
this (avoidance of the acid-catalyzed degradation in the stomach, enzyme degradation in 
the intestine, first-pass metabolism, and low permeability). Additionally, the absence of a 
keratinized layer would result in improved absorption compared to keratinized mucosa. 
Further advantages associated with the buccal route include: a relatively low enzyme 
content compared with the intestinal content, a good supply of vascular and lymphatic 
drainage, ease of administration, and long cellular turnover (5-6 days) which may 
facilitate long term delivery in retentive dosage forms [12]. In order to formulate proteins 
or peptides we have previously reported on the development of films as buccal delivery 
dosage forms [13]. The most conventional approach for film manufacture is the 
combination of drug and excipients in solution followed by casting in a mold and drying. 
However, in general the polymers utilized in formulations containing proteins are more 
hydrophobic in comparison to the hydrophilic nature of Ins.[14] This could potentially 
lead to separation and/or aggregation during storage, or in vivo, leading to possible 
instability.[15] Additionally, homogeneity in drug distribution (and particularly for Ins-
containing films) has not been addressed thoroughly in the literature. Even though 
chitosan has been reported as an adequate candidate as a polymer vehicle for Ins, no 
mention of Ins uniformity makes hard to reach a conclusion in homogeneity [16]. More 
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recently, Giovino et al. (2012) have developed chitosan films for the buccal sustained 
delivery of Ins in PEG-b-PLA nanoparticles as a model for buccal macromolecular 
delivery [17]. Although adequate physico-mechanical properties were achieved, very 
high heterogeneity was revealed by the mechanical variables studied, such as: time to 
break, tensile strength, Young’s modulus, and work done to break. This therefore raises 
concern over the tight control of manufacture necessary to prepare films with 
homogeneous Ins distribution, adequate physico-mechanical properties, high yield and 
retention of macromolecule activity. 
Recent developments in enzyme immobilization in organic solvents have allowed 
the development of novel method for the manufacture of protein-coated nanoparticles 
(PCNP), as described in Chapter 4 of this dissertation. This method was based on an 
improvement of an antisolvent co-precipitation method that has been shown before to 
successfully immobilize nucleic acids [18], proteins [19], enzymes [20], and other 
particulate systems [21]. However, most of these investigations lead to particles in the 
range of 1-5 μm and higher. To guarantee physical stability of the films in terms of 
mechanical and also mucoadhesive properties, such large particles are undesired due to 
potential for aggregation and loss in active distribution homogeneity [22]. However, 
submicron sized and nanosized particles have been found to produce films that comply 
with adequate mechanical and mucoadhesive properties [22]. Here, the antisolvent co-
precipitation method described in Chapter 5 was adapted for the manufacture of 
nanoparticles to obtain Insulin-coated nanoparticles (ICNP). These particles were then 
embedded in film formulations for buccal Ins delivery and studied for physicochemical 
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properties, release and permeation through a human buccal mucosa three dimensional 
model. 
6.2. MATERIALS 
D,L-valine (Val) and insulin (Ins) were obtained from Sigma-Aldrich (Sigma-
Aldrich, St. Louis, MS). Sorbitan monostearate (Span60) was obtained from Spectrum 
(Spectrum Chemical, New Brunswick, NJ). Eudragit RLPO (ERL) was kindly donated by 
Evonik (Evonik Industries, Darmstadt, Germany). Carbopol® 974P (C974P) and 
Noveon® AA-1 Polycarbophil (PCP) were donated by Lubrizol (Lubrizol Advanced 
Materials, Cleveland, OH). Hydroxypropyl methylcellulose (HPMC, Methocel E50 
Premium LV) was donated from Colorcon (Colorcon, Harleysville, PA). Triethyl citrate 
(TEC; Vertellus Specialties Inc, Indianapolis, IN), mucin (Spectrum Chemical, New 
Brunswick, NJ), and Micrococcus lysodeikticus (Worthington Biochemical Corp., 
Lakewood, NJ) were purchased and used as received. Human buccal mucosa was 
obtained from Mattek (Mattek Corporation, Ashland, MA). HPLC-grade 2-propanol 
(IPA) was obtained from Fisher Scientific (Fisher Scientific, Fair Lawn, NJ) while 
deionized water was procured in house. All other chemicals used were of analytical or 
reagent grade. 
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6.3. METHODS 
6.3.1. Insulin-coated nanoparticle (ICNP) manufacture 
The manufacturing process was based on antisolvent co-precipitation and our 
approach has been recently published elsewhere [23]. First, Val was dissolved in acid 
phthalate buffer pH 2.2 for a concentration of 61.2 mg/mL (or 90% w/v of its saturation 
concentration). Two different formulations were then manufactured to contain 10% and 
40% w/w of Ins based in solid content. By means of an Aeroneb Pro® vibrating mesh 
nebulizer (Aerogen, Galway, Ireland), the aqueous phase was then added to the 
antisolvent organic phase. As we have shown earlier [23], IPA as the antisolvent 
combined with Span 60 is the most effective antisolvent; therefore, a 0.008 mM Span 60 
solution was utilized. Finally, during the addition of the aqueous phase high energy 
mixing is provided by means of a Branson Sonifier 450 probe sonicator (Branson 
Ultrasonics, Danbury, CT). After addition of the total volume of aqueous phase 
sonication is maintained for a further 20 minutes to further stop particle growth during 
the early stages of coagulation [23]. 
6.3.2. Particle sizing by dynamic light scattering 
To determine the particle size of the slurries obtained in 6.3.1, a Zetasizer Nano 
ZS (Malvern Instruments Ltd., Worcester, UK) was utilized. Mean particle size was 
obtained as a Z-average which corresponds to the intensity weighted mean hydrodynamic 
size measured by dynamic light scattering (DLS). Additionally, an estimate of the width 
of the distribution was obtained from the instrument as a polydispersity index. 
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Approximately 1 mL of IPA slurry was analyzed by DLS in 1cm path length disposable 
polystyrene cuvettes. A total of 3-5 determinations of 15-20 runs each were conducted. 
6.3.3. Zeta–potential determination 
Zeta-potentials (ZP) of slurries were obtained by laser Doppler micro-
electrophoresis using a Malvern Zetasizer Nano ZS (Malvern Instruments Ltd., 
Worcester, UK). Approximately 1 mL of slurry was added to a polycarbonate capillary 
cell for determination of ZP. A total of 5 determinations of 14–20 runs each were 
conducted to obtain the average ZP of the slurries. 
6.3.4. Ins quantification by RP-HPLC 
Chromatography was performed using a Zorbax 300SB® C18 Rapid Resolution 
column (3.5 μm, 4.6 mm ID x 150 mm length) (Agilent Technologies, Santa Clara, 
CA).The mobile phase consisted of two solvents with different polarities: solvent A 
consisted of water, 5% v/v acetonitrile and 0.1% v/v trifluoroacetic acid, while solvent B 
consisted of acetonitrile, 5% v/v water, and 0.085% v/v trifluoroacetic acid. The mobile 
phase consisted initially of 10% v/v solvent B with a solvent gradient of 60% v/v solvent 
B in 16 minutes. The flow rate was set to 1 mL/min and temperature remained constant at 
25 °C. The injection volume was 50 μL and the UV detector was set to 215 nm. For the 
determination of Ins content on the slurries, particles were separated by centrifugation at 
12,000 rpm then dried overnight at room temperature with an air current. The solids were 
then dissolved in pH 2.2 buffer and quantified with the RP-HPLC method. To determine 
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the content of Ins in films, release of Ins was allowed to occur over 24 hours at 37 °C in 
an orbital shaker and then the media assayed for Ins content by RP-HPLC. 
6.3.5. Preparation of Ins-containing films 
Casting solutions were prepared by combining two organic solutions and cast 
overnight in PTFE molds. Acetone was used to dissolve or suspend the polymer 
combinations as depicted in Table 6.1. This solution was combined in a 4:6 acetone to 
IPA ratio with suitable amounts of slurries obtained in Section 6.3.1 to yield the final 
casting solution. After 24 hours, films were peeled off and stored in aluminum foil 
sachets in a dessicator until characterization. 
Table 6.1. Film formulations studied to investigate drug release and uniformity of films 
containing Ins particles. 
Formulation Eudragit RL % w/w 
HPMC 
% w/w 
TEC 
% w/w 
ERL-Ins 90 -- 10 
ERL-HPMC-Ins 45 45 10 
 
6.3.6. Morphology of particles and films by SEM 
A scanning electron microscope Quanta 650 FEG (SEM, FEI Company, 
Hillsboro, OR) was used for imaging and ultrastructure analysis of both particles and 
particle-containing films. For imaging ICNP, droplets of IPA slurries obtained in Section 
6.3.1 were deposited onto SEM stubs and allowed to dry on carbon tape before coating of 
the particles. For the imagining of films, cross-sections were obtained by a freeze fracture 
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method to ensure clean-cut edges and to avoid plastic deformation (often resulting from 
mechanical cutting) [22]. Fragments of films were flash frozen by submerging in liquid 
nitrogen and thus cracked by freezing. Pieces of the films were fixed on aluminum stubs 
by means of conductive carbon tape for coating. Coating was performed using a 208 HR 
Cressington sputter coater (Cressington Scientific Instruments Ltd, Watford, UK) with 
Pt/Pd to a thickness of 10–12 nm in a high vacuum evaporator. To avoid structural 
deformation during imaging, the electron beam voltage was kept low at 2–3 kV [24]. 
6.3.7. Mucoadhesive and mechanical properties of films in vitro 
Mucoadhesion tests were conducted using a TA.XTPlus texture analyzer (Stable 
Micro Systems, Godalming, UK) equipped with a 5 Kg load cell. Briefly, films were held 
in the horizontal position and 5 μL of model mucus (a freshly made 2% w/v mucin 
solution) was placed on top of the film. This amount is sufficient to mimic the thickness 
of the average saliva thickness [25]. A 7 mm diameter stainless steel cylindrical probe 
was attached to the mobile arm of the texture analyzer and it was brought in contact with 
the film and mucin solution, held at an applied force of 50 mN for 15 seconds and then 
withdrawn at a 0.5 mm/second rate. Mucoadhesive force (MAF) and work of adhesion 
(WoA) were obtained from the peak and the area under the curve in the force versus 
distance profile, respectively. 
For the determination of mechanical properties, rectangular strips of 1 x 5 cm2 
were cut and 1 cm on each end was held between clamps attached to the texture analyzer, 
leaving a testing area of 1 x 3 cm2. The upper clamp (connected to the mobile arm of the 
texture analyzer) was moved upwards at a rate of 0.5 mm/sec until film failure. Stress is 
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obtained from the force measurements obtained from the instrument divided by the cross-
sectional area of the film, while strain is computed by dividing the increase in length by 
the initial film length. From the plot, the tensile strength (TS) and the elongation at break 
(EB) are obtained from the peak stress and the maximum strain, respectively, also 
represented by the following equations [26]: 
 
ܶ݁݊ݏ݈݅݁	ݏݐݎ݁݊݃ݐ݄	ሺܶܵሻ ൌ ܲ݁ܽ݇ ݏݐݎ݁ݏݏܥݎ݋ݏݏ െ ݏ݁ܿݐ݅݋݈݊ܽ ܽݎ݁ܽ ݋݂ ݂݈݅݉ 
 
 
 
ܧ݈݋݊݃ܽݐ݅݋݊	ܽݐ	ܾݎ݁ܽ݇	ሺܧܤሻ ൌ ܫ݊ܿݎ݁ܽݏ݁ ݅݊ ݈݁݊݃ݐ݄ ܽݐ ܾݎ݁ܽ݇ܫ݊݅ݐ݈݅ܽ ݂݈݅݉ ݈݁݊݃ݐ݄ ൈ 100 
 
 
 
Additionally, the elastic modulus (EM) was obtained from the initial elastic 
deformation region in the stress vs. strain plot [27]. Since the rate of the mobile arm was 
constant during the test as well as for all different experiments, direct comparison of the 
slope in this region can be done. To further evaluate mechanical properties TS:EM ratio 
(TS:EM), relative surface energy (RSE), and toughness index (TI) were computed from 
the conventional mechanical parameters obtained from the plot as shown in the equations 
below [28]: 
 
ܶ݁݊ݏ݈݅݁	ݏݐݎ݁݊݃ݐ݄ ݐ݋ ݉݋݀ݑ݈ݑݏ ݎܽݐ݅݋ ൌ ܶܵܧܯ 
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ܴ݈݁ܽݐ݅ݒ݁	ݏݑݎ݂ܽܿ݁ ݁݊݁ݎ݃ݕ ሺܴܵܧሻ ൌ ܶܵ
ଶ
2 ൈ ܧܯ 
 
 
 
ܶ݋ݑ݄݃݊݁ݏݏ ݅݊݀݁ݔ ሺܶܫሻ ൌ 23 ൈ ܶܵ ൈ ܧܤ 
 
 
6.3.8. Ins release and kinetics analysis 
Ins release was performed on Franz diffusion cells and phosphate buffer pH 6.8 as 
media. To support the films and avoid solid disintegration into the receiving chamber a 
0.1 μm nylon membrane filter was used (so as not to limit diffusion). Films were cut into 
1.5 cm diameter circular samples (n=3) and allowed to release into the reservoir media 
for 4 hours. At intervals of 0.25, 0.5, 1, 2, 3, and 4 hours, 300 μL samples were 
withdrawn and replaced with fresh media. Ins content was determined with the method 
described in Section 6.3.4.  
To investigate the mechanisms involved in the lysozyme release, kinetics models 
were compared to the release profiles. The Higuchi [29], Korsmeyer-Peppas [30], and 
first order kinetic models were used to fit the data and were compared on the basis of R2 
adjusted [31]. The evaluation of the drug transport mechanism was addressed in 
accordance with the Korsmeyer-Peppas model.  
6.3.9. Ins permeation through a human buccal mucosa model 
Three dimensional models of human model mucosa obtained by differentiation of 
normal human buccal keratinocytes were obtained for this study (Mattek Corporation, 
Ashland, MA). Tissues grown in inserts were equilibrated at 37 °C for one hour prior to 
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permeation experiments with 0.9 mL of PBS in 6-well plates. In this way only the 
basolateral side of the tissue was exposed to the medium. At 0.25, 0.5, 1, 2, 3, and 4 
hours each insert was transferred to the next well containing 0.9 mL of fresh PBS to 
allow for further permeation of Ins. Ins permeated through into the basolateral solution 
was quantified by the method depicted in Section 6.3.4. 
6.3.10. Statistical analysis 
All statistical analyses were performed with the software Minitab Release 14® 
(Minitab Inc., State college, PA). T-tests were used when comparing two sets of data 
while one-way ANOVAs were used for multiple comparisons and Tukey's post hoc 
pairwise comparisons were performed to compare which results led to significant 
differences. Release kinetics were modeled using the DDSolver program [32] for 
Microsoft Excel®. For comparison of release profiles, the similarity factor (f2) was 
computed using the DDSolver program. f2 values greater than 50 indicate similarity 
between release profiles. All values are reported as the mean and standard deviation of 
the mean shown in parenthesis. 
6.4. RESULTS AND DISCUSSION 
6.4.1. Manufacture of insulin-containing nanoparticles by an antisolvent co-
precipitation process 
Previous findings by our group and others have demonstrated the use of the 
antisolvent precipitation process as a means to obtain multiparticulate systems with high 
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yield and activity. We have previously shown that both BSA and Lys nanosized particles 
can be obtained by a method that combines high energy mixing and a high surface of 
contact between the solvent and the antisolvent [23]. Here we have successfully obtained 
Insulin-coated nanoparticles (ICNP) by a similar method (Table 6.2). It was the use of a 
high content of the peptide that allowed for the smallest particles size (323±8 nm) and 
highest ZP (32.4±0.8 mV). The high value of ZP allowed for the slurry to remain in 
suspension for over two weeks compared to Ins 10% w/wthat sedimented after 48 hours.  
Table 6.2. Particle size reported as z-average, polydispersity index, and zeta-potential of 
the Ins formulations investigated. Results are represented as the mean and 
standard deviation in parenthesis. 
Formulation Z-average /nm Polidispersity index* Zeta-potential /mV 
Ins 10% 819 (48) 0.44 (0.14) 18.3 (0.3) 
Ins 40% 323 (8) 0.42 (0.02) 32.4 (0.8) 
*: except for polydispersity indices, all pairwise comparison were significantly different (p<0.001). 
 
Particles adopted the typical flake-like shape observed before in particles [23] 
where the core is composed of Val (Figure 6.1). In typical antisolvent co-precipitation 
processes the particle shape is determined by the crystalline structure of the core material 
[21,33]. Murdan et al. have found that the use of L-glutamine as the crystalline core 
material in diphtheria toxoid-coated microparticles resulted in crystalline material in 
similar shape to the naked amino acid material processed by the same method. The use of 
diphtheria toxoid in the aqueous phase resulted in a particle size decrease down to less 
than 10 μm [33]. In our studies we found that the addition of Ins significantly decreased 
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particle size from 888±10 nm for pure Val nanoparticles [23] to 819±48 nm with 10% 
w/w Ins and further down to 323±8 nm with 40% Ins w/w. This has been previously 
described for the process in several occasions in the literature [18–20,34] and it is the 
result of the molecule precipitating on the surface of the core material acting as a 
stabilizer much like the effect of a surfactant. Kreiner et al. described the effect of 
subtilisin Carlsberg as a precipitation “poison” by occupying the surface of the crystals 
and impeding further particle growth [34].  
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Figure 6.1. SEM micrographs of ICNP from Ins 10% w/w (top) and Ins 40% w/w 
(bottom). The bar represents 1 μm. 
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The antisolvent co-precipitation process has also been described as a process to 
render highly active and stable protein and peptide-containing particles. Here, even 
though Ins is subjected to high energy mixing via sonication, very high yields are 
achieved following manufacture (Figure 6.2). In general, exposure to organic solvent and 
high mixing energy can decrease the activity of labile molecules such as proteins and 
peptides by modifying their secondary and tertiary structures [35]. Nonetheless, the rapid 
dehydration that Ins molecules go through in the process described here allows for the 
maintenance of the molecular structure. Partridge et al. attributed this effect to the way 
that precipitation occurs [20]. During the precipitation process, molecules of the 
precipitant in their native aqueous form lose their solubilizing water molecules and are 
immobilized onto the surface of the core material crystals and retain this conformation 
after manufacture. Therefore, high yields and high activity can be achieved by using this 
process of nanoparticle manufacture. Similarly, high stability of Ins content in the 
particles manufactured were found after one month of storage under room conditions. 
The differences in Ins yield after one month of storage in room conditions (25 °C and 60 
% relative humidity) were not statistically significant (p>0.05) and it was overall 
excellent over 90% for both formulations (Figure 6.2). We have found similar results 
during production of lysozyme-coated nanoparticles obtained by the same method after 
three months of storage (data not shown). Partridge et al. observed similar results in 
subtilisin Carlsberg-coated microcrystals stored at 60 °C for six months [19]. 
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Figure 6.2. Ins yield after manufacture and stability after one month. *: Only between 
formulations the differences were significant (p<0.05). Yield decrease due 
to storage was not statistically significant (p>0.05).  
6.4.2. Development and of films for buccal delivery of Ins 
6.4.2.1. Morphology, mucoadhesion, and mechanical properties of films  
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Figure 6.3. SEM micrographs of cross-sections of films obtained by freeze-fracture. (a 
and c) ERL-Ins and (b and d) ERL-HPMC-Ins films. Bar on top 
micrographs represents 20 μm while bar on bottom micrographs represents 
5 μm. 
Successful manufacture of films was achieved with both polymers utilized. ERL 
films appeared homogeneous to the eye and inspection of cross-sections obtained by 
freeze fracture revealed a homogeneous distributions of what appears to be flakes of Ins-
coated nanoparticles (Figure 6.3c). Alternatively, films manufactured by combining ERL 
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and HPMC present with a more discontinuous matrix due to the distribution of HPMC 
throughout ERL. However, distinct domains reveal the presence of similar flake-like 
particles in the polymer matrix, similarly to the evidence found in ERL films (Figure 
6.3d). These findings are in agreement with what we have previously found in Lys-coated 
nanoparticle-containing films [13]. Both ERL and ERS were found to exhibit a 
homogeneous appearance in cross-sections and films combined with HPMC revealed 
distribution of HPMC-rich domains [13]. 
ERL was found to be an excellent mucoadhesive material regardless of exhibiting 
a slightly lower MAF compared to typical mucoadhesive materials such as C974P and 
PCP. As previously described, WoA of films containing PCNP was found to be notably 
higher than that observed in typical mucoadhesives [13]. The high solubility of the ICNP 
homogeneously distributed among ERL films allows for water penetration to be faster 
into the polymer matrix. This results in a faster softening effect on the polymer chains 
and an increase in flexibility of the film upon probe withdrawal. Finally upon probe 
withdrawal, the film can deform to a higher extent increasing the distance of the applied 
force resulting in an increase on WoA. In mucoadhesion theories of diffusion [36] and 
water movement [37], water plays a most important role in establishing the 
mucoadhesive bond. Water interacts with the polymer chains and softens the polymer 
matrix allowing for entanglement of domains of mucin molecules and polymer chains. 
Additionally, Nafee et al. have demonstrated that the presence of particulate material 
disrupts the continuum of the polymer matrix allowing for more free space for polymer 
movement and entanglement to happen [38]. A decrease in mucoadhesive properties by 
the addition of HPMC to an ERL polymer matrix has been previously described [13], and 
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is a consequence of slower wetting acting to lower mucoadhesion. A lower extent of 
mucoadhesion than that observed in films containing either C974P and PCP has also been 
reported for HPMC [39,40]. Wong et al. have found a similar trend to a decrease in 
mucoadhesive properties by combining HPMC with polymethacrylates [41]. 
 
Figure 6.4. Mucoadhesive properties of Ins-loaded films and typical mucoadhesive 
materials. Maximum adhesion force ( ) MAF, with non-significant 
differences indicated with asterisks (*, **, p>0.05); and Work of adhesion 
(■) WoA, with significant differences indicated in pairs of letters (a-e, 
p<0.01).  
Not only is mucoadhesion needed for films to be ideally placed in contact with the 
buccal mucosa, but strength and flexibility as determined by the mechanical properties of 
the films, are also paramount to withstand stress that originates from normal mouth 
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mechanical activities [42]. Furthermore, for handling and shipping of films as dosage 
forms, mechanical properties such as elongation, strength, and toughness are needed. In 
Table 6.3 we can observe that the inclusion of particles in the polymer matrix decreases 
strength, toughness, but increase elongation slightly compared to pure ERL films 
plasticized to the same extent with TEC. The disruption of the polymer continuum results 
in slightly softer acceptable films as solid dosage forms [42,43]. The addition of HPMC 
drastically decreased elongation and highly increased strength which is associated with a 
decrease in TI. Films low in TI become more brittle [28] which is further corroborated by 
the increased RSE observed [43]. RSE is used to estimate crack resistance and is 
approximated from the surface energy of the film, thus a high RSE indicates brittleness in 
films. 
Table 6.3. Direct and derived mechanical properties for Ins-containing films. Results are 
represented as the mean and standard deviation in parenthesis.  
Formulation Tensile strength  N/mm2 
Elongation at break  
% 
Elastic modulus  
N/mm2/% 
Control 1.455 (0.120)* 217.7 (30.5) 0.513 (0.062) 
ERL-Ins 0.514 (0.010)* 277.0 (14.3) 0.099 (0.009) 
ERL-HPMC-Ins 5.500 (0.945) 14.6 (3.5) 1.337 (0.275) 
 
TS:EM 
%-1 
Relative Surface Energy 
N/mm2·% 
Toughness index 
N/mm2·% 
Control 2.86 (0.34) 2.09 (0.37)* 212.69 (44.34) 
ERL-Ins 5.21 (0.52) 1.34 (0.14)* 94.83 (3.90)* 
ERL-HPMC-Ins 4.14 (0.21) 11.33 (1.65) 52.68 (10.18)* 
*: indicated pairs of data among parameters were not found to be statistically different (p>0.05). 
 
 
193 
 
6.4.2.2. Ins yield, release and kinetics 
 
Figure 6.5. Ins content uniformity after release over a 24 hours period of time for ERL-
Ins and ERL-HPMC-Ins films.  
 
To establish the yield of Ins-loaded films, release was allowed over 24 hours to 
quantify the content of Ins. Figure 6.5 shows the yields obtained for both formulations by 
comparing the assayed amount of insulin with the theoretical amount. It can be observed 
that practically all the estimated amount of Ins was contained in the films. However, a 
clear difference in uniformity can be depicted. ERL-HPMC-Ins films in particular 
exhibited a relative standard deviation of about 9%, which was much higher than the 
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0.4% obtained for ERL-Ins films. This also translated into high variability of release as 
observed in Figure 6.6. 
 
 
Figure 6.6. Ins release studies for ERL-Ins (♦) and ERL-HPMC-Ins (■) formulations. 
Figure 6.6 reveals that both formulations presented with similar release at early 
time points, but at later times ERL-Ins films released to a higher extent of about 65% 
over 4 hours. This resulted in a similarity factor (f2) lower than 50 (41.9) indicating that 
the release profiles are different. The higher extent of variability observed for ERL-
HPMC-Ins films can be attributed to the presence of HPMC which is responsible for an 
increase in heterogeneity of the polymer matrix. It has been described in the literature 
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that HPMC shows a faster release compared to that observed for ERL and this is 
attributed to a higher extent on swelling upon hydration [44,45]. Similar effects have 
been observed in the addition of HPMC to chitosan buccal films where the extent of 
release was increased from 52.5% to 73.2% over a 210 minute period [46]. Therefore, in 
these studies an increase in variability was observed due to the higher release of HPMC-
rich domains that contribute to heterogeneity. Signs of heterogeneity can also be 
observed in cross-sections obtained by freeze fracture in Figure 6.3. 
Both release profiles are best explained by the Korsmeyer-Peppas equation by 
inspection of the R2 values obtained in Table 6.4. The Korsmeyer-Peppas release model 
classifies release profiles according to the value of the exponent term n. Briefly, when n 
equals 0.5 the drug release mechanism is purely Fickian diffusion (in this particular case 
the KP model equates to the Higuchi model too). When n equals 1 the equation turns into 
a zero order release kinetics that is usually associated to water-soluble drugs contained in 
porous polymer matrices. And the region 0.5 < n <1 is referred to as an anomalous 
transport release mechanism. The n value of ERL-Ins films reveals release profile very 
close to a zero order release mechanism indicating that drug transport is mostly due to 
solubilization of Ins and diffusion out of the porous ERL matrix. Conversely, an n value 
of 0.631 observed for ERL-HPMC-Ins films indicates that a combination of phenomena 
turns the drug release mechanism in an anomalous transport. This is possibly due to the 
distribution of the drug in ERL-rich and HPMC-rich domains from which drug is 
released at different rates according to the release mechanism of each domain. HPMC is a 
highly water swellable and soluble polymer that releases drug by diffusion and erosion of 
the matrix[45] resulting normally in faster release profiles than those observed for either 
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ERL and ERS [13]. This is also in agreement with the higher variability observed in 
ERL-HPMC-films where two mechanisms of release are occurring at all times (Figure 
6.6).  
 
Table 6.4. Model parameters and adjusted R2 values for the insulin-containing films.  
Formulation Korsmeyer-Peppas ܳ ൌ ݇ ൈ ݐ௡ 
Higuchi 
ܳ ൌ ݇ ൈ ݐ଴.ହ 
First order 
ܳ ൌ 100 ൈ ሺ1 െ ݁ି௡௧ሻ 
 k N Adj R2 k Adj R2 n Adj R2 
ERL-Ins 14.311 1.086 0.9885 25.851 0.8378 0.217 0.9569 
ERL-HPMC-Ins 14.669 0.631 0.9595 16.436 0.9456 0.119 0.9211 
 
6.4.2.3. Ins diffusion through a human buccal model 
EpiOral® is a buccal mucosa model developed by culture of primary buccal 
keratinocytes on a fibroblast containing collagen-based matrix. These cells differentiate 
into a three dimensional model of about 8-11 cells layers thick. In comparison with other 
in vitro human buccal mucosa models it has been described as being the histologically 
closest to normal mucosa together with full-thickness oral mucosa [47]. 
Studies on the permeation of Ins through a human buccal mucosa revealed a 
similar trend in permeation compared to the extent of release and variability among 
formulations. Figure 6.7 shows the cumulative permeated Ins as a function of time 
through the buccal mucosa. Compared to the control group, both formulations 
successfully allowed for the penetration of Ins through the mucosa and enhanced the 
permeation extent. This effect of enhancement we believe is similar to what has been 
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described for chitosan [48]. Chitosan is another mucoadhesive material containing 
positively charged groups in its structure which allows for its mucoadhesion, much like 
the ERL. The permeation enhancement effect is attributed to the mucoadhesive material 
acting by increasing the retention time in contact with the buccal mucosa and creating a 
deposition of active material in the vicinity of the cell barrier, creating a high 
concentration gradient directing the release of active in the direction of the buccal 
mucosa [49]. This also explains the differences in extent of permeation enhancement 
between the two formulations. ERL-Ins releases Ins faster increasing the concentration 
gradient resulting is faster penetration of Ins compared to that of ERL-HPMC-Ins. Even 
though the difference in enhancement is clear from Figure 6.7, no statistical differences 
were observed for either Ins flux or lag time (Table 6.5). This is a consequence of the 
very high variability of permeation observed for ERL-HPMC-Ins films having domains 
that permeate Ins similarly to ERL-Ins, as well as HPMC-rich domains responsible for 
slower release of Ins. Regardless of this, permeation of Ins is greatly enhanced by the use 
of ERL and films as solid dosage forms achieving a flux of 0.34±0.05 μg/hr/cm2 and very 
little lag time at 7.8 minutes. 
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Figure 6.7. Cummulative Ins permeation of ERL-Ins (♦), ERL-HPMC-Ins (■) 
formulations, and a control solution of insulin PBS (▲). Permeation was 
performed using a human tridimensional buccal mucosa model. 
 
Table 6.5. Permeation flux and lag time observed for Ins-containing films. Results are 
represented as the mean and standard deviation in parenthesis. 
Formulation Flux μg/hr/cm2 
Lag time 
min 
ERL-Ins 0.34 (0.05) 7.81 (2.66) 
ERL-HPMC-Ins 0.13 (0.13) 5.14 (6.34) 
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6.5. CONCLUSIONS 
We have shown that the antisolvent co-precipitation method of manufacture of 
nanoparticles is suitable for obtaining ICNP with great yield and stability upon storage. 
Particles aligned to the typical flake-like structure of the core material, Val, and the use 
of Ins at higher loadings further decreased particle size.  
ICNP were then successfully formulated into mucoadhesive films for buccal 
delivery of Ins. Particularly, ERL-Ins films were found to perform best in comparison 
with ERL-HPMC-Ins films in most variables studied. Homogeneity was higher in ERL-
films which resulted in a tighter control over physic-mechanical properties as well as 
release and permeation. Higher extent of permeation enhancement by the use of ERL was 
observed in ERL-Ins films compared to an Ins control solution. Studies to test these films 
in an animal model are warranted.  
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7. Conclusions 
Films for buccal delivery of insulin (Ins) were successfully developed. Optimized 
film formulations exhibited excellent mechanical and mucoadhesive properties when 
loaded with protein-coated nanoparticles. Through an investigation of caffeine particles 
in films the existence of a particle size cutoff above which the physical properties of 
films are compromised has been described in this work. A direct consequence of higher 
particle size is non-uniform agglomeration throughout the surface of the film resulting in 
high variability in several properties of the film including content uniformity and drug 
release. In addition, the polymethacrylate Eudragit® RLPO (ERL) was found to be an 
excellent mucoadhesive polymer. Typically regarded in the literature as a hydrophobic 
material, no previous applications as a mucoadhesive in films for buccal delivery have 
been reported. The best performing ERL formulation achieved very high work of 
adhesion (WoA) of 118.9 μJ, which corresponded to about 5-6 times higher than the 
WoA observed for commonly used mucoadhesives such as Carbopol 974P (C974P, 23.9 
μJ) and polycarbophil (PCP, 17.4 μJ). 
Proteins, peptides, and macromolecules in general, are known to be labile 
molecules that could be rendered inactive by a variety of processes. It has been reported 
that adding Ins into polymer matrices as a solid solution results in loss of activity. In 
addition, contact of proteins or peptides with organic solvents can also hinder the 
molecular structure and thus their stability. Chapter 4 described a method for the 
manufacture of protein-coated particles with high yields but more importantly, high 
activity after manufacture even when the process involves the use of organic solvents. 
The antisolvent co-precipitation process consists of precipitating macromolecules on the 
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surface of growing core crystals typically composed of an amino acid. The aqueous phase 
contained both the core forming material and the protein or peptide of interest and this 
solution was then added onto an organic solvent miscible with water. The addition of the 
aqueous phase into the organic phase starts a rapid dehydration process that triggers the 
precipitation of the core material first (due to its high concentration near saturation) and 
of the protein. This work described a novel method of manufacture based on antisolvent 
co-precipitation adapted to render nanoparticles. Investigations on the processing and 
formulation parameters governing this method revealed that a combination of high 
energy mixing by means of a probe sonicator, the use of Span 60 as a stabilizing 
surfactant at its critical micelle concentration, and the addition of the aqueous phase with 
a high surface area for interaction with the organic phase using nebulization resulted in 
submicron sized and nanosized protein-coated particles for all models. These particles 
were found to exhibit excellent yields and activity after manufacture regardless of the 
macromolecule exposure to organic solvents. This is a consequence of the rapid 
dehydration that takes place upon combination of both phases. The protein or peptide of 
interest loses their solubilizing water molecules and it immobilized onto the surface of 
the growing core crystals in a native form. This allows for high stability during the 
process that further translated into high activity after manufacture. 
To render films with adequate physical properties containing particulate material, 
submicron sized particles were found to be needed. The work on protein-coated particles 
described in Chapter 4 and further work on the effect of pH over particle size, yield, and 
activity allowed for obtaining optimized protein-coated nanoparticles (PCNP) based on 
the antisolvent co-precipitation process. These particles were embedded in platform film 
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formulations that are intended to be suitable for the buccal delivery of proteins, which 
was inferred in one respect by the high yield and activity they exhibited. Successful film 
formulations could be obtained by adding slurries of nanoparticles on solutions 
containing mucoadhesive polymers and casting them as described in Chapter 3. Excellent 
mucoadhesive properties were achieved in films containing ERL embedded with PCNP. 
The presence of the water-soluble nanoparticles enhanced mucoadhesion of ERL films 
even further due to an increase in water migration into the polymer matrix. The release of 
Lys could be tuned with the use of HPMC as a water-swellable and soluble material. 
Over four hours of active release could be controlled by adjusting formulation 
parameters, and the Lys remained fully active during this period of time. 
Finally, all the work completed in earlier Chapters of this dissertation led to the 
development of Ins-loaded films. These films were obtained by first adapting the method 
of manufacture of nanoparticles for the manufacture of Ins-coated nanoparticles (ICNP) 
and then embedding said particles on polymer matrices. High loads of Ins (40 % w/w) 
could be achieved in ICNP which resulted in an even greater decrease in particle size 
with excellent yield. The higher loading of Ins limited the growth of particles by acting 
like a stabilizing surfactant on the surface of nanoparticles. ERL was again found to be 
the best performing material in terms of physicochemical properties. Ins release from 
ERL-Ins films was found to achieve greater and more uniform concentrations than those 
observed for ERL-HPMC-Ins films. Additionally, in vitro permeation studies conducted 
on a three dimensional human buccal model revealed an enhancement on permeability 
when Ins was loaded on films. This was due to the higher concentration gradient that is 
achieved by loading the active in films and thus steering the release in the direction of the 
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buccal mucosa. Thus, Ins-loaded films were developed and successfully delivered the 
active through a buccal mucosa model while maintaining excellent physicochemical 
properties.  
The research conducted for this dissertation was aimed at developing a suitable 
dosage form for successful delivery of Ins through a buccal mucosa model. It was found 
that films are suitable candidates as a solid dosage form with great potential for being 
adapted to the delivery objectives sought. Particulate material containing macromolecules 
in the form of protein-coated nanoparticles were found to improve the physicochemical 
characteristics of films and warranted high yields and activity of the loaded active. The in 
vitro demonstration of Ins permeation makes an in vivo study the logical next step in this 
investigation. Due to the similarity to the human mucosa and comparative convenience to 
other models, the mini pig would be the animal of choice for pharmacokinetic and 
pharmacodynamics studies. Rodents, except for the rabbit, have a keratinized buccal 
mucosa limiting their use as animal models. Rabbits possess a para-keratinized mucosa 
also hindering their effectiveness as an animal model. Ultimately, the direction of this 
research is to find a formulation capable of treating diabetes by Ins delivery through the 
buccal mucosa with adequate pharmacokinetics and we believe that the research and 
findings reported here contribute significantly to that goal.  
 
  
 
210 
 
Bibliography 
Abu-Huwaij, R., Assaf, S., Salem, M., & Sallam, A. (2007a). Potential Mucoadhesive 
Dosage Form of Lidocaine Hydrochloride: II. In Vitro and In Vivo Evaluation. 
Drug Development and Industrial Pharmacy, 33(4), 437–448. 
doi:10.1080/03639040601150211 
Abu-Huwaij, R., Assaf, S., Salem, M., & Sallam, A. (2007b). Mucoadhesive Dosage 
form of Lidocaine Hydrochloride: I. Mucoadhesive and Physicochemical 
Characterization. Drug Development and Industrial Pharmacy, 33(8), 855–864. 
doi:10.1080/03639040701377516 
Agu, U., Ugwoke, I., Armand, M., Kinget, R., & Verbeke, N. (2001). The lung as a route 
for systemic delivery of therapeutic proteins and peptides. Respiratory research, 
2(4), 198. 
Ahmed, A., Barry, B. W., Williams, A. C., & Davis, A. F. (2004). Penciclovir solubility 
in Eudragit films: a comparison of X-ray, thermal, microscopic and release rate 
techniques. Journal of Pharmaceutical and Biomedical Analysis, 34(5), 945–956. 
doi:10.1016/j.jpba.2003.11.018 
Ahuja, A., Rahman, S., Ali, J., & Chaudhry, R. (2003). Effect of dental films containing 
amoxycillin and metronidazole on periodontal pathogens: microbiological 
response. Pharmazie, 58(10), 716–720. 
Ahuja, Alka, Khar, R. K., & Ali, J. (1997). Mucoadhesive Drug Delivery Systems. Drug 
Development and Industrial Pharmacy, 23(5), 489. 
doi:10.3109/03639049709148498 
Aitken-Nichol, C., Zhang, F., & McGinity, J. W. (1996). Hot Melt Extrusion of Acrylic 
Films. Pharmaceutical Research, 13(5), 804–808. doi:10.1023/A:1016076306279 
Aksungur, P., Sungur, A., Ünal, S., Iskit, A. B., Squier, C. A., & Senel, S. (2004). 
Chitosan delivery systems for the treatment of oral mucositis: in vitro and in vivo 
 
211 
 
studies. Journal of Controlled Release, 98(2), 269–279. 
doi:10.1016/j.jconrel.2004.05.002 
Alanazi, F. K., Abdel Rahman, A. A., Mahrous, G. M., & Alsarra, I. A. (2007). 
Formulation and physicochemical characterisation of buccoadhesive films 
containing ketorolac. Journal of drug delivery science and technology, 17(3), 
183–192. 
Alsarra, I. A., Alanazi, F. K., Mahrous, G. M., Abdel Rahman, A. A., & Al Hezaimi, K. 
A. (2007). Clinical evaluation of novel buccoadhesive film containing ketorolac 
in dental and post-oral surgery pain management. Pharmazie, 62(10), 773–778. 
Anders, R., & Merkle, H. P. (1989). Evaluation of laminated muco-adhesive patches for 
buccal drug delivery. International Journal of Pharmaceutics, 49(3), 231–240. 
doi:10.1016/0378-5173(89)90347-5 
Arakawa, Y., Kawakami, S., Yamashita, F., & Hashida, M. (2005). Effect of low-
molecular-weight beta-cyclodextrin polymer on release of drugs from 
mucoadhesive buccal film dosage forms. Biological & Pharmaceutical Bulletin, 
28(9), 1679–83. doi:JST.JSTAGE/bpb/28.1679 
Asane, G. S., Nirmal, S. A., Rasal, K. B., Naik, A. A., Mahadik, M. S., & Rao, Y. M. 
(2008). Polymers for Mucoadhesive Drug Delivery System: A Current Status. 
Drug Development and Industrial Pharmacy, 34(11), 1246. 
doi:10.1080/03639040802026012 
ASTM. (1991). Standard test methods for tensile properties of thin plastic sheeting. D 
882. American Standard Testing Methods. 
ASTM. (2008). Standard Test Method for Tear Resistance (Graves Tear) of Plastic Film 
and Sheeting - D 1004. American Standard Testing Methods. 
 
212 
 
Aulton, M. E., Abdul-Razzak, M. H., & Hogan, J. E. (1981). The mechanical properties 
of hydroxypropylmethylcellulose films derived from aqueous systems: The 
influence of solid inclusions. Drug Dev. Ind. Pharm, 7, 649–668. 
Aungst, B. J. (1996). Oral Mucosal Permeation Enhancement: Possibilities and 
Limitations. In M. J. Rathbone (Ed.), Oral mucosal drug delivery (pp. 65–83). 
Informa Health Care. 
Averineni, R. K., Sunderajan, S. G., Mutalik, S., Nayak, U., Shavi, G., Armugam, K., 
Meka, S. R., et al. (2009). Development of mucoadhesive buccal films for the 
treatment of oral sub-mucous fibrosis: a preliminary study. Pharmaceutical 
development and technology, 14(2), 199–207. 
Barnett, M. L., & Szabo, G. (1973). Gap junctions in human gingival keratinized 
epithelium. Journal of Periodontal Research, 8(3), 117–126. doi:10.1111/j.1600-
0765.1973.tb01750.x 
Barnhart, S. D. (2008). Thin Film Oral Dosage Forms. In M. J Rathbone, J. Hadgraft, M. 
S. Roberts, & M. E. Lane (Eds.), Modified-release Drug Delivery Technology 
(2nd ed., pp. 209–216). 
Baszkin, A., Proust, J. E., Monsenego, P., & Boissonnade, M. M. (1990). Wettability of 
polymers by mucin aqueous solutions. Biorheology, 27(3-4), 503–514. 
Bell, G., Halling, P. J., Moore, B. D., Partridge, J., & Rees, D. G. (1995). Biocatalyst 
behaviour in low-water systems. Trends in Biotechnology, 13(11), 468–473. 
doi:10.1016/S0167-7799(00)89004-6 
Benes, L., Claustrat, B., Horriere, F., Geoffriau, M., Konsil, J., Parrott, K. A., Degrande, 
G., et al. (1997). Transmucosal, oral controlled-release, and transdermal drug 
administration in human subjects: A crossover study with melatonin. Journal of 
Pharmaceutical Sciences, 86(10), 1115–1119. doi:10.1021/js970011z 
 
213 
 
Benson, H. A. E., & Namjoshi, S. (2008). Proteins and peptides: Strategies for delivery to 
and across the skin. Journal of Pharmaceutical Sciences, 97(9), 3591–3610. 
doi:10.1002/jps.21277 
BioDelivery Sciences International. (2010, September 24). OnsolisTM. 
http://www.bdsi.com/onsolis.php. Retrieved September 24, 2010, from 
http://www.bdsi.com/onsolis.php 
Bogataj, M., Vovk, T., Kerec, M., Dimnik, A., Grabnar, I., & Mrhar, A. (2003). The 
correlation between zeta potential and mucoadhesion strength on pig vesical 
mucosa. Biological & Pharmaceutical Bulletin, 26(5), 743–746. 
Borrás-Blasco, J., López, A., Morant, M. ., Diez-Sales, O., & Herráez-Dominguez, M. 
(1997). Influence of sodium lauryl sulphate on the in vitro percutaneous 
absorption of compounds with different lipophilicity. European Journal of 
Pharmaceutical Sciences, 5(1), 15–22. doi:10.1016/S0928-0987(96)00184-4 
Brown, C. D., Kreilgaard, L., Nakakura, M., Caram-Lelham, N., Pettit, D. K., Gombotz, 
W. R., & Hoffman, A. S. (2001). Release of PEGylated granulocyte-macrophage 
colony-stimulating factor from chitosan/glycerol films. Journal of Controlled 
Release, 72(1-3), 35–46. doi:10.1016/S0168-3659(01)00260-7 
Bummer, P. M. (2007). Chemical Considerations in Protein and Peptide Stability. In E. J. 
McNally & J. E. Hastedt (Eds.), Protein formulation and delivery (2nd ed., pp. 7–
42). New York: Informa Healthcare. 
Calvo, P., Gouritin, B., Chacun, H., Desmaële, D., d’ Angelo, J., Noel, J. P., Georgin, D., 
et al. (2001). Long-circulating PEGylated polycyanoacrylate nanoparticles as new 
drug carrier for brain delivery. Pharmaceutical research, 18(8), 1157–1166. 
Chang, R. K., Peng, Y., Trivedi, N., & Shukla, A. J. (2009). Polymethacrylates. In R. C. 
Rowe, P. J. Sheskey, & M. E. Quinn (Eds.), Handbook of Pharmaceutical 
Excipients (pp. 525–533). Pharmaceutical Press. 
 
214 
 
Chen, X., Matteucci, M. E., Lo, C. Y., Johnston, K. P., & Williams III, R. O. (2009). 
Flocculation of Polymer Stabilized Nanocrystal Suspensions to Produce 
Redispersible Powders. Drug development and industrial pharmacy, 35(3), 283–
296. 
Chickering, D. E., & Mathiowitz, E. (1999). Definitions, mechanisms, and theories of 
bioadhesion. In E. Mathiowitz, D. E. Chickering, & C. M. Lehr (Eds.), 
Bioadhesive Drug Delivery Systems: Fundamentals, Novel Approaches, and 
Development. New York: Marcel Dekker Inc. 
Ching, C. T. S., & Connolly, P. (2008). A novel diffusion cell ideal for the study of 
membrane extraction/permeation processes and for device/sensor development. 
Sensors and Actuators B: Chemical, 129(1), 30–34. 
doi:10.1016/j.snb.2007.07.070 
Chun, M., Kwak, B., & Choi, H. (2003). Preparation of buccal patch composed of 
carbopol, poloxamer and hydroxypropyl methylcellulose. Archives of Pharmacal 
Research, 26(11), 973–978. doi:10.1007/BF02980208 
Cilurzo, F., Cupone, I. E., Minghetti, P., Selmin, F., & Montanari, L. (2008). Fast 
dissolving films made of maltodextrins. European Journal of Pharmaceutics and 
Biopharmaceutics, 70(3), 895–900. doi:10.1016/j.ejpb.2008.06.032 
Cilurzo, F., Minghetti, P., Selmin, F., Casiraghi, A., & Montanari, L. (2003). 
Polymethacrylate salts as new low-swellable mucoadhesive materials. Journal of 
Controlled Release, 88(1), 43–53. doi:10.1016/S0168-3659(02)00459-5 
Collins, L. M. C., & Dawes, C. (1987). The Surface Area of the Adult Human Mouth and 
Thickness of the Salivary Film Covering the Teeth and Oral Mucosa. Journal of 
Dental Research, 66(8), 1300–1302. doi:10.1177/00220345870660080201 
Colombo, P. (1993). Swelling-controlled release in hydrogel matrices for oral route. 
Advanced Drug Delivery Reviews, 11(1–2), 37–57. doi:10.1016/0169-
409X(93)90026-Z 
 
215 
 
Connolly, P., Cotton, C., & Morin, F. (2002). Opportunities at the skin interface for 
continuous patient monitoring: a reverse iontophoresis model tested on lactate and 
glucose. NanoBioscience, IEEE Transactions on, 1(1), 37–41. 
doi:10.1109/TNB.2002.806939 
Costa, P., & Sousa Lobo, J. M. (2001). Modeling and comparison of dissolution profiles. 
European Journal of Pharmaceutical Sciences, 13(2), 123–133. 
doi:10.1016/S0928-0987(01)00095-1 
Cui, F., He, C., Yin, L., Qian, F., He, M., Tang, C., & Yin, C. (2007). Nanoparticles 
Incorporated in Bilaminated Films: A Smart Drug Delivery System for Oral 
Formulations. Biomacromolecules, 8(9), 2845–2850. doi:10.1021/bm070339e 
Cui, Fuying, He, C., He, M., Tang, C., Yin, L., Qian, F., & Yin, C. (2009). Preparation 
and evaluation of chitosan-ethylenediaminetetraacetic acid hydrogel films for the 
mucoadhesive transbuccal delivery of insulin. Journal of Biomedical Materials 
Research Part A, 89A(4), 1063–1071. doi:10.1002/jbm.a.32071 
Cui, Z., & Mumper, R. J. (2002a). Bilayer Films for Mucosal (Genetic) Immunization via 
the Buccal Route in Rabbits. Pharmaceutical Research, 19(7), 947–953. 
doi:10.1023/A:1016454003450 
Cui, Z., & Mumper, R. J. (2002b). Buccal Transmucosal Delivery of Calcitonin in 
Rabbits Using Thin-Film Composites. Pharmaceutical Research, 19(12), 1901–
1906. doi:10.1023/A:1021462012442 
Danjo, K., Higuchi, F., & Otsuka, A. (1995). Release of lidocaine from polymer film 
dosage forms. Chemical & Pharmaceutical Bulletin, 43(10), 1759–1763. 
Davis, J. R. (Ed.). (2004). Mechanical Behaviour of Materials under Tensile Loads. 
Tensile Testing (2nd ed., pp. 13–31). Materials Park, Ohio: ASM International. 
de Vries, M. E., Boddé, H. E., Verhoef, J. C., Ponec, M., Craane, W., & Junginger, H. E. 
(1991). Localization of the permeability barrier inside porcine buccal mucosa: a 
 
216 
 
combined in vitro study of drug permeability, electrical resistance and tissue 
morphology. International journal of pharmaceutics, 76(1-2), 25–35. 
DeGrande, G., Benes, L., Horriere, F., Karsenty, H., Lacoste, C., McQuinn, R. L., Guo, 
J., et al. (1996). Specialized oral mucosal drug delivery systems: patches. In M.J. 
Rathbone (Ed.), Oral mucosal drug delivery. Informa Health Care. 
Deneer, V. H. M., Drese, G. B., Roemelé, P. E. H., Verhoef, J. C., Lie-A-Huen, L., 
Kingma, J. H., Brouwers, J. R. B. J., et al. (2002a). Buccal transport of flecainide 
and sotalol: effect of a bile salt and ionization state. International Journal of 
Pharmaceutics, 241(1), 127–134. doi:10.1016/S0378-5173(02)00229-6 
Deneer, V. H. M., Drese, G. B., Roemelé, P. E. H., Verhoef, J. C., Lie-A-Huen, L., 
Kingma, J. H., Brouwers, J. R. B. J., et al. (2002b). Buccal transport of flecainide 
and sotalol: effect of a bile salt and ionization state. International Journal of 
Pharmaceutics, 241(1), 127–134. doi:10.1016/S0378-5173(02)00229-6 
Derjaguin, B. V., & Smilga, V. P. (1969). Adhesion: fundamentals and practice. London: 
McLaren. 
Derollez, P., Correia, N. T., Danede, F., Capet, F., Affouard, F., Lefebvre, J., & 
Descamps, M. (2005). Ab initio structure determination of the high-temperature 
phase of anhydrous caffeine by X-ray powder diffraction. Acta Crystallographica 
Section B: Structural Science, 61(3), 329–334. 
Desai, K.-G., Mallery, S., Holpuch, A., & Schwendeman, S. (2011). Development and In 
Vitro-In Vivo Evaluation of Fenretinide-Loaded Oral Mucoadhesive Patches for 
Site-Specific Chemoprevention of Oral Cancer. Pharmaceutical Research, 28(10), 
2599–2609. doi:10.1007/s11095-011-0489-3 
Deshmane, S. V., Channawar, M. A., Chandewar, A. V., Joshi, U. M., & Biyani, K. R. 
(2009). Chitosan based sustained release mucoadhesive buccal patches containing 
verapamil HCL. International Journal of Pharmacy and Pharmaceutical Sciences, 
1(Suppl. 1), 216–229. 
 
217 
 
Diaz del Consuelo, I., Falson, F., Guy, R. H., & Jacques, Y. (2007). Ex vivo evaluation of 
bioadhesive films for buccal delivery of fentanyl. Journal of Controlled Release, 
122(2), 135–140. doi:10.1016/j.jconrel.2007.05.017 
Dixit, R. P., & Puthli, S. P. (2009). Oral strip technology: Overview and future potential. 
Journal of Controlled Release, 139(2), 94–107. doi:10.1016/j.jconrel.2009.06.014 
Doijad, R. C., Manvi, F. V., Malleswara Rao, V. S. N., & Patel, P. S. (2006). 
Buccoadhesive drug delivery system of isosorbide dinitrate: Formulation and 
evaluation. Indian journal of pharmaceutical sciences, 68(6), 744–748. 
Donnelly, R. F., McCarron, P. A., Tunney, M. M., & Woolfson, A. D. (2007). Potential 
of photodynamic therapy in treatment of fungal infections of the mouth. Design 
and characterisation of a mucoadhesive patch containing toluidine blue O. Journal 
of Photochemistry and Photobiology B: Biology, 86(1), 59–69. 
doi:10.1016/j.jphotobiol.2006.07.011 
Dowty, M. E., Knuth, K. E., Irons, B. K., & Robinson, J. R. (1992). Transport of 
Thyrotropin Releasing Hormone in Rabbit Buccal Mucosa in Vitro. 
Pharmaceutical Research, 9(9), 1113–1122. doi:10.1023/A:1015883217858 
Dubolazov, A. V., Nurkeeva, Z. S., Mun, G. ., & Khutoryanskiy, V. V. (2006). Design of 
Mucoadhesive Polymeric Films Based on Blends of Poly(acrylic acid) and 
(Hydroxypropyl)cellulose. Biomacromolecules, 7(5), 1637–1643. 
doi:10.1021/bm060090l 
Edwards, H. G. M., Lawson, E., de Matas, M., Shields, L., & York, P. (1997). 
Metamorphosis of caffeine hydrate and anhydrous caffeine. Journal of the 
Chemical Society, Perkin Transactions 2, (10), 1985–1990. doi:10.1039/a702041d 
El-Kamel, A., Ashri, L., & Alsarra, I. (2007). Micromatricial metronidazole benzoate 
film as a local mucoadhesive delivery system for treatment of periodontal 
diseases. AAPS PharmSciTech, 8(3), E184–E194. doi:10.1208/pt0803075 
 
218 
 
Eouani, C., Piccerelle, P., Prinderre, P., Bourret, E., & Joachim, J. (2001). In-vitro 
comparative study of buccal mucoadhesive performance of different polymeric 
films. European Journal of Pharmaceutics and Biopharmaceutics, 52(1), 45–55. 
doi:10.1016/S0939-6411(01)00146-1 
Evonik Industries. (2009). Sustained-release Formulations. Eudragit Application 
Guidelines (11th ed., pp. 1–12). Darmstadt, Germany: Evonik Rohm GmbH. 
Fabrizio, B., Giulia, B. A., Fabio, S., Paola, R., & Gaia, C. (2009). In vitro permeation of 
desmopressin across rabbit nasal mucosa from liquid nasal sprays: The enhancing 
effect of potassium sorbate. European Journal of Pharmaceutical Sciences, 37(1), 
36–42. doi:10.1016/j.ejps.2008.12.015 
Felton, L. A., O’Donell, P. B., & McGinity, J. W. (2008). Mechanical properties of 
polymeric films prepared from aqueous dispersions. In J. W. McGinity & L. A. 
Felton (Eds.), Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms, 
Drugs and the Pharmaceutical Sciences 176 (3rd ed., pp. 105–128). New York: 
Informa Healthcare. 
Fountain, W., Dumstorf, K., Lowell, A. E., Lodder, R. A., & Mumper, R. J. (2003). Near-
infrared spectroscopy for the determination of testosterone in thin-film 
composites. Journal of Pharmaceutical and Biomedical Analysis, 33(2), 181–189. 
doi:10.1016/S0731-7085(03)00345-5 
Frokjaer, S., & Otzen, D. E. (2005). Protein drug stability: a formulation challenge. Nat 
Rev Drug Discov, 4(4), 298–306. doi:10.1038/nrd1695 
Gandhi, R. B., & Robinson, J. R. (1994). Oral cavity as a site for bioadhesive drug 
delivery. Advanced Drug Delivery Reviews, 13(1-2), 43–74. doi:10.1016/0169-
409X(94)90026-4 
Garg, S., & Kumar, G. (2007). Development and evaluation of a buccal bioadhesive 
system for smoking cessation therapy. Pharmazie, 62(4), 266–272. 
 
219 
 
Ghilzai, N. M. K. (2003). New Developments in Insulin Delivery. Drug Development 
and Industrial Pharmacy, 29(3), 253. doi:10.1081/DDC-120018199 
Giovino, C., Ayensu, I., Tetteh, J., & Boateng, J. S. (2012). Development and 
characterisation of chitosan films impregnated with insulin loaded PEG-b-PLA 
nanoparticles (NPs): A potential approach for buccal delivery of macromolecules. 
International Journal of Pharmaceutics, 428(1–2), 143–151. 
doi:10.1016/j.ijpharm.2012.02.035 
Guo, J. (1994). Bioadhesive Polymer Buccal Patches for Buprenorphine Controlled 
Delivery: Formulation, In-vitro Adhesion and Release Properties. Drug 
Development and Industrial Pharmacy, 20(18), 2809–2821. 
doi:10.3109/03639049409042682 
Guo, J., & Cooklock, K. M. (1998). Theoretical Approaches and Practical Investigations 
in Carbopol Buccal Patches for Drug Delivery. Drug Development and Industrial 
Pharmacy, 24(2), 175–178. doi:10.3109/03639049809085603 
Guo, J., & Cremer, K. (1999). Development of bioadhesive buccal patches. In E. 
Mathiowitz, D. E. Chickering, & C. M. Lehr (Eds.), Bioadhesive Drug Delivery 
Systems: Fundamentals, Novel Approaches, and Development (pp. 541–562). 
New York: Marcel Dekker, Inc. 
Gupta, R. B. (2006). Fundamentals of drug nanoparticles. In Ram B Gupta & U. B. 
Kompella (Eds.), Nanoparticle Technology for Drug Delivery (pp. 1–19). New 
York: Taylor & Francis. 
Hariharan, M., & Bogue, A. (2009). Orally dissolving film strips: The final evolution of 
orally dissolving dosage forms. Drug Delivery Technology, 9(2), 24–29. 
Harris, D., & Robinson, J. R. (1992). Drug delivery via the mucous membranes of the 
oral cavity. Journal of Pharmaceutical Sciences, 81(1), 1–10. 
doi:10.1002/jps.2600810102 
 
220 
 
Hassan, M. A., Barakat, N. S., El-Badry, M., & Shehata, S. M. (2011). Formulation and 
in vitro/in vivo evaluation of naproxen mucoadhesive buccal patches for local 
effect. Journal of drug delivery science and technology, 21(5), 423–431. 
He, C., Cui, F., Yin, L., Qian, F., Tang, C., & Yin, C. (2009). A polymeric composite 
carrier for oral delivery of peptide drugs: Bilaminated hydrogel film loaded with 
nanoparticles. European Polymer Journal, 45(2), 368–376. 
doi:10.1016/j.eurpolymj.2008.11.004 
Heinemann, L., & Jacques, Y. (2009). Oral Insulin and Buccal Insulin: A Critical 
Reappraisal. Journal of Diabetes Science and Technology, 3(3), 568–584. 
Hench, L. L., & Ethridge, E. C. (1982). Biomaterials: an interfacial approach. New York: 
Academic Press. 
Heng, P. W. S., Chan, L. W., & Ong, K. T. (2003). Influence of storage conditions and 
type of plasticizers on ethylcellulose and acrylate films formed from aqueous 
dispersions. Journal of Pharmacy & Pharmaceutical Sciences: A Publication of 
the Canadian Society for Pharmaceutical Sciences, Société Canadienne Des 
Sciences Pharmaceutiques, 6(3), 334–44. doi:14738714 
Higuchi, T. (1963). Mechanism of Sustained-Action Medication. The Theoretical 
Analysis of Rate of Solids Drugs Dispersed in Solid Matrices. Journal of 
Pharmaceutical Sciences, 52, 1145–9. doi:14088963 
Hoogstraate, A. J., Cullander, C., Nagelkerke, J. F., Senel, S., Verhoef, J. C., Junginger, 
H. E., & Boddé, H. E. (1994). Diffusion Rates and Transport Pathways of 
Fluorescein Isothiocyanate (FITC)-Labeled Model Compounds Through Buccal 
Epithelium. Pharmaceutical Research, 11(1), 83–89. 
doi:10.1023/A:1018949828548 
Hoogstraate, A. J., Senel, S., Cullander, C., Verhoef, J., Junginger, H. E., & Boddé, H. E. 
(1996). Effects of bile salts on transport rates and routes of FITC-labelled 
compounds across porcine buccal epithelium in vitro. Journal of Controlled 
Release, 40(3), 211–221. doi:10.1016/0168-3659(95)00187-5 
 
221 
 
Horowitz, M. I. (1977). Gastrointestinal glycoproteins. The Glycoconjugates, 1, 189. 
Howie, N., Trigkas, T., Cruchley, A., Wertz, P., Squier, C., & Williams, D. (2001). 
Short-term exposure to alcohol increases the permeability of human oral mucosa. 
Oral Diseases, 7(6), 349–354. doi:10.1034/j.1601-0825.2001.00731.x 
Ibrahim, M. A., Ismail, A., Fetouh, M. I., & Göpferich, A. (2005). Stability of insulin 
during the erosion of poly(lactic acid) and poly(lactic-co-glycolic acid) 
microspheres. Journal of Controlled Release, 106(3), 241–252. 
doi:10.1016/j.jconrel.2005.02.025 
Imbert, D., & Cullander, C. (1999). Buccal mucosa in vitro experiments: I. Confocal 
imaging of vital staining and MTT assays for the determination of tissue viability. 
Journal of Controlled Release, 58(1), 39–50. doi:10.1016/S0168-3659(98)00143-
6 
International Conference on Harmonization. (2009). ICH topic Q3C(R3) Impurities: 
Residual Solvents. www.emea.europa.eu/pdfs/human/ich/028395en.pdf. 
Retrieved from www.emea.europa.eu/pdfs/human/ich/028395en.pdf 
Jacques, Y., Staub, C., Marquet, I., Crebassa, C., & Buri, P. (1997). Human buccal 
absorption of codeine phosphate from a bioadhesive drug delivery device. STP 
pharma sciences, 7(4), 289–294. 
Jahanshahi, M., & Babaei, Z. (2008). Protein nanoparticle: A unique system as drug 
delivery vehicles. African Journal of Biotechnology, 7(25), 4926–4934. 
Jain, S. K., Jain, A., Gupta, Y., & Kharya, A. (2008). Design and development of a 
mucoadhesive buccal film bearing progesterone. Pharmazie, 63(2), 129–35. 
Jasti, B. R., Marasanapalle, V., & Li, X. (2005). Modulation of oral transmucosal 
permeability: permeation enhancers. In T. K. Ghosh & W. R. Pfister (Eds.), Drug 
delivery to the oral cavity. New York: Taylor & Francis. 
 
222 
 
Jay, S., Fountain, W., Cui, Z., & Mumper, R. J. (2002). Transmucosal delivery of 
testosterone in rabbits using novel bi-layer mucoadhesive wax-film composite 
disks. Journal of Pharmaceutical Sciences, 91(9), 2016–25. doi:12210048 
Jitendra, P. K., Bansal, S., & Banik, A. (2011). Noninvasive Routes of Proteins and 
Peptides Drug Delivery. Indian Journal of Pharmaceutical Sciences, 73(4), 367. 
Johnson, B. K., & Prud’homme, R. K. (2003). Chemical processing and micromixing in 
confined impinging jets. AIChE Journal, 49(9), 2264–2282. 
doi:10.1002/aic.690490905 
Jores, K., Mehnert, W., Drechsler, M., Bunjes, H., Johann, C., & Mader, K. (2004). 
Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded 
solid lipid nanoparticles by photon correlation spectroscopy, field-flow 
fractionation and transmission electron microscopy. Journal of Controlled 
Release, 95(2), 217–227. doi:10.1016/j.jconrel.2003.11.012 
Jug, M., Bećirević-Laćan, M., & Bengez, S. (2009). Novel cyclodextrin-based film 
formulation intended for buccal delivery of atenolol. Drug Development and 
Industrial Pharmacy, 35(7), 796–807. doi:10.1080/03639040802596212 
Juliano, C., Pala, C. L., & Cossu, M. (2007). Preparation and characterisation of 
polymeric films containing propolis. Journal of drug delivery science and 
technology, 17(3), 177–181. 
Juliano, Claudia, Cossu, M., Pigozzi, P., Rassu, G., & Giunchedi, P. (2008). Preparation, 
In Vitro Characterization and Preliminary In Vivo Evaluation of Buccal 
Polymeric Films Containing Chlorhexidine. AAPS PharmSciTech, 9(4), 1153–
1158. doi:10.1208/s12249-008-9153-6 
Kammer, H. W. (1983). Adhesion between polymers. Review. Acta Polymerica, 34(2), 
112–118. doi:10.1002/actp.1983.010340210 
 
223 
 
Khafagy, E.-S., Morishita, M., Onuki, Y., & Takayama, K. (2007). Current challenges in 
non-invasive insulin delivery systems: A comparative review. Advanced Drug 
Delivery Reviews, 59(15), 1521–1546. doi:10.1016/j.addr.2007.08.019 
Khanna, R., Agarwal, S. P., & Ahuja, A. (1997). Preparation and evaluation of muco-
adhesive buccal films of clotrimazole for oral candida infections. Indian journal of 
pharmaceutical sciences, 59(6), 299–305. 
Kharenko, E., Larionova, N., & Demina, N. (2008). Mucoadhesive Drug Delivery 
Systems: Quantitative Assessment of Interaction Between Synthetic and Natural 
Polymer Films and Mucosa. Pharmaceutical Chemistry Journal, 42(7), 392–399. 
doi:10.1007/s11094-008-0132-8 
Kim, T., Ahn, J., Choi, H., Choi, Y., & Cho, C. (2007). A Novel Mucoadhesive Polymer 
Film Composed of Carbopol, Poloxamer and Hydroxypropylmethylcellulose. 
Archives of Pharmacal Research, 30(3), 381–386. doi:10.1007/BF02977622 
Kinloch, A. J. (1980a). The science of adhesion I: surface and interfacial aspects. Journal 
of Materials Science, 15(9), 2141–2166. 
Kinloch, A. J. (1980b). The Science of Adhesion: Part 1 Surface and Interfacial Aspects. 
Journal of Materials Science, 15(9), 2141–2166. 
Klibanov, A. M. (1997). Why are enzymes less active in organic solvents than in water? 
Trends in Biotechnology, 15(3), 97–101. doi:10.1016/S0167-7799(97)01013-5 
Kohda, Y., Kobayashi, H., Baba, Y., Yuasa, H., Ozeki, T., Kanaya, Y., & Sagara, E. 
(1997). Controlled release of lidocaine hydrochloride from buccal mucosa-
adhesive films with solid dispersion. International Journal of Pharmaceutics, 
158(2), 147–155. doi:10.1016/S0378-5173(97)00241-X 
Kopcha, M., Tojo, K. J., & Lordi, N. G. (1990). Evaluation of methodology for assessing 
release characteristics of thermosoftening vehicles. The Journal of Pharmacy and 
Pharmacology, 42(11), 745–751. 
 
224 
 
Korsmeyer, R. W., Gurny, R., Doelker, E., Buri, P., & Peppas, N. A. (1983). Mechanisms 
of solute release from porous hydrophilic polymers. International Journal of 
Pharmaceutics, 15(1), 25–35. doi:10.1016/0378-5173(83)90064-9 
Korytkowski, M. (2002). When oral agents fail: practical barriers to starting insulin. 
International Journal of Obesity, 26(s3), S18–S24. doi:10.1038/sj.ijo.0802173 
Kreiner, M., Fuglevand, G., Moore, B. D., & Parker, M.-C. (2005). DNA-coated 
microcrystals. Chemical Communications, (21), 2675. doi:10.1039/b501045d 
Kreiner, M., Parker, M. C., & Moore, B. D. (2001). Enzyme-coated micro-crystals: a 1-
step method for high activity biocatalyst preparation. Chemical Communications, 
(12), 1096–1097. doi:10.1039/b100722j 
Kreuter, J. (1995). Nanoparticulate Systems in Drug Delivery and Targeting. Journal of 
Drug Targeting, 3, 171–173. doi:10.3109/10611869509015940 
Law, S., Wertz, P. W., Swartzendruber, D. C., & Squier, C. A. (1995). Regional variation 
in content, composition and organization of porcine epithelial barrier lipids 
revealed by thin-layer chromatography and transmission electron microscopy. 
Archives of Oral Biology, 40(12), 1085–1091. 
Leader, B., Baca, Q. J., & Golan, D. E. (2008). Protein therapeutics: a summary and 
pharmacological classification. Nat Rev Drug Discov, 7(1), 21–39. 
doi:10.1038/nrd2399 
Lee, J. W., Park, J. H., & Robinson, J. R. (2000). Bioadhesive-based dosage forms: The 
next generation. Journal of Pharmaceutical Sciences, 89(7), 850–866. 
doi:10.1002/1520-6017(200007)89:7<850::AID-JPS2>3.0.CO;2-G 
Lee, Y., & Chien, Y. W. (1995). Oral mucosa controlled delivery of LHRH by bilayer 
mucoadhesive polymer systems. Journal of Controlled Release, 37(3), 251–261. 
doi:10.1016/0168-3659(95)00082-8 
 
225 
 
Lehr, C.-M., Bouwstra, J. A., Schacht, E. H., & Junginger, H. E. (1992). In vitro 
evaluation of mucoadhesive properties of chitosan and some other natural 
polymers. International Journal of Pharmaceutics, 78(1-3), 43–48. 
doi:10.1016/0378-5173(92)90353-4 
Leuenberger, H., Bonny, J. D., & Kolb, M. (1995). Percolation effects in matrix-type 
controlled drug release systems. International Journal of Pharmaceutics, 115(2), 
217–224. doi:10.1016/0378-5173(94)00266-8 
Li, B., & Robinson, J. R. (2005). Preclinical assessment of oral mucosal drug delivery 
systems. In T.K. Ghosh & W. R. Pfister (Eds.), Drug delivery to the oral cavity 
(pp. 41–66). New York: Marcel Dekker Inc. 
Li, C., Bhatt, P. P., & Johnston, T. P. (1998). Evaluation of a Mucoadhesive Buccal Patch 
for Delivery of Peptides: In Vitro Screening of Bioadhesion. Drug Development 
and Industrial Pharmacy, 24(10), 919. doi:10.3109/03639049809097271 
Llabot, J.M., Palma, S. D., Manzo, R. H., & Allemandi, D. A. (2007a). Design of novel 
antifungal mucoadhesive films: Part I. Pre-formulation studies. International 
Journal of Pharmaceutics, 330(1-2), 54–60. doi:10.1016/j.ijpharm.2006.08.042 
Llabot, J.M., Palma, S. D., Manzo, R. H., & Allemandi, D. A. (2007b). Design of novel 
antifungal mucoadhesive films: Part II. Formulation and in vitro 
biopharmaceutical evaluation. International Journal of Pharmaceutics, 336(2), 
263–268. doi:10.1016/j.ijpharm.2006.12.001 
Llabot, Juan M, Manzo, R. H., & Allemandi, D. A. (2004). Drug release from 
carbomer:carbomer sodium salt matrices with potential use as mucoadhesive drug 
delivery system. International Journal of Pharmaceutics, 276(1–2), 59–66. 
doi:10.1016/j.ijpharm.2004.02.006 
Lochhead, J. J., & Thorne, R. G. (2012). Intranasal delivery of biologics to the central 
nervous system. Advanced Drug Delivery Reviews, 64(7), 614–628. 
doi:10.1016/j.addr.2011.11.002 
 
226 
 
Lode, J., Fichtner, I., Kreuter, J., Berndt, A., Diederichs, J. E., & Reszka, R. (2001). 
Influence of surface-modifying surfactants on the pharmacokinetic behavior of 
14C-poly (methylmethacrylate) nanoparticles in experimental tumor models. 
Pharmaceutical research, 18(11), 1613–1619. 
Longer, M. A., & Robinson, J. R. (1986). Fundamental aspects of bioadhesion. Pharm. 
Int, 7(5), 114–117. 
Manganaro, A. M., & Wertz, P. W. (1996). The effects of permeabilizers on the in vitro 
penetration of propranolol through porcine buccal epithelium. Military medicine, 
161(11), 669–672. 
Mashru, R., Sutariya, V., Sankalia, M., & Parikh, P. (2005). Development and Evaluation 
of Fast-Dissolving Film of Salbutamol Sulphate. Drug Development and 
Industrial Pharmacy, 31, 25–34. doi:10.1081/DDC-43947 
Matoltsy, A. G., & Parakkal, P. F. (1965). Membrane-coating granules of keratinizing 
epithelia. J. Cell Biol., 24(2), 297–307. 
Matteucci, M. E., Hotze, M. A., Johnston, K. P., & Williams, R. O. (2006). Drug 
Nanoparticles by Antisolvent Precipitation:  Mixing Energy versus Surfactant 
Stabilization. Langmuir, 22(21), 8951–8959. doi:10.1021/la061122t 
McQuinn, R. L., Benes, L., & Horriere, F. (2005). Oral transmucosal delivery of 
melatonin. In T.K. Ghosh & W. R. Pfister (Eds.), Drug delivery to the oral cavity: 
molecules to market. New York: Marcel Dekker Inc. 
McQuinn, R. L., Kvam, D. C., Maser, M. J., Miller, A. L., & Oliver, S. (1995). Sustained 
oral mucosal delivery in human volunteers of buprenorphine from a thin non-
eroding mucoadhesive polymeric disk. Journal of Controlled Release, 34(3), 243–
250. doi:10.1016/0168-3659(95)00008-V 
Mikos, A. G., & Peppas, N. A. (1986). Systems for controlled release of drugs. V: 
Bioadhesive systems. STP Pharma, 2, 705–716. 
 
227 
 
Miller, M. A., DiNunzio, J., Matteucci, M. E., Ludher, B. S., Williams, R. O., & 
Johnston, K. P. (2012). Flocculated amorphous itraconazole nanoparticles for 
enhanced in vitro supersaturation and in vivo bioavailability. Drug Development 
and Industrial Pharmacy, 38(5), 557–570. doi:10.3109/03639045.2011.616513 
Mizrahi, B., & Domb, A. J. (2008). Mucoadhesive polymers for delivery of drugs to the 
oral cavity. Recent Patents on Drug Delivery & Formulation, 2(2), 108–19. 
Mollan, M. (2003). Historical Overview. In I. Ghebre-Sellassie & C. Martin (Eds.), 
Pharmaceutical extrusion technology (pp. 1–18). Informa Health Care. 
Moore, J. W., & Flanner, H. H. (1996). Mathematical comparison of dissolution profiles. 
Pharmaceutical Technology, 20(Jun). 
Mora-Huertas, C. E., Fessi, H., & Elaissari, A. (2010). Polymer-based nanocapsules for 
drug delivery. International Journal of Pharmaceutics, 385(1–2), 113–142. 
doi:10.1016/j.ijpharm.2009.10.018 
Morales, J.O., Joks, G. M., Lamprecht, A., Ross, A. C., & McConville, J. T. (2012). A 
design of experiments to optimize a new manufacturing process for high activity 
protein-containing submicron particles. Drug Development and Industrial 
Pharmacy, In Press. 
Morales, J.O., Ross, A. C., & McConville, J. T. (2010). Manufacture of BSA 
Microcrystals by a Co-Precipitation Method. The AAPS Journal, 12(S2), T2059. 
Morales, J.O., Ross, A. C., & McConville, J. T. (2011). BSA microcrystals by a co‐
precipitation method: the effect of solvent type and presence of surfactant. The 
AAPS Journal, 13(S2), R6221. 
Morales, J.O., Ross, A. C., & McConville, J. T. (2012). Protein-containing submicron 
particles embedded in films for buccal delivery. Pharmaceutical Research, 
Submitted. 
 
228 
 
Morales, J.O., Su, R., & McConville, J. T. (2012). The Influence of Recrystallized 
Caffeine on Water-Swellable Polymethacrylate Mucoadhesive Buccal Films. 
AAPS PharmSciTech, In Press. 
Morales, Javier O., & McConville, J. T. (2011). Manufacture and characterization of 
mucoadhesive buccal films. European Journal of Pharmaceutics and 
Biopharmaceutics, 77(2), 187–199. doi:10.1016/j.ejpb.2010.11.023 
Morishita, M., Barichello, J. M., Takayama, K., Chiba, Y., Tokiwa, S., & Nagai, T. 
(2001). Pluronic® F-127 gels incorporating highly purified unsaturated fatty acids 
for buccal delivery of insulin. International Journal of Pharmaceutics, 212(2), 
289–293. doi:10.1016/S0378-5173(00)00615-3 
Morishita, M., & Peppas, N. A. (2006). Is the oral route possible for peptide and protein 
drug delivery? Drug Discovery Today, 11(19-20), 905–910. 
doi:10.1016/j.drudis.2006.08.005 
Müller, G. (2011). Oral delivery of protein drugs: Driver for personalized medicine. Curr 
Issues Mol Biol, 13(1), 13–24. 
Murdan, S., Somavarapu, S., Ross, A. C., Alpar, H. O., & Parker, M. C. (2005). 
Immobilisation of vaccines onto micro-crystals for enhanced thermal stability. 
International Journal of Pharmaceutics, 296(1-2), 117–121. 
doi:10.1016/j.ijpharm.2005.02.022 
Nafee, N. A., Ismail, F. A., Boraie, N. A., & Mortada, L. M. (2003). Mucoadhesive 
buccal patches of miconazole nitrate: in vitro/in vivo performance and effect of 
ageing. International Journal of Pharmaceutics, 264(1-2), 1–14. 
doi:10.1016/S0378-5173(03)00371-5 
Nappinnai, M., Chandanbala, R., & Balaijirajan, R. (2008). Formulation and evaluation 
of nitrendipine buccal films. Indian Journal of Pharmaceutical Sciences, 70(5), 
631–635. 
 
229 
 
Nicolazzo, J. A., Reed, B. L., & Finnin, B. C. (2004a). Assessment of the effects of 
sodium dodecyl sulfate on the buccal permeability of caffeine and estradiol. 
Journal of Pharmaceutical Sciences, 93(2), 431–440. doi:10.1002/jps.10559 
Nicolazzo, J. A., Reed, B. L., & Finnin, B. C. (2004b). Modification of buccal drug 
delivery following pretreatment with skin penetration enhancers. Journal of 
Pharmaceutical Sciences, 93(8), 2054–2063. doi:10.1002/jps.20113 
Nicolazzo, J. A., Reed, B. L., & Finnin, B. C. (2005). Buccal penetration enhancers--
How do they really work? Journal of Controlled Release, 105(1-2), 1–15. 
doi:10.1016/j.jconrel.2005.01.024 
Nikolic, K., Murugesan, M., Forshaw, M., Cunningham, D., Martinez-Albertos, J.-L., & 
Moore, B. D. (2007). Self-assembly of nanoparticles on the surface of ionic 
crystals: Structural properties. Surface Science, 601(13), 2730–2734. 
doi:10.1016/j.susc.2006.12.034 
Okamoto, H., Nakamori, T., Arakawa, Y., Iida, K., & Danjo, K. (2002). Development of 
polymer film dosage forms of lidocaine for buccal administration: II. Comparison 
of preparation methods. Journal of Pharmaceutical Sciences, 91(11), 2424–32. 
doi:12379928 
 
Okamoto, H., Taguchi, H., Iida, K., & Danjo, K. (2001). Development of polymer film 
dosage forms of lidocaine for buccal administration: I. Penetration rate and 
release rate. Journal of Controlled Release, 77(3), 253–260. doi:10.1016/S0168-
3659(01)00509-0 
 
Okhamafe, A. O., & York, P. (1985). Stress crack resistance of some pigmented and 
unpigmented tablet film coating systems. Journal of pharmacy and pharmacology, 
37(7), 449–454. 
Omari, D. M., Sallam, A., Abd-Elbary, A., & El-Samaligy, M. (2004). Lactic acid-
induced modifications in films of Eudragit RL and RS aqueous dispersions. 
 
230 
 
International Journal of Pharmaceutics, 274(1-2), 85–96. 
doi:10.1016/j.ijpharm.2004.01.004 
Palem, C., Gannu, R., Doodipala, N., Yamsani, V., & Yamsani, M. (2011). Transmucosal 
Delivery of Domperidone from Bilayered Buccal Patches: In Vitro, Ex Vivo and 
In Vivo Characterization. Archives of Pharmacal Research, 34(10), 1701–1710. 
doi:10.1007/s12272-011-1014-2 
Panomsuk, S. P., Hatanaka, T., Aiba, T., Katayama, K., & Koizumi, T. (1996). A study 
of the hydrophilic cellulose matrix: effect of drugs on swelling properties. 
Chemical and pharmaceutical bulletin, 44(5), 1039–1042. 
Parikh, N. H., Porter, S. C., & Rohera, B. D. (1993). Tensile Properties of Free Films 
Cast from Aqueous Ethylcellulose Dispersions. Pharmaceutical Research, 10(6), 
810–815. doi:10.1023/A:1018992607245 
Partridge, J., Moore, B. D., & Lyle, C. (2005). Antibody-coated microcrystals. The 
AAPS Journal, 7(S2), 2894. 
Partridge, J., Moore, B. D., & Parker, M. C. (2005). Stabilization of Proteins in the Dry 
State Without Sugars. The AAPS Journal, 7(S2), 2989. 
Partridge, Johann, Halling, P. J., & Moore, B. D. (1998). Practical route to high activity 
enzyme preparations for synthesis in organic media. Chem. Commun., (7), 841–
842. doi:10.1039/A800408K 
Patel, R. S., & Poddar, S. S. (2009). Development and Characterization of Mucoadhesive 
Buccal Patches of Salbutamol Sulphate. Current Drug Delivery, 6, 140–144. 
doi:10.2174/156720109787048177 
Patel, V. M., Prajapati, B. ., & Patel, M. M. (2007a). Effect of hydrophilic polymers on 
buccoadhesive eudragit patches of propranolol hydrochloride using factorial 
design. AAPS PharmSciTech, 8(2), E119–E126. doi:10.1208/pt0802045 
 
231 
 
Patel, V. M., Prajapati, B. G., Patel, J. K., & Patel, M. M. (2006). Physicochemical 
Characterization and Evaluation of Buccal Adhesive Patches Containing 
Propranolol Hydrochloride. Current Drug Delivery, 3(3), 325–331. 
doi:10.2174/156720106777731082 
Patel, V. M., Prajapati, B. G., & Patel, M. M. (2007b). Formulation, evaluation, and 
comparison of bilayered and multilayered mucoadhesive buccal devices of 
propranolol hydrochloride. AAPS PharmSciTech, 8(1), 147–154. 
Pathan, S. A., Iqbal, Z., Sahani, J. K., Talegaonkar, S., Khar, R. K., & Ahmad, F. J. 
(2008). Buccoadhesive drug delivery systems--extensive review on recent patents. 
Recent Patents on Drug Delivery & Formulation, 2(2), 177–88. 
Pather, S. I., Rathbone, M. J., & Senel, S. (2008). Current status and the future of buccal 
drug delivery systems. Expert Opin. Drug Deliv., 5(5), 531–542. 
Peh, K. K., & Wong, C. F. (1999). Polymeric films as vehicle for buccal delivery: 
swelling, mechanical, and bioadhesive properties. Journal of Pharmacy and 
Pharmaceutical Sciences, 2(2), 53–61. doi:10952770 
Peppas, N.A., & Buri, P. A. (1985). Surface, interfacial and molecular aspects of polymer 
bioadhesion on soft tissues. J. Control. Release, 2, 257–275. 
Peppas, Nikolaos A., & Sahlin, J. J. (1996). Hydrogels as mucoadhesive and bioadhesive 
materials: a review. Biomaterials, 17(16), 1553–1561. doi:10.1016/0142-
9612(95)00307-X 
Perioli, L., Ambrogi, V., Angelici, F., Ricci, M., Giovagnoli, S., Capuccella, M., & Rossi, 
C. (2004). Development of mucoadhesive patches for buccal administration of 
ibuprofen. Journal of Controlled Release, 99(1), 73–82. 
doi:10.1016/j.jconrel.2004.06.005 
Perugini, P., Genta, I., Conti, B., Modena, T., & Pavanetto, F. (2003). Periodontal 
delivery of ipriflavone: new chitosan/PLGA film delivery system for a lipophilic 
 
232 
 
drug. International Journal of Pharmaceutics, 252(1-2), 1–9. doi:10.1016/S0378-
5173(02)00602-6 
Perumal, V. A., Govender, T., Lutchman, D., & Mackraj, I. (2008). Investigating a new 
approach to film casting for enhanced drug content uniformity in polymeric films. 
Drug Development and Industrial Pharmacy, 34(10), 1036–47. doi:902381180 
Perumal, V. A., Lutchman, D., Mackraj, I., & Govender, T. (2008). Formulation of 
monolayered films with drug and polymers of opposing solubilities. International 
Journal of Pharmaceutics, 358(1-2), 184–191. doi:10.1016/j.ijpharm.2008.03.005 
Peyrot, M., Rubin, R. R., Kruger, D. F., & Travis, L. B. (2010). Correlates of Insulin 
Injection Omission. Diabetes Care, 33(2), 240 –245. doi:10.2337/dc09-1348 
Polonsky, W. H., Fisher, L., Guzman, S., Villa-Caballero, L., & Edelman, S. V. (2005). 
Psychological Insulin Resistance in Patients With Type 2 Diabetes. Diabetes 
Care, 28(10), 2543 –2545. doi:10.2337/diacare.28.10.2543 
Ponchel, G. (1994). Formulation of oral mucosal drug delivery systems for the systemic 
delivery of bioactive materials. Advanced drug delivery reviews, 13(1-2), 75–87. 
Pongjanyakul, T., & Suksri, H. (2009). Alginate-magnesium aluminum silicate films for 
buccal delivery of nicotine. Colloids and Surfaces B: Biointerfaces, 74(1), 103–
113. doi:10.1016/j.colsurfb.2009.06.033 
Prager, S. (1981). The healing process at polymer–polymer interfaces. The Journal of 
Chemical Physics, 75(10), 5194. doi:10.1063/1.441871 
Prodduturi, S., Manek, R. V., Kolling, W. M., Stodghill, S. P., & Repka, M. A. (2004). 
Water vapor sorption of hot-melt extruded hydroxypropyl cellulose films: Effect 
on physico-mechanical properties, release characteristics, and stability. Journal of 
Pharmaceutical Sciences, 93(12), 3047–3056. doi:10.1002/jps.20222 
 
233 
 
Prodduturi, S., Manek, R. V., Kolling, W. M., Stodghill, S. P., & Repka, M. A. (2005). 
Solid-state stability and characterization of hot-melt extruded poly(ethylene 
oxide) films. Journal of Pharmaceutical Sciences, 94(10), 2232–2245. 
doi:10.1002/jps.20437 
 
Raghuraman, S., Velrajan, G., Ravi, R., Jeyabalan, B., Johnson, D. B., & Sankar, V. 
(2002). Design and evaluation of propranolol hydrochloride buccal films. Indian 
journal of pharmaceutical sciences, 64(1), 32–36. 
Rasenack, N., & Müller, B. W. (2002). Dissolution rate enhancement by in situ 
micronization of poorly water-soluble drugs. Pharmaceutical research, 19(12), 
1894–1900. 
Reckitt Benckiser Pharmaceuticals Inc. (2010, September 24). SuboxoneTM Sublingual 
Film (buprenorphine and naloxone). 
http://www.suboxone.com/hcp/suboxone_film/Default.aspx. Retrieved September 
24, 2010, from http://www.suboxone.com/hcp/suboxone_film/Default.aspx 
Remunan-Lopez, C., Portero, A., Vila-Jato, J. L., & Alonso, M. J. (1998). Design and 
evaluation of chitosan/ethylcellulose mucoadhesive bilayered devices for buccal 
drug delivery. Journal of Controlled Release, 55(2-3), 143–152. 
doi:10.1016/S0168-3659(98)00044-3 
Repka, M. A., Battu, S. K., Upadhye, S. B., Thumma, S., Crowley, M. M., Zhang, F., 
Martin, C., et al. (2007). Pharmaceutical applications of hot-melt extrusion: Part 
II. Drug development and industrial pharmacy, 33(10), 1043–1057. 
Repka, M. A., Gerding, T., Repka, S., & McGinity, J. W. (1999). Influence of Plasticizers 
and Drugs on the Physical-Mechanical Properties of Hydroxypropylcellulose 
Films Prepared by Hot Melt Extrusion. Drug Development & Industrial 
Pharmacy, 25(5), 625–633. doi:Article 
Repka, M. A., Gutta, K., Prodduturi, S., Munjal, M., & Stodghill, S. P. (2005). 
Characterization of cellulosic hot-melt extruded films containing lidocaine. 
 
234 
 
European Journal of Pharmaceutics and Biopharmaceutics, 59(1), 189–196. 
doi:10.1016/j.ejpb.2004.06.008 
Repka, M. A., & McGinity, J. W. (2000). Physical-mechanical, moisture absorption and 
bioadhesive properties of hydroxypropylcellulose hot-melt extruded films. 
Biomaterials, 21(14), 1509–1517. doi:10.1016/S0142-9612(00)00046-6 
Repka, M. A., & McGinity, J. W. (2001a). Bioadhesive properties of 
hydroxypropylcellulose topical films produced by hot-melt extrusion. Journal of 
Controlled Release, 70(3), 341–351. doi:10.1016/S0168-3659(00)00365-5 
Repka, M. A., & McGinity, J. W. (2001b). Influence of Chlorpheniramine Maleate on 
Topical Hydroxypropylcellulose Films Produced by Hot-Melt Extrusion. 
Pharmaceutical Development & Technology, 6(3), 297–304. doi:Article 
Repka, M. A., Munjal, M., ElSohly, M. A., & Ross, S. A. (2006). Temperature Stability 
and Bioadhesive Properties of Δ9-Tetrahydrocannabinol Incorporated 
Hydroxypropylcellulose Polymer Matrix Systems. Drug Development and 
Industrial Pharmacy, 32(1), 21–32. doi:10.1080/03639040500387914 
Repka, M. A., Prodduturi, S., Munjal, M., & Mididoddi, P. (2004). Matrix- and 
Reservoir-Based Transmucosal Delivery Systems: Tailoring Delivery Solutions. 
American Journal of Drug Delivery, 2(3), 173–192. doi:Article 
Repka, M. A., Prodduturi, S., & Stodghill, S. P. (2003). Production and characterization 
of hot-melt extruded films containing clotrimazole. Drug Development and 
Industrial Pharmacy, 29(7), 757–65. 
Ritger, P. L., & Peppas, N. A. (1987). A simple equation for description of solute release. 
I: Fickian and non-Fickian release from non-swellable devices in the form of 
slabs, spheres, cylinders or discs. Journal of controlled release, 5(1), 23–36. 
 
235 
 
Rossi, S., Sandri, G., Ferrari, F., Bonferoni, M. C., & Caramella, C. (2003). Buccal 
delivery of acyclovir from films based on chitosan and polyacrylic acid. 
Pharmaceutical Development and Technology, 8(2), 199–208. doi:12760570 
Rubin, R. R., Peyrot, M., Kruger, D. F., & Travis, L. B. (2009). Barriers to Insulin 
Injection Therapy. The Diabetes Educator, 35(6), 1014 –1022. 
doi:10.1177/0145721709345773 
Sahni, J., Raj, S., Ahmad, F. J., & Khar, R. K. (2008). Design and in vitro 
characterization of buccoadhesive drug delivery system of insulin. Indian Journal 
of Pharmaceutical Sciences, 70(1), 61–65. 
Salamat-Miller, N., Chittchang, M., & Johnston, T. P. (2005). The use of mucoadhesive 
polymers in buccal drug delivery. Advanced Drug Delivery Reviews, 57(11), 
1666–1691. doi:10.1016/j.addr.2005.07.003 
Satishbabu, B. K., & Srinivasan, B. P. (2008). Preparation and Evaluation of 
Buccoadhesive Films of Atenolol. Indian Journal of Pharmaceutical Sciences, 
70(2), 175–179. doi:Article 
Sawyer, L. C., Grubb, D. T., & Meyers, G. F. (2008a). Image Formation in the 
Microscope. Polymer Microscopy (3rd ed., pp. 67–129). New York: Springer. 
Sawyer, L. C., Grubb, D. T., & Meyers, G. F. (2008b). Fundamentals of Microscopy. 
Polymer Microscopy (3rd ed., pp. 27–66). New York: Springer. 
Scharnagl, C., Reif, M., & Friedrich, J. (2005). Stability of proteins: Temperature, 
pressure and the role of the solvent. Biochimica et Biophysica Acta (BBA) - 
Proteins & Proteomics, 1749(2), 187–213. doi:10.1016/j.bbapap.2005.03.002 
Schmidt, W. (1989, July 18). Process for producing an administration or dosage form for 
drugs, reagents or other active ingredients. 
 
236 
 
Schubert, M. A., & Müller-Goymann, C. C. (2005). Characterisation of surface-modified 
solid lipid nanoparticles (SLN): Influence of lecithin and nonionic emulsifier. 
European Journal of Pharmaceutics and Biopharmaceutics, 61(1–2), 77–86. 
doi:10.1016/j.ejpb.2005.03.006 
Sekhar, K. C., Naidu, K. V. S., Vishnu, Y. V., Gannu, R., Kishan, V., & Rao, Y. M. 
(2008). Transbuccal Delivery of Chlorpheniramine Maleate from Mucoadhesive 
Buccal Patches. Drug Delivery, 15(3), 185–191. 
doi:10.1080/10717540801952639 
Semalty, M., Semalty, A., & Kumar, G. (2008). Formulation and Characterization of 
Mucoadhesive Buccal Films of Glipizide. Indian Journal of Pharmaceutical 
Sciences, 70(1), 43–48. doi:Article 
Senel, S., Capan, Y., Sargon, M. F., Ikinci, G., Solpan, D., Güven, O., Boddé, H. E., et al. 
(1997). Enhancement of transbuccal permeation of morphine sulfate by sodium 
glycodeoxycholate in vitro. Journal of Controlled Release, 45(2), 153–162. 
doi:10.1016/S0168-3659(96)01568-4 
Senel, S., & Hincal, A. A. (2001). Drug permeation enhancement via buccal route: 
possibilities and limitations. Journal of Controlled Release, 72(1-3), 133–144. 
doi:10.1016/S0168-3659(01)00269-3 
Senel, S., Ikinci, G., Kas, S., Yousefi-Rad, A., Sargon, M. F., & Hincal, A. A. (2000). 
Chitosan films and hydrogels of chlorhexidine gluconate for oral mucosal 
delivery. International Journal of Pharmaceutics, 193(2), 197–203. 
doi:10.1016/S0378-5173(99)00334-8 
Senel, S., Kremer, M. J., Kas, S., Wertz, P. W., HIncal, A. A., & Squier, C. A. (2000). 
Enhancing effect of chitosan on peptide drug delivery across buccal mucosa. 
Biomaterials, 21(20), 2067–2071. doi:10.1016/S0142-9612(00)00134-4 
Sharma, P., & Hamsa, V. (2001). Formulation and evaluation of buccal mucoadhesive 
patches of terbutaline sulphate. STP pharma sciences, 11(4), 275–281. 
 
237 
 
Shidhaye, S., Saindane, N., Sutar, S., & Kadam, V. (2008). Mucoadhesive Bilayered 
Patches for Administration of Sumatriptan Succinate. AAPS PharmSciTech, 9(3), 
909–916. doi:10.1208/s12249-008-9125-x 
Shojaei, A. H. (1998). Buccal mucosa as a route for systemic drug delivery: a review. 
Journal of Pharmacy & Pharmaceutical Sciences: A Publication of the Canadian 
Society for Pharmaceutical Sciences, Société Canadienne Des Sciences 
Pharmaceutiques, 1(1), 15–30. doi:10942969 
Shoyele, S. A., & Slowey, A. (2006). Prospects of formulating proteins/peptides as 
aerosols for pulmonary drug delivery. International Journal of Pharmaceutics, 
314(1), 1–8. doi:10.1016/j.ijpharm.2006.02.014 
Shugar, D. (1952). The measurement of lysozyme activity and the ultra-violet 
inactivation of lysozyme. Biochimica et Biophysica Acta, 8, 302–309. 
doi:10.1016/0006-3002(52)90045-0 
Simmons, J. H., McFann, K. K., Brown, A. C., Rewers, A., Follansbee, D., Temple-
Trujillo, R. E., & Klingensmith, G. J. (2007). Reliability of the Diabetes Fear of 
Injecting and Self-Testing Questionnaire in Pediatric Patients With Type 1 
Diabetes. Diabetes Care, 30(4), 987 –988. doi:10.2337/dc06-1553 
Singh, R., Singh, S., & Lillard, J. W. (2008). Past, present, and future technologies for 
oral delivery of therapeutic proteins. Journal of Pharmaceutical Sciences, 97(7), 
2497–2523. doi:10.1002/jps.21183 
Singh, S., Jain, S., Muthu, M., Tiwari, S., & Tilak, R. (2008). Preparation and Evaluation 
of Buccal Bioadhesive Films Containing Clotrimazole. AAPS PharmSciTech, 
9(2), 660–667. doi:10.1208/s12249-008-9083-3 
Singh, S., Soni, R., Rawat, M. K., Jain, A., Deshpande, S. B., Singh, S. K., & Muthu, M. 
S. (2010). In vitro and In vivo Evaluation of Buccal Bioadhesive Films 
Containing Salbutamol Sulphate. Chemical & Pharmaceutical Bulletin, 58(3), 
307–311. 
 
238 
 
Sinswat, P., Gao, X., Yacaman, M. J., Williams III, R. O., & Johnston, K. P. (2005). 
Stabilizer choice for rapid dissolving high potency itraconazole particles formed 
by evaporative precipitation into aqueous solution. International Journal of 
Pharmaceutics, 302(1-2), 113–124. doi:10.1016/j.ijpharm.2005.06.027 
Skalsky, B., & Petereit, H. U. (2008). Chemistry and Application Properties of 
Polymethacrylate Systems. In J. W. McGinity & L. A. Felton (Eds.), Aqueous 
Polymeric Coatings for Pharmaceutical Dosage Forms, Drugs and the 
Pharmaceutical Sciences 176 (3rd ed., pp. 237–277). New York: Informa 
Healthcare. 
Skulason, S., Asgeirsdottir, M. S., Magnusson, J. P., & Kristmundsdottir, T. (2009). 
Evaluation of polymeric films for buccal drug delivery. Pharmazie, 64(3), 197–
201. 
Smart, J. D. (1999). The role of water movement and polymer hydration in 
mucoadhesion. In E. Mathiowitz, D. E. Chickering, & C. M. Lehr (Eds.), 
Bioadhesive Drug Delivery Systems: Fundamentals, Novel Approaches, and 
Development (pp. 11–23). New York: Marcel Dekker Inc. 
Smart, J. D. (2004). Recent developments in the use of bioadhesive systems for delivery 
of drugs to the oral cavity. Critical Reviews in Therapeutic Drug Carrier Systems, 
21(4), 319–44. 
Smart, J. D. (2005). The basics and underlying mechanisms of mucoadhesion. Advanced 
Drug Delivery Reviews, 57(11), 1556–1568. doi:10.1016/j.addr.2005.07.001 
Sohi, H., Ahuja, A., Ahmad, F. J., & Khar, R. K. (2010). Critical evaluation of 
permeation enhancers for oral mucosal drug delivery. Drug Development and 
Industrial Pharmacy, (00), 1–29. 
Squier, C. A. (1973). The permeability of keratinized and nonkeratinized oral epithelium 
to horseradish peroxidase. Journal of Ultrastructure Research, 43(1), 160–177. 
 
239 
 
Squier, C. A. (1977). Membrane coating granules in nonkeratinizing oral epithelium. 
Journal of Ultrastructure Research, 60(2), 212–220. 
Squier, C. A. (1982). Zinc iodide-osmium staining of membrane-coating granules in 
keratinized and non-keratinized mammalian oral epithelium. Archives of Oral 
Biology, 27(5), 377–382. 
Squier, C. A., Cox, P. S., & Wertz, P. W. (1991). Lipid Content and Water Permeability 
of Skin and Oral Mucosa. J Investig Dermatol, 96(1), 123–126. 
Squier, C. A., Cox, P. S., Wertz, P. W., & Downing, D. T. (1986). The lipid composition 
of porcine epidermis and oral epithelium. Archives of Oral Biology, 31(11), 741–
747. 
Squier, C. A., & Hill, M. W. (1989). Oral Mucosa. In A. R. Ten Cate (Ed.), Oral 
histology, development, structure, and function (pp. 319–356). Mosby Incorp. 
Squier, C. A., & Lesch, C. A. (1988). Penetration pathways different compounds through 
epidermis and oral epithelia. Journal of Oral Pathology & Medicine, 17(9-10), 
512–516. doi:10.1111/j.1600-0714.1988.tb01326.x 
Squier, C. A., & Wertz, P. W. (1996). Structure and Function of the Oral Mucosa and 
Implications for Drug Delivery. In Michael J. Rathbone (Ed.), Oral mucosal drug 
delivery. Informa Health Care. 
Squier, C. A., Wertz, P. W., & Cox, P. S. (1991). Thin-layer chromatographic analyses of 
lipids in different layers of porcine epidermis and oral epithelium. Archives of 
Oral Biology, 36(9), 647–653. doi:10.1016/0003-9969(91)90017-O 
Sudhakar, Y., Kuotsu, K., & Bandyopadhyay, A. K. (2006). Buccal bioadhesive drug 
delivery -- A promising option for orally less efficient drugs. Journal of 
Controlled Release, 114(1), 15–40. doi:10.1016/j.jconrel.2006.04.012 
 
240 
 
Takeuchi, K., Watanabe, M., Yanagi, M., Murakami, I., Hosono, H., Nishizawa, S., 
Chigono, Y., et al. (2008). In vitro and clinical evaluation of an oral mucosal 
adhesive film containing indomethacin. Yakugaku zasshi: Journal of the 
Pharmaceutical Society of Japan, 128(12), 1791–1805. 
Tan, M. L., Choong, P. F. M., & Dass, C. R. (2010). Recent developments in liposomes, 
microparticles and nanoparticles for protein and peptide drug delivery. Peptides, 
31(1), 184–193. doi:10.1016/j.peptides.2009.10.002 
Thimmasetty, J., Pandey, G. S., & Babu, P. R. S. (2008). Design and in vivo evaluation 
of carvedilol buccal mucoadhesive patches. Pak J Pharm Sci, 21(3), 241–8. 
Thumma, S., ElSohly, M. A., Zhang, S., Gul, W., & Repka, M. A. (2008). Influence of 
plasticizers on the stability and release of a prodrug of [Delta]9-
tetrahydrocannabinol incorporated in poly (ethylene oxide) matrices. European 
Journal of Pharmaceutics and Biopharmaceutics, 70(2), 605–614. 
doi:10.1016/j.ejpb.2008.06.009 
Thumma, S., Majumdar, S., ElSohly, M. A., Gul, W., & Repka, M. A. (2008). 
Preformulation Studies of a Prodrug of Δ9-Tetrahydrocannabinol. AAPS 
PharmSciTech, 9(3), 982–990. doi:10.1208/s12249-008-9136-7 
Tiwari, S., Singh, S., Rawat, M., Tilak, R., & Mishra, B. (2009). L9 Orthogonal Design 
Assisted Formulation and Evaluation of Chitosan based Buccoadhesive Films of 
Miconazole Nitrate. Current Drug Delivery, 6(3), 305–316. 
Tiyaboonchai, W., Tungpradit, W., & Plianbangchang, P. (2007). Formulation and 
characterization of curcuminoids loaded solid lipid nanoparticles. International 
Journal of Pharmaceutics, 337(1–2), 299–306. doi:10.1016/j.ijpharm.2006.12.043 
Utoguchi, N., Watanabe, Y., Suzuki, T., Maehara, J., Matsumoto, Y., & Matsumoto, M. 
(1997). Carrier-Mediated Transport of Monocarboxylic Acids in Primary 
Cultured Epithelial Cells from Rabbit Oral Mucosa. Pharmaceutical Research, 
14(3), 320–324. doi:10.1023/A:1012046021028 
 
241 
 
Voiutskii, S. (1963). Autohesion and Adhesion of High Polymers. New York: Wiley-
Interscience. 
Wang, W. (1999). Instability, stabilization, and formulation of liquid protein 
pharmaceuticals. International Journal of Pharmaceutics, 185(2), 129–188. 
doi:10.1016/S0378-5173(99)00152-0 
Weatherell, J. A., Robinson, C., & Rathbone, M. J. (1996). The Flow of Saliva and Its 
Influence on the Movement, Deposition and Removal of Drugs Administered to 
the Oral Cavity. In M.J. Rathbone (Ed.), Oral mucosal drug delivery (pp. 157–
189). New York: Marcel Dekker Inc. 
Wertz, P. W., Cox, P. S., Squier, C. A., & Downing, D. T. (1986). Lipids of epidermis 
and keratinized and non-keratinized oral epithelia. Comparative Biochemistry and 
Physiology. B, Comparative Biochemistry, 83(3), 529–531. 
Wertz, P. W., & Squier, C. A. (1991). Cellular and molecular basis of barrier function in 
oral epithelium. Critical Reviews in Therapeutic Drug Carrier Systems, 8(3), 237–
269. 
Wertz, P. W., Swartzendruber, D. C., & Squier, C. A. (1993). Regional variation in the 
structure and permeability of oral mucosa and skin. Advanced Drug Delivery 
Reviews, 12(1-2), 1–12. doi:10.1016/0169-409X(93)90037-5 
Wong, C. F., Yuen, K. H., & Peh, K. K. (1999a). Formulation and evaluation of 
controlled release Eudragit buccal patches. International Journal of 
Pharmaceutics, 178(1), 11–22. doi:10.1016/S0378-5173(98)00342-1 
Wong, C. F., Yuen, K. H., & Peh, K. K. (1999b). An in-vitro method for buccal adhesion 
studies: importance of instrument variables. International Journal of 
Pharmaceutics, 180(1), 47–57. doi:10.1016/S0378-5173(98)00402-5 
Wu, X., Desai, K.-G. H., Mallery, S. R., Holpuch, A. S., Phelps, M. P., & Schwendeman, 
S. P. (2012). Mucoadhesive Fenretinide Patches for Site-Specific 
 
242 
 
Chemoprevention of Oral Cancer: Enhancement of Oral Mucosal Permeation of 
Fenretinide by Coincorporation of Propylene Glycol and Menthol. Mol. 
Pharmaceutics, 9(4), 937–945. doi:10.1021/mp200655k 
Xiang, J., Fang, X., & Li, X. (2002). Transbuccal delivery of 2’,3’-dideoxycytidine: in 
vitro permeation study and histological investigation. International Journal of 
Pharmaceutics, 231(1), 57–66. doi:10.1016/S0378-5173(01)00865-1 
Yadev, N. P., Murdoch, C., Saville, S. P., & Thornhill, M. H. (2011). Evaluation of tissue 
engineered models of the oral mucosa to investigate oral candidiasis. Microbial 
Pathogenesis, 50(6), 278–285. doi:10.1016/j.micpath.2010.11.009 
Yanagi, M., Hisajima, T., Ishibashi, H., Amemiya, A., Abe, S., & Watanabe, M. (2008). 
Oral candidiasis deteriorated by local application of a glucocorticoid-containing 
film in a mouse model. Biological & Pharmaceutical Bulletin, 31(2), 278–283. 
Yang, R.K., Fuisz, R. C., Myers, G. L., & Fuisz, J. M. (2008, September 16). Thin film 
with non-self-aggregating uniform heterogeneity and drug delivery systems made 
therefrom. Retrieved from http://www.freepatentsonline.com/7425292.html 
Yang, Robert K., Fuisz, R. C., Myers, G. L., & Fuisz, J. M. (2003, June 12). Thin film 
with non-self-aggregating uniform heterogeneity and drug delivery systems made 
therefrom. Retrieved from 
http://www.freepatentsonline.com/y2003/0107149.html 
Yehia, S. A., El-Gazayerly, O. N., & Basalious, E. B. (2009). Fluconazole Mucoadhesive 
Buccal Films: In Vitro/In Vivo Performance. Current Drug Delivery, 6, 17–27. 
doi:10.2174/156720109787048195 
Zhang, D. (2009). Sorbitan Esters (Sorbitan Fatty Acid Esters). In R. C. Rowe, P. J. 
Sheskey, & M. E. Quinn (Eds.), Handbook of Pharmaceutical Excipients (pp. 
675–678). Pharmaceutical Press. 
 
243 
 
Zhang, H., & Robinson, J. R. (1996). In Vitro Methods for Measuring Permeability of the 
Oral Mucosa. In M.J. Rathbone (Ed.), Oral mucosal drug delivery (pp. 85–100). 
Informa Health Care. 
Zhang, M., Li, X. H., Gong, Y. D., Zhao, N. M., & Zhang, X. F. (2002). Properties and 
biocompatibility of chitosan films modified by blending with PEG. Biomaterials, 
23(13), 2641–2648. doi:10.1016/S0142-9612(01)00403-3 
Zhang, Y., Huo, M., Zhou, J., Zou, A., Li, W., Yao, C., & Xie, S. (2010). DDSolver: An 
Add-In Program for Modeling and Comparison of Drug Dissolution Profiles. The 
AAPS Journal, 12(3), 263–271. doi:10.1208/s12248-010-9185-1 
  
 
244 
 
Vita 
 
Javier O. Morales received his professional degree in Pharmacy from The 
University of Chile in December of 2007 in Santiago, Chile. After graduation, he was 
awarded a Fulbright/CONICYT scholarship to attend graduate school in the United States 
He then moved to Austin, Texas and in August of 2008 started his research for obtaining 
his Ph.D in Pharmaceutics at The University of Texas at Austin under the supervision of 
Dr. Jason T. McConville. During his time in Austin he was awarded several prestigious 
fellowships including: Dr. Feng Zhang & Dr. James McGinity Graduate Fellowship 
(2010 and 2011), AAPS Formulation Design and Development (FDD) section travel 
award (2010), Dr. Bill and Jill Wiliams & Dr. Jim and Kitty McGinity Graduate 
Fellowship (2012) and others. He obtained two poster presentation awards at the 
ExcipientFest Americas Annual Meeting (2009 and 2012) and was first author for the 
most downloaded article in the European Journal of Pharmaceutics and Biopharmaceutics 
with: “Manufacture and Characterization of Mucoadhesive Buccal Films”, for the period 
of January-March 2011. He has authored 7 articles which have been submitted to and 
published in leading journals of the field; he has authored 2 book chapter; presented more 
than 20 abstracts at national and international meetings; and is an inventor in 2 patent 
applications.  
 
 
Permanent address (or email): jomorales@utexas.edu 
This dissertation was typed by Javier Octavio Morales. 
